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Abstract  
Analysis of genome-wide mRNA expression data from 45 bladder cancer-derived 
cell lines revealed a Basal/Squamous subgroup exhibiting upregulation of 
extracellular matrix protein 1 (ECM1). Assessment of ECM1 at the mRNA and 
protein levels confirmed an ECM1-high subset of cell lines and primary tumours. 
Mucin 1 (MUC1) was also significantly upregulated in the ECM1-high subgroup. 
MUC1 expression was strongly correlation with ECM1 expression. Mining of 
publicly available microarray data showed significantly reduced overall survival in 
bladder cancer (BC) patients whose tumours expressed high levels of both ECM1 
and MUC1.  
 
ECM1 knockdown cell lines were established and in vitro phenotypic assays 
showed that ECM1 knockdown had an inhibitory effect on wound-healing ability. A 
previous study in breast cancer reported that ECM1 interacts with and stabilises 
epidermal growth factor receptor (EGFR) enhancing Ras/Raf/MEK/ERK signalling. 
A direct interaction between ECM1 and EGFR could not be confirmed in ECM1-
high BC-derived cell lines. Treatment of knockdown cell lines with recombinant 
ECM1 indicated that ECM1 initiates activation of downstream effectors in the EGFR 
pathway. Comparison of ECM1 knockdown and control cell lines using a phospho-
receptor tyrosine kinase array showed that activation of the MET receptor is also 
ECM1 dependent in ECM1-high cells. Differential gene expression and pathway 
analysis conducted on ECM1 knockdown and control cell lines revealed that ECM1 
modulates the mRNA levels of several extracellular matrix genes and genes linked 
to a more aggressive Basal/Squamous phenotype including the EGFR ligand 
amphiregulin, keratins 5 and 6, and the transcription factor ELF5. Drug sensitivity 
experiments targeting EGFR and mesenchymal epithelial transition factor (MET) 
revealed partial resistance in the ECM1 high cell lines. Comparison of the inhibitors’ 
effects on ECM1 KD and control cell lines indicated that high ECM1 expression 
alone was not influencing this lack of sensitivity and it is likely that there are multiple 
alternative mechanisms mediating survival in these cells.  
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Chapter 1  
Introduction 
1.1 Bladder Cancer 
1.1.1 Epidemiology  
The normal bladder urothelium is a specialised transitional epithelium that acts as a 
physical blood-urine barrier [1]. This barrier consists of regenerative basal cells, 
intermediate cells, and large superficial hexagonal cells known as umbrella cells [1, 
2]. Roughly 90% of primary bladder tumours diagnosed in the UK arise in 
the urothelium [3]. Each year 165,000 deaths attributed to the disease globally, and 
over 10,000 new cases of bladder cancer are diagnosed in the UK and making it 
the seventh most common cancer in the UK [4, 5].  
 
Most cases of bladder cancer occur in people aged over 60 [5], and the disease is 
generally diagnosed following the appearance of visible blood in the urine 
(hematuria) or blood-traces found upon urine testing [5]. The disease is more 
prevalent in men compared to women with 75% of diagnoses occurring in males [6]. 
The reasons for this gender discrepancy are still being debated, but a number of 
explanations have been offered including the potential for sex steroid hormone 
regulation of the disease, and differences in exposure to risk factors [6]. 
 
1.1.2 Aetiology  
The majority of bladder tumours are thought to develop following exposure to 
exogenous carcinogens which may enter the circulatory system through ingestion, 
inhalation or contact with the skin[7]. Risk factors include tobacco smoking and 
occupational exposure to aromatic amines and polycyclic hydrocarbons [7]. 
 
Smoking is the highest risk factor for bladder cancer development accounting for 
over 50% of all cases [7]. Tobacco contains numerous carcinogenic compounds 
such as aromatic amines that result in DNA damage [6].  A systematic review and 
meta-analysis of 83 studies showed a significant increase in relative risk of bladder 
cancer development for current, former and second-hand smokers compared to 
non-smokers, highlighting the strong association between bladder cancer 
development and tobacco [8].   
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Bladder cancer development is also associated with carcinogenic contact in an 
occupational setting.  In 1981, it was estimated that 10% of all bladder cancer 
cases were directly related to workplace exposure to carcinogens [9]. More current 
estimates are nearer 5-7% with health and safety legislation most likely playing a 
key role in this reduction [7]. Recent reviews on the relative risk of developing 
bladder cancer and the associated mortality as a result of occupational exposure to 
carcinogens have highlighted that workers exposed to aromatic amines through 
involvement in rubber and plastic production, textile dying, and hairdressing are still 
at elevated risk and such exposure remains an important issue for public health [7]. 
Furthermore, exposure to aromatic amines as part of lifestyle choices such as 
regular hair dying could also increase risk [6].  
 
1.1.3 Pathology and prognosis  
Bladder cancer is a heterogenous malignant disease that has traditionally been 
divided into two main forms (muscle-invasive and non-muscle-invasive) based on 
their pathology, response to treatment and distinctive genetic backgrounds [10, 11]. 
Stage and grade of tumours is assessed by histological examination. The Tumour-
Node-Metastasis system is used to describe the stage of tumours, which relates to 
the degree to which the tumour has invaded the tissue layers of the bladder (Figure 
1-1)[12]. Tumours are further classified as low grade or high grade based on the 
2004 World Health Organization (WHO) classification system [12], and Grade 1, 2, or 
3 based on the 1973 WHO classification system[13]. Grading describes the degree 
of similarity between tumour cells and healthy tissue. Tumour cells that are well 
differentiated and bare high resemblance to healthy urothelial cells are low grade 
(Grade 1 or 2), while tumours that are poorly differentiated and bear little 
resemblance to healthy urothelium are high grade (Grade 2 or 3).  
 
Approximately 70% of all newly diagnosed cases present as non-muscle-invasive 
bladder cancer (NMIBC)[14]. NMIBC consists of three pathological stages: Ta, T1 
and Tis (Figure 1-1). The majority of non-muscle-invasive bladder cancers present 
as stage Ta with the tumour being confined to the urothelium or mucosa. These 
tumours are also mostly low grade [10]. Approximately 20% of cases are diagnosed 
as stage T1 where the tumour has invaded the subepithelial connective tissue or 
lamina propria, of which the majority are high grade. Carcinoma in situ (CIS or Tis) 
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is a high grade non-papillary lesion which lies flat to the urothelium. CIS accounts 
for 10% of cases and is thought to be a precursor of MIBC [10, 14]. Five-year survival 
in patients with NMIBC is good (>90%), although there is a high rate of disease 
recurrence (50-70%) [14] and 10–20% of cases initially diagnosed as NMIBC will 
progress to MIBC [14].  
 
Approximately 25% of patients will present with muscle-invasive bladder cancer 
(MIBC) at diagnosis [14]. This muscle-invasive form encompasses tumours which 
have invaded the muscle wall or muscularis propria (stage T2 to T4) (Figure 1-1), 
and are typically high grade [10]. Although these tumours account for a lower 
proportion of cases than NMIBC, five-year survival rates are much poorer having 
been reported to be as low as 49% [15]. This is in part due to the increased 
progression and metastatic potential of these tumours [14] but also as a result of 
limited treatment options which consist of cisplatin-based chemotherapy and radical 
cystectomy [15].  
 
 
Figure 1-1: Bladder cancer staging.  
The pathological staging of bladder cancer according to the World Health Organisation’s 
Tumour-Node-Metastasis (TNM) staging system [12]. NMIBC consists of stages Tis, Ta and 
T1. MIBC consists of stages T2a, T2b, T3 and T4. 
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1.1.4 Treatment of bladder cancer  
Treatment of NMIBC is dependent upon perceived risk of recurrence and 
progression, which is largely based on the stage and grade of the tumour [16]. Low 
grade non-invasive tumours are considered low-risk and are normally treated with 
intravesical mitomycin C following transurethral resection. High grade NMIBC, that 
is normally considered higher risk, is treated by transurethral resection, adjuvant 
chemotherapy and maintenance intravesical Bacillus Calmette–Guérin (BCG) [17]. It 
is challenging to predict which high grade non-invasive tumours will progress, thus 
it is a difficult choice to decide which patients require complete removal of the 
bladder and surrounding lymph nodes, known as radical cystectomy, and for which 
patients, tumour resection and BCG treatment may be sufficient [16]. Current 
recommendations call for radical cystectomy only if patients fail BCG treatment [16]. 
Ten-year survival rates are around 80% if cystectomy is performed prior to 
progression to MIBC, while 10-year survival rates in delayed cystectomy in patients 
who fail BCG is just 51% [18]. Radical cystectomy comes with the risks associated 
with major surgery and can lead to reduced quality of life for patients, thus many 
patients and clinicians are unwilling to choose this option unless it is deemed 
necessary [19].   
 
Treatment of MIBC has remained largely unchanged for over 30 years and 5-
year survival rates have remained static [20]. The limited treatment options consist 
mainly of radical cystectomy and complimentary neoadjuvant or adjuvant 
chemotherapy [15]. Chemotherapeutic options for MIBC are most often cisplatin-
based, with patients receiving either methotrexate, vinblastine, doxorubicin and 
cisplatin (MVAC) or gemcitabine and cisplatin (GC) combination therapies [21].The 
major concern for MVAC therapy is toxicity, a problem augmented by the typically 
elderly patient profile which is often associated with numerous medical 
comorbidities [3]. In early studies, severe MVAC toxicity was seen with more than 
half of patients requiring hospitalisation for toxic complications as a direct result of 
treatment [22]. The most common side effects include a dramatic reduction in 
neutrophil levels resulting in complications due to infection, and significant 
ulceration of the digestive tract causing difficulty in eating and drinking [23]. Renal 
and cardiac toxicities as well as nausea can also be problematic [23]. MVAC is 
associated with a toxic death rate of 4% [24]. In the early 2000s, GC combination 
therapy was implemented for use in patients with bladder cancer [23]. While overall 
survival statistics of 14-15 months are comparable with MVAC, toxicity is much 
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lower [23].  Even though MVAC and GC are the standard regimens for MIBC, the 
best reported estimate of response rate to these cisplatin-based options in MIBC is 
50% highlighting a need for new treatment options [21]. Furthermore, pre-screening 
to identify “non-responders” to cisplatin prior to treatment is difficult and there is an 
urgent need for predictive biomarkers that would allow identification of patients who 
require alternative regimens [21]. 
 
MIBC that initially respond well to treatment often progress later with half of patients 
who undergo chemotherapeutic treatment and radical cystectomy eventually dying 
as a direct result of disease recurrence or pre-existing metastatic disease [25]. 
Currently there are no effective second-line chemotherapeutic options for patients 
with paclitaxel, pemetrexed, docetaxel and vinflunine giving a median overall 
survival of just 5 months [26]. There has been increasing interest in immune 
intervention-based therapies for the treatment of MIBC which are aimed at initiating 
or enhancing a host immune response against the tumour [27, 28]. 
 
Immune based therapy is not a new concept in bladder cancer treatment. In the 
1960s, intravesical BCG was demonstrated to be beneficial in the treatment of 
NMIBC as it was thought to initiate a local immune response [3]. BCG treatment is 
still used as the current standard of care for patients with high risk NMIBC [29]. As 
muscle-invasive tumours have a very high frequency of somatic mutations 
compared to other solid tumours, potentially leading to an increase in neoantigens, 
it is hoped that this may result in an increased sensitivity to immune checkpoint 
therapy drugs [27, 30].  Recently, the field of immune-based therapy for treatment of 
MIBC has focused mainly on a group of T-cell checkpoint inhibitors [3]. 
 
Currently five immune checkpoint inhibitors have been approved by the United 
States Food and Drug Administration (US-FDA) for first-line or second-line 
treatment of metastatic MIBC. These drugs include two monoclonal antibodies that 
target programmed death receptor-1 (PD-1) (pembrolizumab and nivolumab) and 
three that target its counterpart programmed death receptor ligand-1 (PD-L1) 
(atezolizumab, durvalumab, and avelumab) [25]. The interaction of the PD-1 receptor 
and its ligand suppresses the immune response, and in normal cells this is 
important in preventing an autoimmune response following infection [25]. In the 
context of cancer, PD-L1 is expressed by tumour cells and interacts with PD-1 
presented by T-cells allowing the tumour cells to evade immune recognition. Drugs 
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that block this molecular interaction can therefore increase immune response 
resulting in tumour shrinkage [25].  
 
Although these immune checkpoint drugs provide promise for the treatment of 
patients with MIBC who are “non-responders” to cisplatin, response rates have 
been reported to range from just 20 to 25% [3]. A significant challenge still lies in 
assigning the right therapeutic agent to each patient and identification of new 
biomarkers to predict patient response is still necessary. Molecular characterisation 
may help to provide insight into disease behaviour and be used to stratify patients 
into groups most likely to respond to therapeutic options. Improved understanding 
of the correlation between molecular and clinical features may therefore help to 
advance clinical management of the disease.  
 
1.2 Genomic landscape of bladder cancer 
Early studies of the genomic alterations in bladder cancer assessed somatic 
mutations in specific candidate genes including fibroblast growth factor receptor 3 
(FGFR3), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 
(PIK3CA), cyclin dependent kinase inhibitor 2A (CDKN2A), tumour protein 53 
(TP53), tuberous sclerosis complex subunit 1 (TSC1), retinoblastoma protein 1 
(RB1) and the rat sarcoma (RAS) gene family, loss of heterozygosity (LOH) and 
copy number alterations. Whole genome and whole exome sequencing studies 
have confirmed somatic mutations in these genes and have also identified 
alterations in new candidates including numerous chromatin modifier genes. 
 
Low stage and grade bladder tumour genomes are very stable whereas MIBC 
genomes commonly contain numerous copy number alterations, rearrangements 
and high-level amplifications [31-35]. The genomes of stage T1 tumours show varying 
levels of complexity with some resembling Ta tumours and others resembling MIBC 
[33]. 
 
Loss of heterozygosity or copy number loss of chromosome 9 is the most common 
genomic alteration detected in bladder tumours. Copy number loss is found in 
approximately 50% of all tumours. Many studies have investigated potential 
candidate genes and several critical regions have been identified. A critical region 
on the p-arm is 9p21 containing the CDKN2A gene which encodes p16 and 
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p14ARF, two cell-cycle regulators that negatively regulate the RB and p53 
pathways, respectively [10]. TSC1 is another tumour suppressor gene on 9q which 
has been reported to be biallelically inactivated in 12-16% of tumours and has a 
function in negative regulation of mTOR [36, 37]. 
 
Activating mutations in the fibroblast growth factor receptor 3 (FGFR3) gene are 
commonly detected in hotspot regions in exons 7, 10 and 15 and lead to 
constitutive activation of the receptor. The frequency of FGFR3 mutation is ≥ 70% 
in stage Ta tumours, 10-45% in stage T1 tumours and 15% in muscle-invasive 
tumours [38]. Muscle-invasive bladder tumours exhibit upregulated FGFR3 protein 
expression in 40-50% of non-mutant cases [38]. FGFR3 can be also be activated in 
2-5% of cases by chromosomal translocation to generate fusion proteins, the most 
common of which is FGFR3-TACC3 [32, 39, 40]. Activating mutations in the RAS gene 
family (HRAS, KRAS and NRAS) occur in hotspot regions in approximately 10% of 
all tumours and are not associated with stage or grade. Mutual exclusivity of RAS 
and FGFR3 mutations has been reported [41] and may reflect the involvement of 
both proteins in the activation of the RAS-MAPK pathway. The phosphatidylinositol-
3 kinase (PI3K) pathway is also an important signalling pathway that is altered in 
bladder cancer. The p110α catalytic subunit (PIK3CA) gene is mutated in 40-50% 
of low grade, low stage Ta tumours and 20% of stage T1 and muscle-invasive 
tumours [42]. Activating point mutations are commonly located in the helical domain 
(E542K and E545K) and less frequently in the kinase domain (H1047R).  
 
Telomerase reverse transcriptase (TERT) promoter mutations occur in 60-80% of 
all bladder tumours making them the most common genomic alteration in bladder 
cancer [43, 44]. It has been suggested that these mutations represent an early event 
in all urothelial cancers. These mutations commonly occur in two hotspots and are 
predicted to create binding sites for ETS/TCF transcription factors leading to 
increased transcriptional activity [45]. 
 
The tumour suppressor genes TP53, RB1 and CDKN2A are commonly inactivated 
in muscle-invasive tumours and result in p53/cell-cycle alterations in approximately 
89% of MIBC [32]. TP53 is mutated in approximately 50% of all MIBC making it the 
most commonly mutated gene in these tumours [32]. In contrast, TP53 mutation 
occurs in only 1% of low grade Ta tumours. A higher frequency of mutation occurs 
in T1 tumours and these mutations can co-occur with FGFR3 mutations [46].  
Deletion of the RB1 gene region at 13q14 and loss of RB1 protein expression 
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occurs commonly in muscle-invasive tumours [10]. RB1 and p16 expression is 
inversely correlated in MIBC and is associated with poor prognosis [10]. 
 
Whole exome and whole genome sequencing studies in MIBC have revealed a high 
median somatic mutation rate per megabase (5.5 mutations/Mb) that is comparable 
to rates reported in melanoma and non-small cell lung cancer [47-49]. The mutation 
rates in NMIBC are much lower with rates of 1.64 (median) overall and 1.8 (median) 
non-synonymous mutations per megabase having been reported in two studies of 
stage Ta and Ta/T1 tumours, respectively [31, 50]. A major finding of these next-
generation sequencing studies has been the discovery of frequent mutations in 
chromatin modifier (CM) genes including KDM6A, KMT2A, KMT2C, KMT2D, 
CREBBP, EP300, ARID1A, ARID4A, ASXL1, ASXL2 and STAG2 [50-52]. CM 
mutations are present in tumours of all stages and grades, with the highest frequent 
in non-muscle-invasive bladder cancers [31, 50, 51]. Inactivating mutations are 
common in many of these genes, suggestive of a tumour suppressor function [32].  
 
1.3 The role of  receptor tyrosine kinases in bladder cancer  
One finding of large-scale genomic studies has been the presence of various 
alterations in the genes encoding for receptor tyrosine kinases (RTKs). RTKs are a 
family of 58 cell surface receptors that are unified by their characteristic structure of 
an extracellular N-terminal domain, a transmembrane domain, and a cytoplasmic 
kinase domain. Upon activation by a ligand, conformational changes are induced 
resulting in the homo or hetero-dimerisation of two RTKs. Intrinsic kinase activity of 
the cytoplasmic domain of one receptor results in phosphorylation of specific 
residues on the cytoplasmic region of the other providing a scaffold to recruit 
effector proteins and thus activate downstream pathways including the 
RAS/RAF/MEK/ERK, PI3K/PTEN/AKT and JAK/STAT pathways [42]. The activation 
of these pathways ultimately leads to the transcriptional activation of genes involved 
in cell proliferation, cell migration, cell differentiation and decreased apoptosis.  
 
Abnormal RTK activation is a common feature of many epithelial carcinomas 
including bladder cancers and is mediated by four main mechanisms: gain-of 
function mutations, genomic amplification, chromosomal rearrangements, and 
autocrine activation [47]. A number of key RTK subfamilies have been implicated in 
bladder cancer development and progression. For example, activating mutations in 
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the fibroblast growth factor receptor 3 (FGFR3) gene are common in low stage and 
grade tumours and overexpression of FGFR1 has been reported in a large 
proportion of tumours of all stages and grades [38, 53, 54]. The ERBB subfamily of 
RTKs also play an important role in bladder cancer. There have been several 
studies suggesting that epidermal growth factor receptor (EGFR) plays a key role in 
the development and progression of bladder cancer, with approximately half of all 
bladder tumours overexpressing the receptor [55-59]. There is also a significant 
association between EGFR expression and increased invasiveness of tumours and 
poorer survival for patients [reference]. Mesenchymal epithelial transition factor 
(MET), a receptor that normally plays a role in embryogenesis and wound-healing 
[60], has also been implicated in MIBC with increased MET signalling showing a 
strong correlation with increased metastatic potential and poor outcome for patients 
[59]. 
 
Constitutive and aberrant activation of pathways downstream of RTKs are important 
in bladder cancer. Activation of the RAS/RAF/MEK/ERK pathway by RTKs triggers 
a cascade of phosphorylation events involving downstream kinases leading to a 
multitude of physiological and pathological cellular processes such as growth, 
proliferation, differentiation, migration and apoptosis. Activating RAS mutations are 
seen in approximately 10% of all bladder tumours, and increased signalling via the 
RAS/RAF/MEK/ERK pathway has been associated with poorer prognosis for 
bladder cancer patients [32, 47-49]. Similarly, RTK activation may also trigger the 
activation of the PI3K/PTEN/AKT pathway. This is one of the most frequently 
dysregulated pathways in cancer and is thought to play a major role in bladder 
carcinogenesis with immunohistochemical studies demonstrating an increase in the 
level of phosphorylated AKT in up to 88% of bladder cancer cases [47-49]. 
 
1.4 Molecular subtypes of MIBC 
Large-scale genome-wide studies of mRNA, microRNAs, DNA-methylation, copy 
number alterations and somatic mutations have enabled the identification of cancer 
subtypes [61-65]. The most widespread approach to cancer subtyping remains 
genome-wide gene expression profiling [65-68]. This approach has enabled the 
identification of molecular subtypes based on mRNA expression profiles in multiple 
cancer types including breast, lung, colorectal, pancreatic, leukaemia and bladder 
[66]. It is hoped that the classification of cancers into subtypes will ultimately aid the 
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identification of actionable drug targets and biomarkers to predict prognosis and 
response to therapy.  
 
Over the past 20 years genome-wide gene expression profiling of breast cancer 
has led to the identification and extensive characterisation of four molecular 
subtypes termed luminal A, luminal B, HER2-enriched (HER2-E) and basal-like [69]. 
Collectively, these are known as the intrinsic subtypes of breast cancer and each 
exhibits differences in response to treatment, incidence and patient survival [69]. 
Subtyping of breast cancers provides both prognostic and predictive information 
that can be used to support information provided by traditional clinical parameters 
such as tumour size, histological stage and grade, and node status, to guide better 
informed treatment decisions for patients [70]. Several research groups are now 
working towards providing similar information for bladder cancer. A timeline of the 
main studies and the molecular subtypes described is shown in Figure 1-2.  
 
In 2010, a research group from Lund University were the first to classify bladder 
tumours based on molecular data including genome-wide gene expression data [71]. 
They carried out hierarchical cluster analysis of gene expression data from 144 
bladder tumours across all stages and grades, and combined this information with 
whole genome copy number data and mutational analysis data for 8 key genes for; 
fibroblast growth factor receptor 3 (FGFR3), phosphatidylinositol 3-kinase 
(PIK3CA), Kirsten rat sarcoma (KRAS), Harvey rat sarcoma (HRAS), 
neuroblastoma rat sarcoma (NRAS), tumour protein 53 (TP53), cyclin dependent 
kinase inhibitor 2A (CDKN2A) and tuberous sclerosis (TSC1) [71]. This identified 2 
subgroups of bladder tumours which they termed MS1 and MS2. MS1 tumours had 
a high frequency of activating mutations in FGFR3 and PIK3CA suggesting they are 
dependent on activation of receptors early on in signalling pathways [71]. Genomic 
instability was the most notable characteristic of tumours classified into the MS2 
subtype, and while this group also had a high level of TP53 mutations and MDM2 
amplification, genomic instability was independent of these traits [71]. They also 
found that the MS2 subtype could be further divided into two groups, one with no 
TP53 impairment, and the other with TP53 impairment and a significantly higher 
number of focal genomic amplifications [71]. 
 
In a subsequent study, the Lund group identified five major molecular subtypes of 
bladder tumours based on hierarchical cluster analysis of gene expression data 
from 308 urothelial cell carcinomas of all stages and grades [72]. The five subtypes 
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defined were urobasal A (UroA), urobasal B (UroB), genomically unstable (GU), 
squamous cell carcinoma-like (SCC-like) and “infiltrated”.  UroA was identified as a 
group with good prognosis that mainly consisted of NMIBC of low pathological 
grade. This subtype was characterised by frequent FGFR3 mutations and elevated 
levels of FGFR3, GATA binding protein 3 (GATA3), cyclin D1 (CCND1) and tumour 
protein 63 (TP63). The UroB subtype shared many similarities with the UroA 
subtype but were characterised by more frequent TP53 mutation and increased 
expression of keratins 5, 13, 15 and 17. A high frequency of muscle-invasive 
bladder tumours (50%) were assigned to this subtype. The GU subtype also had a 
high number of muscle-invasive bladder tumours, with 40% of cases being muscle-
invasive, and the group was described as ‘high risk’. This subtype was also 
characterised by frequent TP53 mutation, high cyclin E1 (CCNE) and human 
epidermal growth factor receptor 2 (HER2) expression, and low keratin (KRT) 
expression. The majority of tumours classified as SCC-like showed squamous-cell 
differentiation. The SCC-subtype was characterised by expression of a number of 
keratins (4, 6A/B/C, 14 and 16) and also exhibited elevated expression of EGFR. 
The UroB and SCC-like subtypes had the poorest prognosis and the SCC-like was 
more commonly seen in females. The “infiltrated” subtype had a high level of 
immune cell infiltration and also expressed the epithelial-to-mesenchymal transition 
(EMT) associated genes Snail Family Transcriptional Repressor 1 (SNAI1) and Zinc 
Finger E-Box Binding Homeobox 1 (ZEB1). 
 
The Lund group later expanded upon this study by using both global mRNA and 
extensive immunohistochemical analysis of 307 advanced bladder tumours 
(cystectomised) and defined five tumour-cell phenotypes characterised by the 
expression patterns of a specific set of markers [73]. Urobasal (CCND1+; FGFR3+; 
RB1+; CDKN2A-), genomically unstable (CCND1-; FGFR3-; RB1-; CDKN2A+), 
mesenchymal-like (VIM+; ZEB2+; EPCAM-; CDH1-), basal/SCC-like (KRT5+; 
KRT14+; GATA3-; FOXA1-), and small-cell/neuroendocrine-like (TUBB2B+; 
EPCAM+; CDH1-; GATA3-). The authors did however acknowledge that these 
subtypes require independent validation [73]. 
 Figure 1-2: A
 tim
eline of bladder cancer subtyping studies since 2010.
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In 2014, Damrauer et al. from the University of North Carolina (UNC) used 
consensus cluster analysis of genome-wide gene expression data for 262 high-
grade muscle-invasive bladder tumours, and defined two molecular subtypes of 
MIBC that share similarities to the luminal and basal intrinsic subtypes of breast 
cancer [74]. Tumours in the luminal subgroup demonstrated largely papillary 
histology, and had upregulated expression of uroplakins, keratin 20, FGFR3, CDH1 
and cell cycle genes such as CCND1. The basal subtype expressed markers 
similar to those seen in the basal layer of the urothelium [74], including upregulated 
keratins 5, 6B and 14, and upregulated CD44, suggestive of squamous metaplasia. 
The basal subtype had a much poorer survival rate compared to the luminal 
subtype [74]. They also identified a subgroup of the basal subtype which they 
labelled “Claudin-low” as it shared features reminiscent of a subset of breast 
tumours with the same name. This subgroup had low claudin expression and 
increased expression of EMT markers. No difference in overall or disease free 
survival was noted between the Claudin-low tumours and the other basal tumours.  
 
These MIBC subtyping studies do not stand alone and comparisons between them 
reveal overlapping features. For example, the basal subtype identified by Damrauer 
et al. shows similarities to both the SCC-like and UroB subtypes defined by the 
Lund group. Although there is overlap in the studies’ findings, Damrauer et al. were 
the first to assign a breast cancer molecular subtyping system to bladder cancer 
which interestingly was found to hold clinical relevance. It is now widely accepted 
that MIBC subtypes can be broadly divided into basal and luminal tumours.   
 
Luminal and basal subtypes of bladder cancer were also reported by a group from 
the MD Anderson (MDA) Cancer Center that identified three subgroups following 
whole genome mRNA expression profiling and unsupervised cluster analysis of a 
discovery cohort of 73 MIBC patient samples [75]. Two of these subtypes were 
termed basal and luminal as they shared gene expression features with their breast 
cancer namesakes. The MDA group also identified an intermediate subtype that, 
due to an upregulation of a gene expression signature associated with activated 
wild-type p53, was labelled p53-like [75]. Similar to the “infiltrated” subtype denoted 
by the Lund group, this p53-like subtype also had a high level of non-tumour cell 
infiltration, particularly of cancer-associated fibroblasts. The p53 subtype was also 
characterised by an enrichment of an extracellular matrix related gene expression 
signature [75]. The MDA group was the first to introduce the idea that molecular 
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subtypes could predict response to traditional neoadjuvant cisplatin-based 
chemotherapy (NAC) and demonstrated that patients with p53-like tumours had a 
lower response rate to NAC [75]. 
 
A group from the University of British Columbia (UBC) subsequently examined the 
concept of bladder cancer subtypes being used to predict response to NAC [76]. 
They aimed to validate the work of the MDA group using a larger cohort, and also 
sought to investigate the relationship between NAC resistance and other previously 
annotated subtypes [76]. They also proposed a subdivision of the UNC luminal 
subtype into luminal and luminal-infiltrated. The luminal-infiltrated subtype was seen 
to be similar in many aspects to the luminal subtype, but also had an increased 
immune-infiltration gene expression signature and was associated with a low 
response rate to NAC [76]. Division of the basal subtype into a basal subtype which 
may benefit from NAC and a claudin-low subtype which did not respond well to 
NAC was also proposed. The claudin-low subtype was characterised by an EMT 
phenotype, low PPARG expression and high activity of nuclear factor kappa light 
chain enhancer of activated B cells (NF-κB) [76]. While the molecular subtyping of 
MIBC has highlighted clinically relevant findings in relation to response to NAC, 
subtyping based on hierarchical clustering requires large cohorts of patients, which 
means it cannot be implemented on an individual patient basis in the clinic. In 
response to this, the UBC group trained a single-sample genomic subtyping 
classifier (GSC) in order to assign individual tumours to one of their four subtypes. 
Such an approach may be more applicable in a diagnostic setting [76].  
 
One of the largest subtyping studies has come from The National Cancer Institute 
and National Human Genome Research Institute who have developed a multi-
institutional collaboration known as The Cancer Genome Atlas (TCGA) Research 
Network. The TCGA has collected and analysed the molecular data for hundreds of 
tumour samples from 33 different cancer types including bladder cancer [77]. Initially, 
a study of 130 muscle invasive tumours was carried out by the TCGA in 2014, 
identifying four subtypes named clusters I-IV [47]. Clusters I and II were identified as 
luminal subgroups with high expression of GATA3 and FOXA1. Cluster I also 
exhibited mainly papillary histology similar to the luminal subtype identified by the 
UNC group. Cluster III was identified as a more basal-squamous subtype similar to 
the previously annotated basal subtypes of other research groups, and expressed 
high levels of keratins 5 and 14 which are also high in urothelial stem-like progenitor 
cells [47, 78]. The addition of non-
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identification of a new subtype called cluster IV which expressed genes 
characteristic of epithelial-to-mesenchymal transition.  
 
In 2017, the TCGA expanded upon their original study and reported data for a 
larger MIBC cohort consisting of 412 tumours [32]. This larger sample set enabled 
refinement of their original subtypes, and provided insights into prognosis and 
therapeutic response, with suggestions of which subtypes would benefit from FDA 
approved immune checkpoint inhibitors, or alternative more targeted therapeutic 
strategies. The five subgroups were named: luminal papillary, luminal-infiltrated, 
luminal, basal/squamous, and neuronal. The luminal-papillary, luminal-infiltrated 
and luminal subtypes all share features with the previously identified luminal 
subtype, expressing high levels of uroplakins, KRT20, GATA3 and forkhead box A1 
(FOXA1), but each group also possesses some unique features. The luminal-
papillary subset, for example, showed the best overall survival, and had a papillary 
morphology. FGFR3 mutations and FGFR3-TACC3 fusions were enriched in this 
subtype, and high expression of CDH1 and ERBB2 was also observed.  The 
luminal-infiltrated subgroup had a strong mesenchymal expression signature and 
low tumour purity, and the luminal subtype had high expression of genes that are 
commonly expressed in terminally differentiated umbrella cells such as KRT20 and 
SNX31, and had extremely high expression of the uroplakins UPK1A and UPK2. 
 
The molecular data and patient metadata collated from the TCGA studies have 
been made publicly available to aid research into diagnosis, treatment and 
preventative strategies for cancer. As a result, the focus of research regarding 
treatment of MIBC is now trending towards targeted therapies and away from 
traditional chemotherapeutics [77]. In the first study of its kind, a phase II trial of 
platinum-treated locally advanced MIBC adopted the TCGA classification approach 
to assign 195 patients into the four original subtypes (I-IV), and assessed the 
differences in treatment response to the monoclonal antibody atezolizumab that 
inhibits PD-L1 [79]. Analysis revealed a higher response in the luminal cluster II 
patients, suggesting that subtypes may independently predict response to new 
immune checkpoint inhibitors. This highlights the potential for the stratification of 
MIBC based on molecular subtypes as an effective approach for the allocation of 
therapeutic options. Further studies to elucidate the association between molecular 
subtypes of MIBC and response to immune checkpoint inhibitors are planned[28].  
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In order for this process to be adopted in the clinic it is important that a consensus 
on subtype classification is reached. While these studies have provided good 
groundwork in the identification of MIBC molecular subtypes, they have all been 
based on relatively small cohort sizes of between 100 and 500 samples. However 
over 5000 samples may be need in order to reliably detect mutations that occur in 
less than 2% of the samples [80]. Thus cohorts this large may also be required to 
detect rarer molecular subtypes. The increased ability to detect subtypes when 
using larger cohorts is highlighted by the TCGA studies which identified five 
subtypes when 412 samples were examined, compared to only four subtypes that 
were identified when the original 130 samples were examined.  
 
In September 2018, a much larger study was conducted by a group from the 
National University of Singapore collating and analysing 2411 gene expression 
profiles from a total of 19 MIBC and NMIBC cohorts [81]. This study identified 6 
major molecular subtypes (MC1-6) [81]. These subtypes were compared to 
previously annotated subtypes through analysis of key markers, cross referencing 
with existing subtype annotation, and re-performing consensus clustering on a 
subset of the bladder tumours using the most significantly altered genes and 
previously published subtype signatures [81]. This revealed that MC1-6 
corresponded well with previously annotated subtypes. MC1 (also called Neural-like 
or NEURAL) is similar to the Lund group’s small-cell/neuroendocrine-like subtype 
and the TCGA neuronal subtype. MC2 (also called Luminal-like or LUM) is similar 
to a NMIBC subtype known as class 3, identified by Hedegaard et al. [82]. MC3 (also 
called Papillary-like or PAP) is similar to the Lund group’s urobasal subtype and the 
TCGA luminal-papillary subtype. MC4 (also called HER2-like or HER2L) is similar 
to Lund group’s genomically unstable subtype and the TCGA luminal subtype. MC5 
(also called squamous cell carcinoma-like or SCC) is similar to the Lund group’s 
SCC-like subtype, the MD Anderson Cancer Center basal subtype and the TCGA 
basal-squamous subtype. MC6 (also called Mesenchymal-like or MES) is similar to 
the Lund group’s “infiltrated” subtype, the MD Anderson Cancer Center p53-like 
subtype and the TCGA luminal-infiltrated.  
 
Tan et al. also related this new subtyping information to potential therapeutic 
approaches [81]. In order to predict the treatment approaches best suited to each 
subtype, cell line drug response analysis was conducted using the UBC-40, a panel 
of 40 well characterised bladder tumour derived cell lines [83]. The 40 cell lines were 
assigned to each of the six subtypes. Subtypes were then correlated with the 50% 
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growth inhibitory concentration (GI50) for 25 different therapeutic compounds [81]. 
This revealed differing responses amongst subtypes. MES demonstrated the 
highest resistance to the majority of compounds compared to the other subgroups 
which was thought to be related to its stem-like features. The LUM subtype showed 
high resistance to the FGFR1 and FGFR3 inhibitor PD-173074. It was noted that 
while there were differences in levels of resistance to these therapeutic compounds, 
there was no clear association between the subtypes and sensitivity to any of the 
therapeutic compounds. This analysis was conducted on a limited number of cell 
lines, and does not represent a large-scale tumour screen, but it may still be useful 
as a preliminary analysis and provide information for future more in-depth and 
larger scale studies.   
 
This large-scale study in principle could help a consensus on the molecular 
subtyping of bladder cancer to be reached and improve understanding of the 
clinical implications of such subtypes. However, the study of Tan et al. has been 
regarded as flawed, as the manner in which datasets were merged was problematic 
and internal validation was not systematically performed. This led to bias in the 
classification system. For example, the “MC1” or “neural” subtype comprised of 
77% FFPE tumour samples compared to only 7% in the MC2 or luminal subtype [84].  
 
In December of the same year a pre-print was released from an international 
collaboration known as ‘The Bladder Cancer Molecular Taxonomy Group’ who have 
undertaken a more robust study aimed at providing a consensus classification of 
MIBC subtypes based on 1750 transcriptome profiles of muscle-invasive tumours 
from six different studies[32, 74, 75, 85-87] (doi: http://doi.org/10.1101/488460). Six 
molecular subtypes were defined, which largely overlapped with previously 
annotated classifications. These subtypes were named: Luminal Papillary (LumP), 
Luminal Non-specified (LumNS), Luminal Unstable (LumU), Stroma-rich, 
Basal/Squamous (Ba/Sq) and Neuroendocrine(NE)-like.  
 
The LumP accounted for nearly a quarter of the samples. The majority of tumours 
assigned to this group showed papillary morphology, and bared similarity the TCGA 
luminal papillary and Lund UroA subtypes. LumP was characterised by a high 
expression of FGFR3 and low expression of CDKN2A at the mRNA level, and had 
a high frequency of mutations to FGFR3, KDM6A, and STAG2. These features are 
also common in low stage (Ta - T1) non-muscle-invasive tumours, implying this 
group may have progressed from NMIBC. This group also had the best prognosis. 
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LumNS was a much smaller subset with just 8% of samples assigned to this 
subtype. Similar to the MDA luminal, UNC luminal, and Lund genomically unstable 
subtypes, this group showed high mRNA expression of PPARG and mutations to 
the ELF3 gene. This subtype was also characterised by a high level of fibroblasts 
infiltrating the tumour, and had the worst prognosis of the three luminal subtypes. 
Fifteen percent of samples were assigned to the LumU subtype, similar to TCGA 
luminal subtype. This group was typically genomically unstable, and had a high 
mutational burden. This group had a high level of mutations to TP53, ERCC2, and 
had increased activation of the ERBB2/HER2. The Stroma-rich subtype was 
comprised of patients with both luminal and non-luminal tumours, and showed 
similar characteristics to TCGA luminal infiltrated and MDA p53-like subtypes. 
There were also tumours assigned to this group that had previously been assigned 
to the Lund group’s mesenchymal-like, genomically unstable and Urobasal 
subtypes. The main characteristic of this subtype was the high level of non-tumour 
cell infiltration including B cells, smooth muscle, fibroblasts, and myofibroblasts. 
The Ba/Sq subtype was the largest with 35% of tumours assigned to this group. It 
was seen to be similar to the UNC basal, MDA basal, Lund basal-SCC-like, and 
TCGA basal-squamous subtypes, and showed high expression of EGFR, KRT14 
and KRT5/6, and low expression of GATA3, FOX1A, and PPARG. This group also 
had a high level of TP53 and RB1 mutations, and showed squamous differentiation 
by histological assessment. The NE-like subtype by contrast was a very small 
subsete with just 3% of sample assigned to this group. It was similar to the TCGA 
neuronal and the Lund group small-cell/neuroendocrine-like subtypes, and was 
characterised by inactivating mutations to TP53 and RB1. It is hoped that these 
consensus biological subtypes will be useful in treatment stratification, and the 
group also presented a single-patient classifier in order to enable application of this 
consensus classification system in the clinic.  
 
1.5 Preceding work in our laboratory implicating ECM1 and 
MUC1 in a subgroup of MIBC 
Cell line panels such as the UBC-40 represent a valuable resource for use as 
model systems in which to test therapeutic approaches [83, 88, 89]. It is essential that 
the molecular features of such cell line panels are fully characterised and that these 
characteristics faithfully reflect those present in the tumours from which they were 
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derived. Prior to the start of this study, our laboratory assembled a panel of 45 
bladder tumour-derived cell lines and carried out genome-wide expression profiling 
in order to determine whether molecular subgroups were present within the (Hurst 
et al., unpublished data). This analysis will be discussed fully in Chapter 3. One of 
the subgroups identified exhibited unique features compared to previously 
annotated subtypes and was chosen for further study in the current project. This 
subgroup has Basal/Squamous features but also exhibits significant upregulation of 
a subset of 50 genes including extracellular matrix protein 1 (ECM1) and mucin 1 
(MUC1). 
 
1.6 ECM1 
1.6.1 ECM1 in normal physiology 
Extracellular matrix protein 1 (ECM1) is an 85kDa highly glycosylated protein [90]. It 
was first identified in 1994 as a secreted protein in a mouse osteogenic stromal cell 
line [91], and later in 1997 the human form of ECM1 was characterised [92]. The 
human ECM1 gene maps to 1q21, adjacent to the epidermal differentiation 
complex, and encodes for a protein expressed mainly in the basal layers of the skin 
and specialised epithelia [91]. The normal physiological function of ECM1 is not fully 
understood, nor is the mechanism by which ECM1 exerts it’s biological functions, 
however, it is thought to be important in embryo development and wound healing, 
as the protein is linked to angiogenesis [93, 94], cell differentiation including 
keratinocyte differentiation and endochondral ossification [95], and cell proliferation 
[96]. 
 
The ECM1 protein contains a 19 amino acid signalling peptide and four functional 
domains: a cysteine-free N-terminus, two tandem repeats, and a C-terminus [94] 
(Figure 1-3). The tandem repeat and C-terminus domains have a CC-(X7–10)C motif 
that may form protein double loops similar to those involved in protein–protein 
interactions seen in other molecules such as the serum albumin family of proteins 
and a protein known as Endo 16 calcium-binding protein expressed by sea urchins 
[92, 97, 98]. These similarities suggest that ECM1 may act in a similar manner by 
serving as a transporter protein or having the capability to bind growth and 
differentiation factors [94, 99]. Indeed, within the epidermal layers of the skin ECM1 
has been noted to bind to several extracellular matrix proteins such as collagen 
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type IV, fibronectin, laminin 332, fibulin-1C/1D and MMP9 implying that ECM1 could 
have a role as an extracellular fixative important for maintaining the structural 
integrity of the skin [90]. This role has not been fully elucidated as in vivo, transgenic 
mice overexpressing ECM1a did not have significant changes in the structure of the 
epidermis [100]. 
 
 
Figure 1-3: A schematic representation of the ECM1 protein slice variants and 
functional domains.  
The figure has been created from information obtained from [93]. 
 
 
In addition to its involvement in extracellular matrix integrity, ECM1 has also been 
suggested to play other key roles as part of its normal physiological function. ECM1 
may influence cell-type specific cell growth as it has been reported to stimulate 
epithelial cell proliferation [96, 101] and may inhibit chondrocyte proliferation [102]. 
Furthermore, ECM1 is thought to be involved in the regulation of endochondral 
bone and cartilage formation [94, 95, 103], and it has been noted to influence 
calcification of the extracellular matrix [102]. Gene expression analysis has suggested 
that ECM1 is a late-response, downstream molecule of parathyroid hormone-
related protein (PTHrP) signalling which is an important pathway in the regulation of 
chondrogenesis [104].  
 
The function of ECM1 may be splice variant dependent as there are four known 
splice variants of ECM1. ECM1a is the main isoform expressed in basal 
keratinocytes, dermal blood vessels and adnexal epithelia [105]. ECM1b is smaller 
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than ECM1a as it lacks the amino acid chain encoded by exon 7 and is found in the 
spinous and granular layers of the epidermis [105]. ECM1c is the largest isoform and 
is only found in the basal layer of the epidermis [94]. ECM1d is the smallest isoform 
consisting of just 57 amino acids, and has so far only been observed a fibroblast 
cell line in vitro, thus its biological importance in vivo is still unknown [106, 107]. While 
each variant has been observed in different tissue types, the potential differences in 
function have not yet been explored.  
 
1.6.2  ECM1 in human disease 
The normal function of ECM1 has in part been clarified by studies that have 
examined diseases associated with malfunctioning ECM1. In 1929 Urbach and 
Wiethe, a dermatologist and an otorhinolaryngologist respectively, first described an 
autosomal recessive condition known as Urbach–Wiethe disease (UWD) or lipoid 
proteinosis that was later shown to be caused by loss of function mutations in the 
ECM1 gene [108, 109]. UWD is rare with only 300 reported cases since its discovery 
[110]. However it can significantly impact the quality of life for patients. Symptoms 
vary amongst sufferers but it is usually characterised by early childhood 
presentation of a hoarse voice due to a thickening of the vocal cords, and pox-like 
scars covering the skin. Later in the disease course, excessive thickening of the 
skin and mucous membranes develops, often presenting on the face and tonsils 
[111]. This can lead to complications such as breathing difficulties or blindness due to 
thickening of the skin around the eyes [110]. The dermatological nature of the 
condition implies ECM1 plays a crucial role in skin homeostasis. Furthermore, 
damage by minor physical trauma leads to severe scarring and blistering in patients 
hinting at a role for ECM1 in wound healing. Deposition of calcium in blood vessels 
can occur in patients resulting in ischemia, suggesting that calcium metabolism may 
also be influenced by ECM1 [110]. 
 
The chronic inflammatory skin disease known as lichen sclerosis has a similar 
clinical presentation to lipoid proteinosis and may also be associated with reduced 
ECM1 function. Autoantibodies against the ECM1 protein have been identified in 
the circulation of patients with this disease, substantiating the idea that ECM1 
influences skin homeostasis [112].  
 
ECM1 has also been linked to the chronic inflammatory diseases ulcerative colitis 
(UC) and Crohn's disease [102]. While the development and progression of these 
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conditions are multifaceted and include genetic, environmental and immunogenic 
factors, a significant association between a single nucleotide polymorphism (SNP) 
in the ECM1 gene (rs3737240) and the development of the two conditions has been 
established [113]. However, the functional impact of this SNP has not yet been 
elucidated. 
 
1.6.3  ECM1 in cancer 
In contrast to the loss of ECM1 function in human diseases, high ECM1 expression 
has been reported in a number of carcinomas including thyroid, biliary, 
hepatocellular, laryngeal and breast [114, 115, 116 , 117]. While the precise nature of the 
role of ECM1 in carcinogenesis is not clear, it has been linked to a number of pro-
carcinogenic pathways. The application of ECM1 to chorioallantoic membranes of 
chicken embryos was seen to promote new blood vessel growth (angiogenesis) on 
a level comparable to that seen when membranes are treated with vascular 
endothelial growth factor (VEGF) [93]. Angiogenesis is considered a turning point in 
tumour development, when previously slow growing and localised tumours may 
become more invasive with rapid growth [93]. Thus, it is possible that ECM1 
contributes to tumour progression and metastasis by its involvement in this process. 
The role of ECM1 in angiogenesis may be attributed to its interactions with other 
proteins. For example, ECM1 has been reported to interact with the vascular 
regulator, perlecan [94]. This indicates a possible co-regulatory role for ECM1 in 
blood-vessel development.  
 
ECM1 may also play a role in metastasis. A correlation between ECM1 and 
metastatic potential of hepatocellular carcinoma (HCC) was reported in 2011 [118] 
and in a later study a similar correlation was observed in laryngeal cancer [119]. 
ECM1 has also been shown to have a potential role in breast cancer metastasis, 
with breast cancer cell lines overexpressing ECM1 having increased rates of 
migration and invasion as seen by the transwell assay [120].  
 
ECM1 may contribute to metastasis by its involvement in lymphatic vessel 
development (lymphangiogenesis) as ECM1 and vascular endothelial growth factor 
c (VEGF-c) have been seen to have a synergistic effect in promoting 
lymphangiogenesis in human breast cancer [121]. Further evidence that ECM1 is 
involved in the metastatic process comes from a positive correlation between matrix 
metallopeptidase 9 (MMP9) activity and ECM1 expression [122].  The proteolytic 
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activity of MMP9 causes degradation of many components of the extracellular 
matrix allowing tumours, no longer contained by an intact basement membrane, to 
invade surrounding tissues eventually leading to metastatic spread [122]. 
Furthermore, cleavage of collagen IV by MMP9 exposes a cryptic epitope that is 
known to increase angiogenesis [90] thus it is reasonable to propose that an 
interaction between ECM1 and MMP9 may not only lead to an increase in 
metastatic potential but may also promote angiogenesis. ECM1 has also been 
shown to influence cell proliferation [93, 122]. Increased proliferation rates have been 
demonstrated in both healthy endothelial cells transfected with recombinant ECM1 
and breast cancer cell lines overexpressing ECM1 [93, 122]. 
 
Two proteins that have been reported to physically interact with ECM1 in breast 
cancer are EGFR and MUC1 [122]. EGFR, also known as ERBB1, is a member of 
the ERBB family of tyrosine kinase receptors which includes three other receptors 
ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4 all of which are the products of 
the c-erbB oncogenes [55]. EGFR is encoded by the proto-oncogene c-erbB-1 
located on chromosome 7 [123]. Like the other receptors of this family, EGFR has a 
highly conserved intracellular domain with several phosphorylation sites and kinase 
activity. EGFR also contains an extracellular ligand binding region which is less well 
conserved between members of the ERBB family of receptors. There are seven 
known ligands for EGFR: epidermal growth factor (EGF), transforming growth factor 
alpha (TGF- α), amphiregulin (AREG), heparin binding EGF like factor (HB-EGF), 
betacellulin (BTC) epiregulin (EPR), and epigen (EPGN) [55].  
 
Upon activation by a ligand, conformational changes are induced resulting in the 
homo or hetero-dimerisation of two ERBB receptors [55]. Intrinsic kinase activity of 
one receptor in the dimer, phosphorylates specific residues present on the 
intracellular region of the other receptor [124, 125]. This provides a scaffold which can 
recruit effector proteins and activate downstream signalling pathways including the 
PI3K/PTEN/AKT, Ras/Raf/MEK/ERK, Src/FAK and JAK/Stat pathways [125, 126]. 
Pathway activation ultimately results in transcriptional activation of genes involved 
in cell proliferation, migration, differentiation and decreased apoptosis [127]. EGFR 
overactivation as a result of overexpression, mutation, decreased inhibition or 
increased ligand availability has been observed in a number of carcinomas and is 
often related to poorer survival [128]. Overexpression of EGFR has been described in 
a number of epithelial malignancies including lung, breast and colon cancer [55, 129-
131].  
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There have been several studies suggesting that EGFR overexpression also plays 
an important role in the development and progression of bladder cancer [55-58]. 
Normal urothelium expresses relatively low levels of EGFR [132]. In contrast, 
approximately half of all bladder tumours overexpress EGFR [59] and there is a 
significant association between EGFR expression and prognostic factors including 
reduced differentiation and invasion of the muscularis propria [55]. EGFR 
overexpression has also been associated with poorer survival in patients [133] and 
with increased recurrence following adjuvant chemotherapy for the treatment of 
advanced MIBC [134]. EGFR-targeted agents have had limited success in current 
ongoing clinical trials due to acquired resistance [59]. The association between 
EGFR overexpression and cisplatin resistance has highlighted the potential need 
for kinase inhibitors or monoclonal antibody treatments targeting the receptor to be 
used in combination with cisplatin-based treatments [59]. 
 
1.6.4 MUC1 
MUC1 is part of a family of proteins known as mucins [135]. These are large highly-
branched, high molecular weight glycoproteins that fall into three categories: 
membrane-associated mucins, gel-forming-secreted mucins, and soluble-secreted 
mucins [136]. MUC1 is a membrane-associated mucin encoded by a gene mapping 
to 1q21 [135]. While MUC1 is typically expressed in basal epithelial cells, in the 
urothelium MUC1 is expressed only in the apical membranes of superficial umbrella 
cells where it not only acts as a physical barrier between the urine and urothelial 
cells [137] but also plays an important role in cell adhesion and morphogenetic signal 
transduction [136]. 
 
Changes in the gene expression, rate of synthesis, and glycosylation patterns of 
MUC1 have been reported during malignant transformation of epithelial cells 
[138]. These changes can lead to multiple pro-carcinogenic effects, for example, 
overexpression of MUC1 is associated with reduced cell-to-cell adhesion, which is 
associated with more metastatic and invasive tumours [139]. Furthermore, changes in 
glycosylation of the extracellular domain have been reported to impact host immune 
recognition of tumours through alterations to the immunogenic epitopes that are 
displayed [135]. High protein expression of MUC1 as determined by 
immunohistochemistry has shown that MUC1 is overexpressed in over 90% of 
breast carcinomas, and high expression has been associated with poorer prognosis 
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in a number of carcinomas including ovarian, lung, colon, and pancreatic 
carcinomas [140]. 
 
Several studies have associated altered MUC1 expression with bladder cancer. 
Expression of MUC1 is normally confined to umbrella cells in healthy tissue but in 
nearly 75% of bladder carcinomas moderate staining of MUC1 can also be 
observed in the basal and intermediate layers of the urothelium [135, 141]. High levels 
of MUC1 expression are associated with multifocality [142] and higher-grade tumours 
[143]. Despite links between altered MUC1 expression and the invasiveness of 
bladder tumours, there is no association between MUC1 expression and patient 
outcome [143] or pathological stage of bladder cancer [135]. The majority of muscle-
invasive bladder tumours stain positively for MUC1, and changes in the level of 
glycosylation of MUC1 early in tumour formation may impact invasive potential of 
these tumours [135]. 
 
MUC1 has also been demonstrated to physically interact with EGFR [122, 144, 145]. Co-
immunopreciptation experiments in a breast cancer cell line showed that MUC1 can 
physically interact with EGFR and HER3, and these interactions were increased in 
cells overexpressing ECM1 or in cells treated with recombinant ECM1 [122]. 
Moreover, this study also established a physical interaction between ECM1 and 
EGFR, and ECM1 was seen to increase the half-life of EGFR and HER3, implying 
that ECM1 stabilises these receptors both through direct interaction with EGFR, 
and the promotion of interactions between MUC1, EGFR and HER3 [122]. Galectin 3 
(gal-3) has also been demonstrated to interact with MUC1 and facilitate EGFR-
MUC1 interactions [122, 144], and high ECM1 expression has been correlated with 
increased gal-3 secretion and increases in protein expression levels of MUC1 [122]. 
The sum of these findings has led to the proposal of a membrane-embedded stable 
complex formed between ECM1, MUC1 and EGFR which may mediate 
trastuzumab-resistance in the breast cancer cell line BT-474 TR (Figure 1-4). This 
study also showed that siRNA knockdown of MUC1, gal-3 or ECM1 led to reduced 
p-EGFR and p-ERK expression, suggesting this complex may mediate signalling 
through the Ras/Raf/MEK/ERK pathway.  
 
The suggestion of potential interactions between ECM1, MUC1 and EGFR in breast 
cancer is of particular interest to the current study. Many similarities exist between 
the molecular features of breast cancer and bladder cancer, as highlighted by 
molecular subtyping studies [72, 74, 75]. Upregulation of EGFR is characteristic of the 
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basal subtypes of both carcinomas [86] and EGFR levels are elevated in the 
Basal/Squamous subgroup of cell lines (subgroup 2) expressing high levels of 
ECM1 and MUC1. Investigation of the complex reported by Lee et al. (2014) in 
breast cancer is, therefore, worthy of further investigation in bladder cancer. 
 
 
 
Figure 1-4: A proposed ECM1 complex in breast cancer.  
A schematic model showing the proposed complex formed by ECM1, EGFR, MUC1 and 
HER3 and the potential interactions with gal-3, MMP9 and EGF [122]. 
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1.7 Project Aims 
• To validate the existence of a subset of ECM1-high and MUC1-high bladder 
tumour-derived cell lines.  
• To evaluate ECM1 expression in primary tumours, and determine if there is 
an association between ECM1 expression and patient survival or metastatic 
potential of tumours.  
• To identify a potential interaction between the ECM1 and EGFR proteins 
and evaluate the impact of ECM1 on the activation of the EGFR pathway. 
• To investigate the phenotypic effects of ECM1 shRNA knockdown on cell 
growth, migration and wound healing capabilities of bladder tumour-derived 
cells. 
• To investigate the potential impact of shRNA knockdown of ECM1 on the 
effectiveness of therapies targeting the EGFR pathway.  
1.8 Hypotheses 
• There is a relationship between ECM1 expression and an aggressive, 
metastatic phenotype of MIBC. 
• ECM1 and MUC1 have a functional relationship in promoting this 
phenotype. 
• ECM1 enhances EGFR signalling potentially through physical interaction. 
• ECM1 influences resistance to EGFR inhibitors in MIBC. 
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Chapter 2  
Materials and Methods 
2.1 Gene expression profiling of bladder tumour-derived 
cell lines  
Total RNA from 45 bladder tumour-derived cell lines was used for whole genome 
expression profiling that was performed prior to the start of this study (Hurst et al., 
unpublished data). A pooled sample of normal human urothelial samples (NHU-
Pool) was also used in gene expression profiling experiments, and refers to a 
pooled normal sample generated by mixing together total RNA from 3 different 
normal urothelial cell lines.  
 
Total RNA was extracted from cultured cells using TRIZOL (Invitrogen, Paisley, UK) 
according to the manufacturer’s instructions. RNA was DNase-treated and cleaned 
up using a Qiagen RNeasy Mini Kit (Qiagen, Crawley, UK) according to the 
manufacturer’s instructions. Whole-genome expression profiling was performed 
using GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, 
CA, USA). 
  
2.2 Data Mining 
Human gene expression data were mined using the publicly available R2 
microarray analysis and visualisation platform (developed by Dr. Jan Koster in the 
Academic Medical Center (AMC) at the University of Amsterdam) that can be 
accessed at http://r2.amc.nl. This is a web-based interface for the statistical 
computing language ‘R’ which can be used to correlate the expression profile of a 
gene of interest in publicly available gene expression datasets. Expression profiles 
for 308 fresh-frozen urothelial carcinomas of all stages and grades [72], 116 formalin-
fixed paraffin-embedded (FFPE) muscle-invasive bladder tumours [75], 142 fresh-
frozen muscle-invasive tumours [75] and 412 fresh-frozen muscle-invasive bladder 
tumours [32] were examined. These datasets can also be accessed through the 
Gene Expression Omnibus (GEO) database at the National Center for 
Biotechnology Information (NCBI) website (GSE32894, GSE48276, GSE48075, 
and GSE97768 respectively). R2 was used to generate dendrograms by 
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hierarchical clustering of expression data from selected microarray datasets for all 
probes that detected ECM1. These were used to select IDs for patients with 
tumours overexpressing ECM1 so comparisons could be made to all other samples.  
 
The data generated from TCGA study of 412 fresh-frozen muscle-invasive bladder 
tumours [32] were used to generate Kaplan–Meier survival plots in GraphPad Prism 
version 7.00 for Mac OS X (GraphPad Software, La Jolla California USA). Survival 
data was obtained from the Memorial Sloan Kettering Cancer Centre cBioPortal 
(www.cbioportal.org). 
 
Based on R2 analysis, the IDs of samples identified as having high ECM1 
expression in the Sjödhal [72] and the Choi [75] datasets were obtained. Using 
another online platform, GEO2R, genes differentially expressed between the two 
groups were determined using the Bioconductor Linear Model for Microarray 
Analysis (LIMMA) package. Stringency settings were applied to include only probes 
that had a fold change greater than 2 and a p value less than 0.05. Venn analysis 
was conducted using Partek® Genomics Suite® software and used to identify 
genes consistently upregulated in both datasets. These genes were analysed using 
MetaCore (Thomson Reuters) to determine the pathways that were most altered in 
ECM1-high tumours 
 
2.3 Cell lines and tissue culture 
Forty-five bladder tumour-derived cell lines were used in this study (Table 2-1). Cell 
culture was performed in a BioMAT class II laminar flow hood (MAT) under sterile 
conditions. In order to avoid contamination, the working surface of the hood was 
cleaned with 2% Trigene (Medichem) then 70% ethanol before and after each use. 
Cell density and cell morphology was observed routinely with a phase-contrast light 
microscope. Pictures were obtained using a Zeiss Axiovert 10 microscope with a 
Canon Powershot G6 7.1 Megapixel camera.  
 
Cells were removed from liquid nitrogen storage and rapidly thawed in a water bath 
at 37 °C. Cells were recovered into 10 ml of growth medium appropriate for each 
cell line (Table 2-1) and pelleted by centrifugation at 1000 x g for 4 min. The formed 
cell pellet was re-suspended in 5 ml medium and transferred to 25 cm2 vented 
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canted-neck cell culture flasks (Corning). All cell lines were grown under standard 
cell culture conditions in a humidified incubator (Sanyo) at 37 °C in 5% CO2 in air in 
media outlined in Table 2-1. 
 
Cells were routinely passaged once 90% confluence was reached. Medium was 
aspirated from cell flasks, and cells were rinsed once in phosphate-buffered saline 
(PBS). Cells were incubated in PBS containing 0.1 % ethylenediaminetetraacetic 
acid (EDTA) at 37 °C for 5 min after which the PBS-EDTA was subsequently 
aspirated and cells were incubated for 5 min in 0.5 ml 0.05% trypsin-versene -
0.02% EDTA in PBS (TV) (Sigma Aldrich) for a 25 cm2 flask, or 1 ml TV for a 75 
cm2 flask, until cells became detached. Inhibition of TV was achieved by 
resuspension of the cells in 15 ml fresh media containing 10% serum and culturing 
was continued with a fraction of this cell suspension being transferred to a 75 cm2 
vented canted-neck cell culture flask (Corning) containing fresh medium. For cells 
cultured in media containing less than 10% serum, cells were resuspended in 10 ml 
media containing 1 ng/ml of trypsin inhibitor (TI) (Sigma). Cell suspensions were 
centrifuged at 1000 x g for 4 min and the formed cell pellet was resuspended in 10 
ml medium. A fraction of this cell suspension was transferred to a 75 cm2 flask 
containing fresh medium and cell culture was continued. Cells were cultured for no 
more than 10 passages from thawing. All LUCC cell lines were cultured in Corning 
Primaria vented canted-neck cell culture flasks which have a modified polystyrene 
surface (Corning). 
 
2.4 Cell counting  
For assays in which a specific number of cells per well was required, cells were 
counted prior to seeding in plates. Cells were harvested and a single cell 
suspension was produced as outlined in section 2.3. 100 μl of the cell suspension 
was then added to 10 ml ISOTON™ and cells were counted using a Beckman 
Coulter Z2 Cell and Particle Counter (Beckman Coulter). Counts were performed in 
triplicate and an average reading used. 
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Table 2-1: Media and supplements required for cell culture.  
An overview of all cell lines used in the project and the medium and supplements they were 
cultured in. Standard cell culture conditions of 37 °C in 5% CO2 in air were used for all cell 
lines.  
  
Cell Lines Media Media Supplements  
DSH1, JO’N, SD, SW-1710, 
RT112M, 5637, KU-19-19, 
JMSU-1, HCV 29 
RPMI 1640 medium (Sigma) 10% fetal bovine serum (FBS) 
1% L-glutamine (L-glut) 
TCC-SUP, T24, CAL-29, UM-
UC-3, VM-CUB1, VM-CUB2, 
VM-CUB3, 639V, 647V, SW-
780, BFT905, BFT909 
Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma) 
10% FBS 
1% L-glut 
LUCC1, LUCC2, LUCC3, 
LUCC4, LUCC5, LUCC7 
Nutrient mixture F12 (Ham) 
(Gibco) 
1% FBS 
1% Insulin-Transferrin-
Selenium  
Hydrocortisone (1 µg/ml) 
1% Non-essential amino acids 
Cholera toxin (30 ng/ml) 
HT-1376, SCaBER, HT-1197, 
J82, MGH-U3 
Modified Eagle’s Medium 
(MEM) (Sigma) 
10% FBS 
1% L-glut 
1% Non-Essential Amino Acids 
RT4, BC3C McCoy’s 5A Modified Medium 
(Sigma) 
10% FBS 
1% L-glut 
253J 50% Dulbecco’s Modified 
Eagles’s Medium (DMEM) 
(Sigma), 50% RPMI 1640 
medium (Sigma)  
5% FBS 
1% L-glut 
U-BLC1 66% Dulbecco’s Modified 
Eagles’s Medium (DMEM) 
(Sigma), 33% RPMI 1640 
medium (Sigma) 
5% FBS 
1% L-glut 
92-1, 94-10, 96-1, 97-7, 97-18, 
97-1, 97-24 
Nutrient mixture F12 (Ham) 
(Gibco) 
1% FBS 
1% Insulin-Transferrin-
Selenium  
Hydrocortisone (1 µg/ml) 
1% L-glut  
1% Non-essential amino acids 
LUCC6, LUCC8, TERT-B Keratinocyte Growth Medium 
(Kit 2) (PromoCell) 
1% FBS 
Bovine Pituitary Extract (4 
µl/ml) 
Recombinant Human 
Epidermal Growth Factor 
(0.125 ng/ml) 
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2.5 Single cell cloning 
In order to assess the heterogeneity of ECM1 expression in cell populations, cell 
lines cloned from a single cell were generated using the HT-1376 cell line. When 
90% confluency was reached, cells were harvested from 75 cm2 flasks as described 
(section 2.3) and counted using the Beckman Coulter Z2 Cell and Particle Counter 
(Beckman Coulter) as previously outlined (section 2.4).  Cells were resuspended in 
media at a concentration of 1 cell per 100 µl. To each well of a 96-well plate 
(Corning), 100 µl of cell suspension was added and plates were incubated in a 
humidified incubator for 1 hour at 37 °C in 5% CO2 in air to allow cells to attach. 
Each well was examined using phase-contrast light microscopy to confirm the 
presence of a single cell. The media in these wells was changed every 4 days. 
Once 90% confluency was reached, cells were detached as previously described 
(section 2.3) and resuspended in 1 ml fresh media. This cell suspension was then 
transferred to a single well of a 24-well plate (Corning) and cell culture continued 
with media being changed every 3-4 days. Cells were passaged when 90% 
confluency was reached, and all cells from each well were transferred into a single 
well of a 6-well plate (Corning). When 90% confluency was reached in the 6-well 
plate, cells were again passaged, this time into 25 cm2 vented canted-neck cell 
culture flasks (Corning).  
 
2.6 Total RNA extraction  
Total RNA was extracted from the bladder tumour-derived cell lines when 70% 
confluency was reached. To each 75cm2 flask, 350 μl of RNeasy Lysis Buffer (RLT) 
(Qiagen) containing 1% beta-mercaptoethanol was added and cells were incubated 
on ice for 1 min. A cell scraper was used to detach lysed cells from the flask surface 
and crude lysate was transferred to 1.5 ml microcentrifuge tubes and frozen at -80 
°C for up to 3 months prior to total RNA extraction carried out using a Qiagen 
RNeasy kit (Qiagen).  
 
Crude lysate was thawed on ice then one volume of 70% ethanol was added and 
the sample was transferred to an RNeasy MinElute spin column sitting in a 
collection tube. Samples were centrifuged for 15 s at 8000 x g in a microcentrifuge 
and flow through discarded. To each column, 350 μl of RW1 buffer was added and 
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samples were centrifuged for 15 s at 8000 x g in a microcentrifuge and flow through 
discarded. Two further washes were carried out using 500 μl RPE Buffer (Qiagen) 
each time with samples being centrifuged first at 8000 x g in a microcentrifuge for 
the first wash step then at 13,000 x g for 1 min in a microcentrifuge for the second 
wash step.  Columns were then transferred to new collection tubes and centrifuged 
at 13,000 x g for 1 min to remove excess wash buffer and to dry the columns. The 
columns were then placed into a new 1.5ml microcentrifuge tubes and 30 μl RNase-
free water was added. Columns were spun in a microcentrifuge at 13,000 x g for 1 
min to elute the RNA. Total RNA was quantified using a Nanodrop 8000 UV-Vis 
spectrophotometer (LabTech) measuring light absorbance at a wavelength of 260 
nm in order to determine the samples’ concentrations and purity. RNA was stored at 
-80 °C for up to 1 year. 
 
2.7 cDNA synthesis 
First strand cDNA was synthesised using the SuperscriptTM II RT system 
(Invitrogen) according to the manufacturer’s instructions. Reactions containing 10 μl 
total RNA (100 ng/µl stock), 1 μl random primers (250 ng/µl stock) and 1 μl dNTPs 
(10 mM stock) were mixed gently with a pipette and denatured in a heat-block at 65 
°C for 5 min. Samples were placed immediately on ice. To each sample 4 μl 5x First 
Strand Buffer (Invitrogen), 2 μl DTT ( 0.1M stock) (Invitrogen), 40 U RNaseOUTTM 
(Invitrogen), and 200 U SuperscriptTM II RT (Invitrogen) were added. Reactions 
were incubated in a water bath at 42 °C for 50 min followed by a heat inactivation 
step at 70 °C for 15 min in a heat-block. cDNA was diluted 1 in 5 by addition of 80 
µl of molecular biology grade water prior to storage at -80 °C. Samples were stored 
in 20 µl aliquots to avoid repeated freeze thawing. 
 
2.8 qRT-PCR 
Quantitative real time polymerase chain reaction (qRT-PCR) analysis of gene 
expression was carried out using Taqman Gene Expression Assays (Applied 
Biosystems). Template cDNA was synthesised as previously described (section 
2.7). Reactions were carried out in a total volume of 20 μl containing 10 μl 2x 
TaqMan® Gene Expression Master Mix (Applied Biosystems), 1 μl TaqmanTM gene 
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expression assay (ECM1 [H00189435_m1{; MUC1 [H001159357_m1]; or SDHA [H 
H00417200_m1]) (Applied Biosystems), 2 μl cDNA sample, and 7 μl molecular 
biology grade water. Two microliters of molecular biology grade water was used in 
place of cDNA for PCR negative controls. Expression was normalised relative to the 
expression of a succinate dehydrogenase complex flavoprotein subunit A (SDHA) 
control and measured relative to the NHU-pool sample (section 2.1). Reactions 
were performed in triplicate in 96-well optical plates (Applied Biosystems) and run 
on a QuantStudio 5 Real-Time PCR System (ThermoFisher Scientific) with cycling 
conditions set as follows: initial 2 min hold at 50 °C, followed by 95 °C for 10 min 
then 40 cycles of 95 °C for 15 s and 60 °C for 1 min. 
 
2.9 DNA extraction and quantification 
DNA was extracted using the QIAamp DNA mini kit (Qiagen) according to 
manufacturer’s instructions. DNA was extracted from the bladder tumour derived 
cell lines when 70% confluency was reached. Medium was aspirated from one T75 
flask and cells were washed twice with PBS. Cells were harvested with trypsin as 
outlined in section 2.3. Harvested cells were collected in a 1.5 ml microcentrifuge 
tube and centrifuged at 300 x g for 5 min to pellet cells. The cell pellet was 
resuspended in 200 µl PBS and 20 µl of proteinase K was added (Qiagen). To each 
sample, 200 µl of Buffer AL (Qiagen) and the samples were pulse-vortexed for 15 s 
to ensure a homogenous suspension was achieved prior to incubation in a heat-
block at 56 °C for 10 min. Samples were briefly centrifuged and 200 µl of 100% 
ethanol added before they were pulse-vortexed for 15 s and briefly centrifuged. 
Samples were transferred to a QIAamp Mini spin column (Qiagen) placed in a 1 ml 
collection tube and centrifuged at 6000 x g for 1 min. The flow through was 
discarded and columns placed in new 2 ml collection tubes. To each collection tube, 
500 µl of Buffer AW2 (Qiagen) was added and samples were centrifuged at 20, 000 
x g for 3 min. The flow through was discarded and columns placed in a new 2 ml 
collection tubes before being centrifuged at 20,000 x g for 1 min. Columns were 
placed in 1.5 ml microcentrifuge tubes, and 200 µl of molecular biology grade water 
was added to each column. Samples were incubated for 1 min at room temperature 
(RT)  prior to being centrifuged at 600 x g for 1 min. Columns were discarded, and 
the flow through containing purified DNA was quantified using a Nanodrop 8000 
UV-Vis spectrophotometer (LabTech) measuring light absorbance at a wave length 
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of 260 nm in order to determine the samples’ concentrations. DNA was stored at -
80 °C until required.  
 
2.10 Protein extraction and quantification 
RIPA lysis buffer (1% Triton X-100, 1mM EDTA, 0.5% sodium deoxycholate, 0.1% 
SDS in PBS) was routinely used for the extraction of proteins for western blot 
analysis and coimmunoprecipitation. Cells were lysed when 70-90% confluence 
was reached. Medium was aspirated and cells were rinsed twice in cold PBS. Cells 
were lysed on ice by the addition of 250 μl RIPA buffer containing protease 
inhibitors (P8340; Sigma) and phosphatase inhibitors (P5726; Sigma). Crude 
lysates were transferred to 1.5 ml micro-centrifuge tubes and cleared by 
centrifugation at 13,000 rpm for 10 min at 4 °C. 
 
Protein concentration was determined using the Bradford protein quantification 
assay (BioRad) according to manufacturer’s instructions. 1x Bradford dye reagent 
(Biorad) was filtered through grade 1 Whatman® qualitative filter paper (Whatman). 
A set of protein standards containing 0, 0.2, 0.4, 0.6 and 0.8 mg/ml bovine serum 
albumin (BSA) (New England Biolabs) in PBS was prepared. Samples were 
prepared by adding 4 µl protein lysate to 16 µl of molecular biology grade water. To 
20 µl of each standard and protein sample, 1 ml of filtered 1x Bradford dye reagent 
was added and samples were mixed gently with a pipette. Samples were 
transferred to 1 ml spectrophotometer cuvettes (Sigma) and absorbance was 
measured at 595 nm using a SmartSpec Plus spectrophotometer (BioRad). A 
standard curve was generated using the BSA standards and this was used to 
determine the protein concentrations of the samples based on their absorbance.  
 
2.11 Western blotting 
Protein lysates were extracted and quantified from cell lines as previously outlined 
(section 2.10). Samples were diluted to a concentration of 1.5 mg/ml in a total 
volume of 100 μl in PBS containing 1x SDS loading dye (50 mM TrisHCl pH6.8, 
0.2% SDS, 6% glycerol, 0.01% bromophenol blue, and 10% beta-mercaptoethanol). 
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Twenty microliters of each protein sample (30 μg) was heated for 3 min at 100 °C 
before being loaded onto precast Any kDTM SDS-polyacrylamide gels (BioRad). 
Gels were run at 3 W per gel until the dye-front had just run off the bottom of the 
gel. Proteins were transferred to Trans-Blot® Turbo Midi Nitrocellulose membranes 
(BioRad) using the Trans-Blot Turbo Transfer System (BioRad) set on the high 
molecular weight program. Membranes were blocked using 4% w/v MPS in PBS 
containing 0.1%-Tween (PBS-T) for 30 min.  
 
All primary antibodies used in this study are shown in Table 2-2. The primary 
antibodies were diluted in 2% MPS and incubated with the blots overnight at 4 °C. 
Blots were washed four times for 15 min in PBS-T. Horseradish peroxidase (HRP) 
conjugated secondary antibodies (Goat-Antimouse HRP, Abcam; Mouse-Antirabbit 
HRP, Southern Biotech) were added at 1:3000 in 2% MPS for 2 h at RT. The HRP 
labelled antibody was visualised by chemiluminescence using Luminata Forte 
Western HRP Substrate (Merk Millipore) and imaged with a ChemiDoc MP System 
and Image Lab Software (BioRad). Blots were stripped in 50 mM Tris pH7.5, 10 M 
urea at 55 °C for 50 min before re-probing with an anti-alpha tubulin (AbD Serotec) 
primary antibody as a loading control. Detection and visualisation was carried out 
as previously described. 
 
Table 2-2: Primary antibodies used in western blot analysis.  
An overview of the primary antibodies used in western blot analysis including the species from 
which they were derived, the manufacturing company and the concentration at which they 
were used.  
Antibody name Species Company Dilution factor Type 
Anti-ECM1 
(C-12; sc-365946) 
Mouse Santa Cruz 
Biotechnology 
1:2000 Polyclonal 
Anti-MUC1 (C595; 
sc-59798) 
Mouse Santa Cruz 
Biotechnology 
1:1000 Polyclonal  
Anti-EGFR  
(A300-388-A) 
Rabbit Bethyl 
Laboratories 
1:10,000 Monoclonal 
Anti-phospho-EGFR 
(Tyr1068; D7A5) 
Rabbit  Cell Signalling 
Technology 
1:2000 Monoclonal 
Anti-ERK (K-23; sc-
94) 
Rabbit Santa Cruz 
Biotechnology 
1:1000 Polyclonal 
Anti-phospho-ERK 
(E4; Try204; Sc-
7383) 
Mouse 
 
Santa Cruz 
Biotechnology 
1:1000 Monoclonal 
Anti-MET (4560) Rabbit Cell Signalling 
Technology 
1:2000 Polyclonal 
p-HGR R/c-MER 
(Y1234/Y1235; 
AF2480) 
Rabbit R&D Systems 1:2500 Polyclonal 
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2.12 Fixation of cell pellets for immunohistochemistry  
When 80% confluence was reached in one T75 flask, cells were rinsed in PBS and 
detached from the flask using trypsin as outlined previously (section 2.3). Cells 
were re-suspended in 9 µl of the appropriate media and the cell suspension was 
transferred to a 15 ml falcon tube before centrifugation at 3000 rpm for 10 min at 4 
°C. Media was aspirated and 5 ml of 4% formalin in PBS added to the pellet 
overnight at RT. Formalin was removed and discarded, and pellets were stored in 
70% ethanol for up to 2 weeks. Pellets were removed intact from the falcon tubes, 
placed in histological cassettes (Simport), washed once in PBS, then stored in 70% 
ethanol prior to processing by Filomena Esteves in the core histology facility at the 
Leeds Institute of Medical Research. Processing was carried out using a Leica 
ASP200 Tissue Processor (Leica Biosystems) according to manufacturer’s 
instructions. Specimens were dehydrated at 37 °C in a series of ethanol 
concentrations in water: 70% ethanol for 30 min; 80% ethanol for 30 min; 90% 
ethanol for 30 min; 95% ethanol for 30 min; 100% ethanol for 1h; 100% ethanol for 
1h; and 100% ethanol for 1.5 h. Ethanol was then displaced from the samples using 
three separate incubations in xylene at 37 °C for 1 h, 1.5 h and 1.5 h, respectively. 
Specimens were infused with paraffin wax (CellPath Ltd) for 1 h at 65 °C a total of 
three times. Each sample was finally embedded in liquid paraffin wax (CellPath Ltd) 
heated to 60 °C, and once set, stored at RT until needed for sectioning.  
 
2.13 Immunohistochemistry 
Immunohistochemical (IHC) staining of FFPE tumour sections, cell pellets and 
tissue microarrays (TMAs) was carried out with the assistance of Filomena Esteves. 
Sections of paraffin embedded tumours were cut to 4 µm from formalin fixed 
paraffin embedded tissue blocks using a microtome (AS325 retraction; Thermo 
Shandon) and mounted onto SuperfrostTM microscope slides. Previously sectioned 
TMAs were kindly gifted by Professor Martha Sanchez-Carbayo (University of the 
Basque Country, Spain). Slides were heated for 20 min at 70 °C then deparaffinised 
in 100% xylene (three times for 3 min each time), rehydrated in 100% ethanol (four 
times for 1 min each time) and finally washed once in water to remove excess 
ethanol.  
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Antigen retrieval was carried out to unmask epitopes in FFPE material. Slides were 
heated in a Menarini Antigen Retrieval Unit pressure cooker (Menarini Diagnostics) 
in 1x Access Revelation Buffer solution (Menarini Diagnostics) to 125 oC for 2 min. 
Slides were briefly washed in 1x Tris-Buffered Saline (TBS) Automation Wash 
Buffer (Menarini Diagnostics). Slides were then rinsed under running water before 
washing in TBS for 30 s and Menarini Wash Buffer (Menarini Diagnostics) for 30 s. 
Endogenous peroxidase and alkaline-phosphatase activity was blocked with 2 
drops of Bloxall blocking solution (Vector Laboratories) for 10 min. Non-specific 
antigen binding was blocked by incubation in a 10% casein solution (Invitrogen) for 
20 min.  
 
The following primary antibodies were used: anti-ECM1 (C-12; sc-365946; Santa 
Cruz Biotechnology) and anti-MUC1 (C595; sc-59798; Santa Cruz) (Table 2-2). An 
IgG negative control was also used (Santa Cruz). Primary antibodies were diluted to 
1:200 in antibody diluent (Invitrogen) and applied to slides for 1 h at RT. Slides were 
washed twice in 1x TBS automation wash buffer (Menarini Diagnostics). Post-
primary HRP conjugation of antibodies was achieved using a Novocastra post-
primary blocking kit (Leica Biosystems). Slides were incubated with 2 drops of post 
primary (rabbit anti-mouse IgG) reagent (Leica Biosystems) for 30 min, then 
washed twice in 1x TBS automation wash buffer (Menarini Diagnostics) for 5 min. 
Each slide was treated with 2 drops of polymer reagent (anti-rabbit Poly-HRP-IgG) 
(Leica Biosystems) to conjugate rabbit immunoglobulins to horseradish peroxidase. 
Slides were then washed twice in TBS for 5 min. 
 
Detection was performed using DAB peroxidase substrate (Vector Laboratories). 
Two hundred microliters of ImmPACTTM DAB substrate was applied to each slide 
for 5 min. Each slide was transferred to a water reservoir for 5 min before 
counterstaining in haematoxylin for 30 s.  Slides were then washed in running water 
for 1 min, Schotts water for 1 min, 100% ethanol once for 15 s, 100% ethanol once 
for 2 min and 100% ethanol twice for 3 min, and immersed in 100% xylene (three 
times for 3 min). Coverslips were mounted on the slides with DEPEX (Fisher 
Scientific UK Ltd) and slides were visualised using an Olympus Bx50 microscope 
(Olympus Optical Co.). 
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2.14 Immunofluorescence  
Cells were grown on glass coverslips for use in immunofluorescence. Glass 
coverslips (Corning) were sterilised in 100% ethanol, air dried and placed in the 
centre of each well of a 6-well tissue-culture plate (Corning). When 80% confluence 
was reached, cells were detached from flasks and counted using the Beckman 
Coulter Z2 Cell and Particle Counter (Beckman Coulter) as previously outlined 
(section 2.4). 6 x 105 cells in a total volume of 2 ml of the appropriate medium were 
transferred to each individual well of a 6-well plate containing a coverslip. Cells 
were incubated overnight in a humidified incubator (Sanyo) at 37 °C in 5% CO2 in 
air or until 70% confluency was reached. 
 
Media was aspirated from the wells and cells were washed three times in PBS 
before fixation by the addition of 200 μl of 4% paraformaldehyde (PFA) for 20 min at 
RT. Cells were then permeabilised with 2 ml 0.1% Triton-X100 in PBS for 5 min at 
RT. Slides were then washed three times in PBS and non-specific antibody-binding 
sites blocked by incubating in 2 ml PBS containing 200 μl 0.1% MPS for 10 min.  
 
The following primary antibodies were used: anti-ECM1 (C-12; sc-365946; Santa 
Cruz Biotechnology), anti-ECM1 (N17; sc-65086; Santa Cruz Biotechnology), anti-
EGFR (199.12; AHR5072; Invitrogen), anti-EGFR (1005; sc-03; Santa Cruz 
Biotechnology), and anti-MUC1 (C595; sc-59798; Santa Cruz) (Table 2-2). Primary 
antibodies were prepared at a concentration of 1:100 in 0.1% milk powder solution 
(MPS) in PBS and centrifuged at 13,000 rpm for 5 min at RT to remove debris. 
Coverslips were removed from the wells and incubated with 200 μl of primary 
reagent, inverted on parafilm in a humidified chamber for 1 h RT, after which 
coverslips were returned to the 6-well dish and washed three times in PBS.  
 
The following secondary reagents were used: Alexa Flour 488 goat anti-mouse IgG 
(H+L) (A11029; Thermo Fisher Scientific), Alexa Flour 594 goat anti-rabbit IgG 
(A11037; Thermo Fisher Scientific), Alexa Flour 594 chicken anti-goat IgG (A21468; 
Thermo Fisher Scientific), and TRITC-conjugated phalloidin and DAPI (FAK100 
Actin Cytoskeleton / Focal Adhesion Staining Kit; Merck Millipore). Secondary 
reagents were prepared at a concentration of 1:500 in 0.1% MPS in PBS and 
centrifuged at 13,000 rpm for 5 min RT to remove debris. Coverslips were 
incubated with 200 μl of the appropriate secondary reagent, inverted on parafilm in 
a darkened humidified chamber for 1 h at RT. Coverslips were then returned to the 
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6-well dish and washed three times in PBS before being mounted on microscope 
slides with 50 μl Flouromount G (SouthernBiotech). Slides were left to set overnight 
and stored in the dark before viewing on an EVOS FL Cell Imaging System 
(Thermo Fisher Scientific).  
 
2.15 Protein precipitation from media  
Protein was extracted from cell media in order to determine if ECM1 was being 
secreted by the ECM1-high cell lines and to assess glycosylation state. When cells 
grown in a 75 cm2 flask were 40% confluent, media was aspirated and replaced 
with serum free media. After 48 h media was collected from cells and 1.2 ml was 
transferred to a 1.5 ml micro-centrifuge tube and cleared of cell debris by 
centrifugation at 13,000 rpm for 10 min at 4 °C. The media was then passed 
through a 0.45 µm pore syringe filter (Corning) to remove any remaining cell debris. 
Two-hundred and fifty microliters of trichloroacetic acid (TCA) (100% W/V) was 
added to 1 ml of cleared media and samples were incubated at 4 °C for 10 min 
before being spun at 14,000 rpm for 5 min. The supernatant was removed and an 
acetone wash step conducted by adding 200 μl ice cold acetone, centrifuging at 
14,000 rpm for 5 min, and removing and discarding the supernatant. This acetone 
wash step was repeated once more before the pellet was dried at 95 °C in a heat 
block for 10 min with the cap removed from the microcentrifuge tube. The dried 
pellet was either (1) re-suspended in 200 μl of 1x SDS loading dye in PBS, heated 
for five min at 90 °C and ECM1 protein expression analysed by western blotting as 
previously outlined or (2) was resuspended in 200 µl molecular biology grade water 
and vortexed for 5 min to resuspend prior to deglycosylation treatment (section 
2.16). 
 
2.16 Deglycosylation 
Protein extracted from cultured media was isolated as outlined above. De-
glycosylation of the secreted proteins was carried out using the GlycoProfile™ II 
Enzymatic In-solution N-Deglycosylation Kit (Sigma Aldrich) according to the 
manufacturer’s instructions. In a 1.5 ml microcentrifuge tube, 90 µl of resuspended 
secreted protein or 90 µl of RNase B Standard Positive Control (Sigma Aldrich), 
were added to 5 µl Denaturant Solution (Sigma Aldrich) and vortexed briefly. 
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Samples were heated to 100 °C in a heat block for 10 min then allowed to cool to 
RT. To each sample, 5 µl 1x Reaction Buffer (Sigma Aldrich) was added and each 
sample was divided into two 50 µl aliquots. To one aliquot 5 µl (2.5 U) of PNG F 
Enzyme (Sigma Aldrich) was added, and to the second aliquot 5 µl of molecular 
biology grade water was added as an enzyme negative control. Samples were 
incubated in a water bath at 37 °C for 2 h, then heated to 100 °C for 10 min in a 
heat block to stop the reaction. Protein quantification was conducted using the 
Bradford protein quantification assay (BioRad) and ECM1 was analysed by western 
blotting as previously outlined.  
 
2.17 Mutation screening and copy number analysis 
In order to investigate potential molecular mechanisms associated with ECM1 over-
expression, the ECM1 gene was screened for the presence of somatic mutations 
and existing copy number data covering the region containing the ECM1 gene was 
interrogated.  
 
2.17.1 Mutation screening 
Somatic mutations in the ECM1 gene were examined in the Catalogue of Somatic 
Mutations in Cancer (COSMIC), an online database 
(http://cancer.sanger.ac.uk/cosmic) that holds information of somatic mutations in 
human cancers assembled from large-scale experiments such as The Cancer 
Genome Atlas (TCGA) and scientific literature. This identified potential mutational 
hotspot positions in 3 different exons that were deemed worthy of further 
investigation. Two mutations were found in COSMIC in two or more different tumour 
samples in exons 7 and 10 (hg19 coordinates: chr1:150483939 G>A, and 
chr1:150485894 C>T, respectively). A further two mutations were identified in 
COSMIC in exon 8 that were a single base pair apart (hg19 coordinates: 
chr1:150484937 G>A, and chr1:150484939 C>T).  
 
The regions in exons 7, 8 and 10 of the ECM1 gene containing the potential 
mutations of interest identified by interrogation of the COSMIC database were 
screened by PCR and direct sequencing. Primers were designed using Primer3 
software (http://primer3.ut.ee/) [146]. The target specificity of each primer pair was 
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analysed using the online platform NCBI Primer-BLAST. Primers with the least 
ECM1 unspecific binding were selected. Primers were designed to include a 
minimum of 30 bases before and after the mutation site, and to give a total PCR 
product length of between 150 and 300 base pairs (b.p.). A list of the final primers 
selected can be found in Table 2-3. 
 
PCR was performed in a volume of 25 μl containing 1x AmpliTaq Gold buffer, 2.5 
mM MgCl2, 0.2 mM dNTPs, 5 pmoles of each primer (Table 2-3), 2.5 U AmpliTaq 
Gold (Applied Biosystems) and 10 ng of template DNA extracted as previously 
described. The following cycle parameters were used: 95 °C for 5 min followed by 
35 cycles of 95 °C for 30 s; 60 °C for 30 s; and 72 °C for 30 s. Samples were then 
incubated at 72 °C for 10 min and chilled to 4 °C. To check product length and 
efficiency of amplification gel electrophoresis was used. A gel was cast using 2% 
agarose (w/v) in 1x Tris-Boric acid-EDTA buffer (TBE) (BioRad) containing 0.25 
µg/ml ethidium bromide (Severn Biotech Five microlitres of PCR product was mixed 
with 5 µl Gel loading dye (NEB) and loaded on the gel. Ten microliters of Quick-
Load® 100 bp DNA Ladder (NEB) was also loaded as a reference to determine the 
molecular weights of the PCR products. The gel was electrophoresed in 1x TBE 
buffer at 90 V for 40 min and imaged using a Bio-Rad ChemiDoc MP.  
 
PCR products were treated with Illustra ExoProStar 1-step (Fisher Scientific) to 
remove excess deoxyribonucleotide triphosphates and primers. One microliter of 
ExoProStar (GE Healthcare Life Scienes) was added to 2.5 μl of PCR product and 
incubated at 37 °C for 15 min before heat inactivation at 80 °C for 15 min. Sanger 
sequencing was carried out in 96-well PCR plates using the primers listed in Table 
2-3 and a BigDye Terminator V1.1 Cycle Sequencing Kit (Applied Biosystems). 
Reactions contained 0.16 μM of primer (forward or reverse), 1 μl  ExoProStar-
treated PCR product, 0.25 μl 1x BigDye Terminator Ready Reaction Mix V1.1 (Life 
Technologies) and molecular biology grade water to give a total volume of 10 μl. 
The following cycle parameters were used: 96 °C for 1 min followed by 25 cycles of 
96 °C for 10 s; 50 °C for 5 s; and 60 °C for 4 min. 
 
Reactions were cleaned-up using precipitation by the addition of 1 μl sodium 
acetate (3 M) and 25 μl ice cold 100% ethanol and incubation at RT for 30 min. 
DNA was pelleted by centrifuging at 1800 x g for 1 min in a Beckman Allegra X12R 
benchtop centrifuge (Beckman Coulter) and the supernatant was discarded by 
 43 
inverting the reaction plate. Pellets were washed in 70 µl of 70% ethanol and plates 
centrifuged at 1650 x g for 15 min at 8 °C. The plates were inverted to remove 
ethanol and pellets were air dried prior to resuspension in 15 μl HiDiTM formamide 
(Invitrogen Life Technologies). Prior to capillary electrophoresis on an ABI PRISM 
3100 Genetic Analyzer (Applied Biosystems) samples were heated for 1 min at 95 
°C and snap cooled on ice. Sequencing data was analysed using 4Peaks (A. 
Griekspoor and Tom Groothuis, mekentosj.com) and visual inspection of the 
electropherograms. 
 
Table 2-3 Primers used for PCR and Sanger sequencing analysis of ECM1.  
An overview of all primers used in PCR and mutational screening by Sanger sequencing of 
regions of exons 7, 8 and 10 of the ECM1 gene.  
 
 
2.17.2 Copy number analysis 
Whole genome copy number analysis was performed on a panel of 45 bladder 
tumour-derived cell lines prior to the start of this study using Genome-Wide Human 
SNP 6.0 Arrays (Affymetrix, Santa Clara, CA USA) (Hurst et al, unpublished data). 
Five hundred nanograms of DNA from each cell line was labelled and hybridised 
according to the array manufacturer’s instructions. Data was analysed and viewed 
using Partek® Genomics Suite® software, version 6.6 (Partek Inc., St. Louis, MO, 
USA). 
 
 
Primer Name Sequence (5’ -> 3’) Melting temp 
(°C) 
Expected 
product 
length (b.p.) 
ECM1 Ex7 F1 CTGGGAGGAAGGCAGGAATG  68.1 186 
ECM1 Ex7 R1 CTGGTAGTGTGGCTGGGGAG 67 
ECM1 Ex7 F2 GGAGGAAGGCAGGAATGTGG 68 247 
ECM1 Ex7 R2 CAGGAGGGAAAGGCAGCTC 66.3 
ECM1 Ex8 F1 GAGAGAAGGGGCCAAGTGTC 65.1 297 
ECM1 Ex8 R1 GTGGGGAAGGACTAGGCAAC 64.7 
ECM1 Ex8 F2 CTGTGACCGGGAGTATGCTG 60.1 198 
ECM1 Ex8 R2 TGCTTGGTGAGAACTCTTTGGT 64.9 
ECM1 Ex10 F1 ACGTGGCTCTAGTGTCTGGA 62.6 169 
ECM1 Ex10 R1 GTTCAGATGGGTGGGGCAG 68 
 44 
2.18 Analysis of ECM1 mRNA isoform expression 
Analysis of ECM1 mRNA isoform expression was carried out in order to determine 
which ECM1 isoforms are expressed by the ECM1-high cell lines as well as an 
additional 4 bladder tumour derived cell lines not classified into the ECM1-high 
subtype, and a pooled normal human urothelial sample (NHU-Pool). Primers were 
designed using reference sequences for each isoform of ECM1 (ECM1a, ECM1b, 
and ECM1c) from The National Center for Biotechnology Information (NCBI) gene 
database (Appendix F). Using each isoform’s individual NCBI reference sequence, 
genomic sequences were cross referenced with exon sequences as denoted on the 
Ensembl genome browser in order to identify differences between exonic and 
intronic regions in the different isoforms. This revealed that isoform ECM1b did not 
contain exon 7, and ECM1c had an extended form of exon 4. Using this information, 
candidate primers were designed using Primer3 software (http://primer3.ut.ee/) [146] 
that would generate products of differing sizes for each isoform. The target 
specificity of each primer pair was analysed using the online platform NCBI Primer-
BLAST. Primers with the least ECM1 unspecific binding were selected. Details of 
these primers are given in Table 2-4. 
 
PCR was performed using the selected primers and cDNA generated from total 
RNA as previously described (section 2.7). Reactions contained 1x Q5 Reaction 
Buffer (New England Biolabs, NEB), 200 μM dNTPs, 0.05 μM forward primer, 0.5 
μM reverse primer, 1.25 U Q5 Hot Start High-Fidelity DNA Polymerase (NEB) and 1 
μl cDNA sample in a total reaction volume of 25 μl made up with molecular biology 
grade water. One microliter of molecular biology grade water was used in place of 
cDNA for PCR negative controls. The following cycle parameters were used: 98 °C 
for 30 s followed by 30 cycles of 98 °C for 10 s; 58 °C for 30 s; and 72 °C for 30 s. 
Samples were then incubated at 72 °C for 2 min and chilled to 4 °C.  
 
PCR products were analysed using gel electrophoresis to check product length and 
efficiency of amplification. Five microliters of PCR product was mixed with 5 µl of 
Gel loading dye (NEB) and loaded on a 2% agarose-TBE gel. The gel was 
electrophoresed in 1x TBE buffer at 90 V for 40 min and imaged using a Bio-Rad 
ChemiDoc MP.  
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Table 2-4: Primer pairs used to determine ECM1 isoform expression and the 
expected product size for each isoform.  
   
Primer 
Pair  
Primer 
Name 
Sequence (5’ -> 3’) Tm 
(ºC) 
Exon 
location  
Product Length (bp) 
ECM1a ECM1b ECM1c 
1 1F GGATCACCCTGACTCCTCTC 58.75 3 130 130 211 
1R CTTTTCAGCAGGGAGTTGGG 58.59    5 
2 2F CCCCACCCCTATCCCGAA 60.04 3 0 0 144 
2R GTGAGCAGCCCACCCTTT 59.88 4 
3 3F CACAAACCGCCTAGAGTGTG 58.85    6 204 0 204 
3R CCCGAGGAAATATCAGGCTG    57.82    7 
4 4F CACAAACCGCCTAGAGTGTG 58.85 6 447 72 447 
4R GCATACTCCCGGTCACAGTA 58.89    8 
5 5F CCCAACTATGACCGGGACAT 59.16 8 136 136 136 
5R GGGCAGTCATGTTGTGGATC 58.90    9 
6 6F GCCTAGAGTGTGCCAAACTT 58.10 6 541 166 541 
6R ATGTCCCGGTCATAGTTGGG 59.16 8 
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2.19 Puromycin selection dose curves 
The lowest concentration of puromycin required to kill 100% of cells was 
determined for each cell line chosen for ECM1 knockdown experiments (section 
2.20). Cells were cultured as previously described and counted using the Beckman 
Coulter Z2 Cell and Particle Counter (Beckman Coulter). Cells were seeded at 
250,000 cells per well in two 6 well dishes for each cell line, and cultured for 48 h 
before 2 ml of media containing puromycin was introduced across a range of 
concentrations (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1, 1.5, 2, or 3 µg/ml). Media 
containing puromycin was changed every 3 days. After 7 days cells were rinsed 
twice with PBS and 0.5 ml of methylene blue added to each well for 15 minutes. 
Plates were rinsed three times in water or until the water ran clear and were then 
dried upside down. Images were taken with a 13 megapixel autofocus camera 
(Huawei). The lowest concentration of puromycin that killed all of the cells was 
chosen as the selection dose for short hairpin RNA (shRNA) knockdown studies. 
 
2.20 shRNA knockdown of ECM1  
shRNA plasmid DNAs were purchased from Sigma Aldrich. shRNA sequences 
were cross referenced with ECM1a, ECM1b and ECM1c gene sequences obtained 
from NCBI and analysed using NCBI BLAST. Three plasmids targeting all three 
isoforms of ECM1 and predicted to have the least ECM1 unspecific binding were 
selected. Details of these shRNA plasmids can be found in Table 2-5 and a plasmid 
map of the vector can be found in Figure 2-1.  
 
 
Table 2-5: shRNA constructs used for ECM1 knockdown. 
The sequence for each shRNA used in the ECM1 knockdown studies, the regions they target, 
and their abbreviated names are shown. CDS refers to coding DNA sequence, 3’UTR refers 
to the three prime un-translated region. 
Clone ID Target Sequence (5’ -> 3’) Vector Region Abbreviation 
in text 
TRCN0000059575 CAACTGCTTCAACATCAATTA pLKO.1 CDS KD1 
TRCN000037051 CTGAACACTCATTACACTAAA pLKO.1 3’UTR KD2 
TRCN0000059576 CGCTGCTGTGACCTGCCATTA pLKO.1 CDS KD3 
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Glycerol stocks of shRNA plasmids were made using an Agilent General Cloning kit 
as per manufacturer’s instructions. Two-hundred microliters of XL1-Blue Competent 
Cells (Agilent) were gently mixed with 1.85 μl β-Mercaptoethanol (1.42 M, Agilent) 
and left on ice for 10 min. Fifty microliters of the competent cells were added to 14 
ml BD Falcon polypropylene round-bottom tubes and 20 ng shRNA plasmid (Sigma) 
was added before incubation on ice for 30 min. Cells were heat-shocked in a 42 °C 
water bath for 45 s before being placed immediately on ice for a further 2 min. Off 
ice, 500 μl Super Optimal broth with Catabolite repression (SOC) medium was 
added to each tube and samples were incubated at 37 °C for 45 min in a shaking 
incubator. Ten microliters of transformed cells were plated on 1.5% agar (w/v) 
plates in Lysogeny broth (LB)* (1% Tryptone (w/v); 1% NaCl (w/v); 0.5% yeast 
extract (w/v)) containing 1 μg/ml ampicillin that were prepared 12 h previously. 
Plates were incubated at 37 °C for 12 h.  
 
Isolated colonies of transformed cells for each of the shRNAs were picked and used 
to inoculate 5 ml of LB containing 1 μg/ml ampicillin which was then incubated at 37 
°C for 8 h in a shaking incubator. One millilitre of cell culture was added to 150 ml 
LB containing 1 μg/ml ampicillin and incubated for a further 12 h at 37 °C in a 
shaking incubator. The cell cultures were centrifuged at 6000 rpm for 20 min at 4 °C 
in a Beckman J2-21 floor model centrifuge (Beckman Coulter) and supernatant 
discarded. Plasmids were isolated from cell pellets a using PureYield™ Plasmid 
Maxiprep System (Promega) according to the manufacturer’s instructions. Pellets 
were re-suspended in 12 ml of re-suspension buffer (Promega), before 12 ml of 
lysis buffer (Promega) was added. Cells were lysed for 2 min before 12 ml of 
neutralising buffer (Promega) was added and samples centrifuged at 14000 x g for 
20 min at 21 °C. The supernatant was collected and purified by filtering through a 
PureYield™ Clearing Column (Promega). The flow through was added to a 
PureYield™ Maxi Binding Column (Promega) stacked on a vacuum manifold and 
maximum vacuum was applied. Twenty millilitres of Column Wash was added to the 
binding column and the vacuum applied until the membrane was dry. DNA was 
eluted into 1.5 ml microcentrifuge tubes by adding 1 ml of nuclease-free water to 
the binding column. DNA was quantified using a Nanodrop 8000 UV-Vis 
                                            
* The acronym LB can also interpreted as Luria broth, Lennox broth, or Luria-Bertani 
medium, however I am using the term “Lysogeny broth” as originally intended by its 
creator Giuseppe Bertani [147]. 
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spectrophotometer (LabTech) measuring light absorbance at a wavelength of 260 
nm in order to obtain the samples’ concentrations.  
 
Cell lines from the ECM1-high subgroup were chosen for mRNA knockdown and 
functional studies. These cell lines were HT-1376, LUCC4, HT-1197 and 647V. 
Lentiviral particles containing the purified shRNA plasmids were synthesised in HEK 
293-FT cells to transduce these cell lines. Briefly, in a 1.5 ml microcentrifuge tube, 
750 µl opti-MEM medium, 1 µg PLKO.1 shRNA plasmid, 1 µg pCMV-dR8.2 dvpr 
packaging plasmid, 200 ng pCMV-VSV-G envelope plasmid and 8 µl TransIT-293 
were mixed gently prior to incubation at RT for 30 min.  
 
HEK 293-FT cells were cultured under standard conditions (section 2.3) and split 
into one 25 cm2 flask for each transduction with ECM1 knockdown shRNAs or with 
one of the three control vectors representing a scramble control vector in which the 
shRNA does not target any known genes, or a non-hairpin (NHP) control which 
does not form a hairpin when transcribed (Sigma). Once 60% confluence was 
reached the lentiviral components described above were added to each flask and 
rocked gently for 1 minute to allow mixing. Cells were incubated overnight before 
the media was changed. Media was harvested at 24 h and 48 h and the harvests 
were pooled. Pooled media was filtered through a 0.45 µm pore syringe filter to 
remove cell debris, and divided into 1 ml aliquots. Aliquots were frozen at -80 °C 
until needed.  
 
Cell lines to be transduced were cultured in 25 cm2 flasks as previously outlined. 
Once 60% confluence was reached media was aspirated and 4 ml of media 
containing 1 ml shRNA lentivirus was added. The cell lines HT-1376, HT-1197, and 
647V were incubated with lentivirus overnight before media containing virus was 
removed and fresh media was added to each flask. Cells were cultured for a further 
24 h prior to puromycin selection. For the LUCC4 cell line, cells were incubated in 
media containing lentivirus for 5 h before virus was removed from the flasks and 
media was changed. Cells were incubated for 24 h in media without virus, before 
virus was re-introduced for a further 5 h.  Cells were then incubated for 72 h in 
media containing no virus before puromycin selection.  
 
Cells were incubated in media containing selection concentrations of puromycin as 
determined previously for 7 days or until all cells in the control flask that had not 
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been infected with virus were dead. After this, cells were maintained as previously 
outlined with the addition of maintenance concentrations of puromycin which were 
determined to be half that of the selection concentration. Cells were removed from 
puromycin for 24 h prior to lysate (protein or RNA) preparation.  
in ECM1 overexpressing samples. 
 
 
 
Figure 2-1: A schematic representation of the pLKO.1 shRNA carrying vector 
used in this study.  
As well as shRNA targeting ECM1 or controls, the following genes were also present in the 
plasmid: central polypurine tract (cppt) which improves transduction efficiency as it facilitates 
the lentiviral preintergration complex (PIC) import into the host cell’s nucleus; human 
phosphoglyceratekinase (hPGK) eukaryotic promoter which drives transcription of the 
puromycin resistance gene (puroR) for selection of cells successfully transduced with the 
pLKO.1 plasmid; SIN/3’ LTR 3’ - self inactivating long terminal repeat; f1 origin (f1 ori) of 
replication; ampicillin resistance (ampR) gene for selection of the presence of the pLKO.1 
plasmid in bacterial cells during the generation of glycerol stocks ; pUC bacterial origin of 
replication (pUC ori); 5’ LTR -  5’ long terminal repeat; Psi - RNA packaging signal; RRE - Rev 
response element; U6 promoter region that drives transcription and thus the generation of the 
shRNA transcripts by RNA polymerase III. This figure was adapted from “Mission RNAi: 
Vector Maps” (Sigma) retrieved 25.07.18 from: <https://www.sigmaaldrich.com/life-
science/functional-genomics-and-rnai/shrna/library-information/vector-map.html>. 
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2.21 Growth curve 
Cells were seeded at a density of 5 x 103 cells per well in 2 ml media in 6-well 
plates. Plates were incubated under standard conditions and media was changed 
every three days. Cells were counted on days 1, 4, 7, 10, 13, 16, 19 and 21 as 
previously outlined in section 2.4. Triplicate wells were plated for each cell line and 
readings were carried out in triplicate per well. 
 
2.22 Wound healing assay  
Cells were seeded in triplicate into 6-well plates at a cell density of 5 x 105 cells per 
well in 2 ml media appropriate for each cell line. Cells were incubated under 
standard conditions overnight or until 100% confluence was reached. Samples to be 
treated with recombinant ECM1 were seeded in triplicate into 6-well plates at a cell 
density of 4 x 105 cells per well in 2 ml media appropriate for each cell line. Cells 
were incubated under standard conditions for 8 h. Recombinant ECM1 (R&D 
Systems™: 3937-EC) was reconstituted in PBS to 100 µg/ml. Recombinant ECM1 
was added to the samples at a final concentration of 100 ng/ml, 200 ng/ml, 300 
ng/ml, 400 ng/ml, 500 ng/ml, 750 ng/ml, 1 µg/ml, or 2 µg/ml in 2 ml media 
appropriate for each cell line. Cells were incubated under standard conditions 
overnight when 100% confluence was reached. A sterile 30 μl pipette tip was used 
to create a cross patterned scratch in the confluent monolayer in each well. Images 
were captured using a Zeiss Axiovert 10 microscope with a Canon Powershot G6 
7.1 Megapixel camera at 0 h, 24 h and 48 h. Plates were marked to ensure the 
images were captured across the same region of the scratch at each time point. 
Three images were taken per well.  
 
Images were analysed using ImageJ software with the MRI wound healing macro 
add on to calculate wound area. Percentage differences in wound area over time 
were calculated as follows: 
 (#$%&'	)*+)	),	0	ℎ − 	#$%&'	)*+)	),	24	ℎ	$*	48	ℎ)#$%&'	)*+)	),	0	ℎ 	× 	100 
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Ordinary one-way ANOVA with post analysis multiple comparisons was performed 
on the data to determine statistical significance between samples using GraphPad 
Prism 7.0 software.  
 
2.23 Transwell assay  
Falcon® Permeable Supports with 8.0 μm pore size transparent PET membranes 
(Corning) were placed in 24 well plates containing 500 µl serum-supplemented 
media appropriate to each cell line (Table 2-1) to act as a chemoattractant and 
encourage cell migration through the insert pores. Cells cultured in 75 cm2 flasks 
were detached when 70% confluency was reached and counted as described in 
section 2.4. Cells were seeded into inserts at 5 x 104 cells per well in 200 µl serum 
free media and incubated in a humidified incubator (Sanyo) under standard 
conditions for 24 h.  
 
Media was aspirated from both the wells and inserts, and each insert was washed 
once in PBS. A cotton swab was used to remove all cells from the interior surface of 
each insert and cells were fixed by the addition of 4% formalin. Plates were 
incubated at RT for 15 min to fix cells. Formalin was aspirated and inserts were 
washed twice in PBS. Inserts were incubated in 0.2% crystal violet in 2% ethanol for 
10 min at RT. Inserts were airdried and viewed using phase-contrast light 
microscopy. Cells were counted from five random 1 mm2 sections of the insert and 
an average reading taken. 
 
2.24 Co-immunoprecipitation 
SureBeads™ Protein G and Protein A Magnetic Beads (Biorad) were prepared 
according to the manufacturer’s instructions. One hundred microliters of beads were 
transferred to 1.5 ml microcentrifuge tubes and washed three times in PBS-T by 
adding 200 μl PBS-T vortexing briefly, concentrating the beads using a magnet and 
removing the supernatant. One to two micrograms of antibody was diluted to a final 
volume of 200 μl with molecular biology grade water. Diluted antibodies were added 
to washed beads and then rotated at RT for 1 h. The following antibodies were 
used: anti-ECM1 (C-12; sc-365946; Santa Cruz Biotechnology), anti-EGFR (A300-
388A, Bethyl Laboratories Inc.), anti-BAD (C-20, sc-943, Santa Cruz), and anti-Sv-
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40 T Ag (sc-147, Santa Cruz). After 1 h tubes were removed from the tube rotator 
and the beads were concentrated using a magnet. The supernatant containing 
unbound antibody was removed and the beads were washed four times in PBS-T 
as previously described. 
 
Cells were cultured to 70-90% confluence, medium was aspirated and cells were 
rinsed twice in ice cold PBS. If crosslinking was conducted, 10 ml of 1 mM 3,3'-
Dithiobis(sulfosuccinimidylpropionate) (DTSSP) was added to each flask for 30 min, 
followed by a 15 min treatment with 1M Tris 7.5 pH to stop the reaction. Cells were 
rinsed once with ice cold PBS to remove traces of DTSSP and Tris. All cells were 
lysed on ice in RIPA buffer and quantified using the Bradford protein quantification 
assay (BioRad) as previously outlined (section 2.10). 
 
One hundred microliters (300-500 μg) of protein lysate was added to the antibody-
bound beads and samples were rotated at 4 °C overnight. Beads were magnetised 
and supernatant removed. Beads were washed four times in PBS-T. Forty 
microliters of 1x Laemmli buffer (Sigma) was added and beads where briefly 
vortexed before being incubated at 70 °C for 10 min to elute the bound protein. 
Beads were concentrated using a magnet and the supernatant containing 
immunoprecipitated (IP) protein was run on a western blot as previously outlined 
(section 2.11).  
 
2.25 Phospho-RTK array analysis 
Phosphoarray analysis was carried out using the Human Phospho-Receptor 
Tyrosine Kinase Array Kit (R&D Systems™) as per manufacturer’s instructions. 
Cells were cultured to 70-90% confluence. For “serum-free” samples, samples were 
incubated in serum free media for 24 h prior to harvesting protein lysates. For 
ECM1-treated samples, samples were incubated in serum free media for 24 h and 
treated with 1 µg/ml recombinant ECM1 (R&D Systems™: 3937-EC) for 5 min prior 
to harvesting. Forty microliters of protease inhibitor (P8340; Sigma) was added to 2 
ml of Lysis Buffer 17 (R&D Systems™). Medium was aspirated from the cells and 
500 µl of Lysis Buffer 17 was added to each 75 cm2 flask. Cells were incubated with 
the lysis buffer on ice on a rocking platform for 30 min. A cell scraper was used to 
detach lysed cells from the flask, and the crude lysate was transferred into a 
microcentrifuge tube and spun at 14,000 g for 5 min in a microcentrifuge to clear.  
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The supernatant was transferred into a new microcentrifuge tube on ice and 
quantified using the Bradford protein quantification assay (BioRad) as previously 
outlined (section 2.10). 
 
All reagents were brought to RT prior to use and 2 ml of Array Buffer 1 (R&D 
Systems™) was added to each well of a four well array dish provided with the kit. 
Array membranes were incubated in Array Buffer 1 for 1 h on a rocking platform. 
300 µg of total protein was prepared in a final volume of 1.5 ml with Array Buffer 1 
(R&D Systems™). Array Buffer 1 was removed from the array dish, and 
membranes were incubated with protein lysates at 4 °C overnight on a platform 
rocker. Membranes were removed from the four well array dish and placed in 
individual plastic dishes with 20 ml of 1x Wash Buffer (R&D Systems™) and 
incubated for 10 min at RT on a rocking platform. The Wash Buffer was removed 
from each dish, and a further two wash steps were carried out in 1x Wash Buffer 
(R&D Systems™). 
 
Anti-phospho-tyrosine HRP detection antibody (R&D Systems™) was diluted 
1:10,000 in 1x Array Buffer 2 (R&D Systems™) and 2 ml added to each well of the 
four-well dish. Membranes were transferred to the four-well dish and incubated with 
the detection antibody for 2 h at RT on a rocking platform. The array membranes 
were removed from the four well array dish and placed in individual plastic dishes 
and washed three times in 20 ml of 1x Wash Buffer (R&D Systems™) as previously 
described.  
 
The bound HRP labelled antibody was visualised by chemiluminescence using the 
Chemi Reagent Mix (R&D Systems™) and imaged with a ChemiDoc MP System. 
Images were analysed using Image J Software (SciJava). 
 
2.26 Microarray analysis of ECM1 knockdown cells 
Total RNA was harvested as previously outlined. RNA was treated to remove any 
contaminating DNA prior to analysis using the Affymetrix GeneChiP® Human 
Transcriptome Array 2.0. DNase reactions contained 6 μg of total RNA, 40 U 
RNase OUT™, 4 µl of 10x Digest buffer, and 3 U DNase 1, in a total volume of 36 
µl made up with molecular biology grade water. Reactions were incubated at RT for 
15 min before 4 µl of 25 mM EDTA was added to stop the reaction. The volume of 
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each sample was adjusted to 100 µl with molecular grade water prior to enzymatic 
clean-up using a Qiagen RNeasy kit (Qiagen) as follows. To each sample 350 μl 
buffer RLT (Qiagen) containing 1% beta-mercaptoethanol and 250 μl 100% ethanol 
were added to each sample.  Samples were transferred to an RNeasy MinElute 
spin column sitting in a collection tube (Qiagen) and centrifuged for 30 s at 8000 x g 
and flow through discarded. Samples were washed by adding 500 μl RPE Buffer 
(Qiagen) to the columns and centrifuging at 8000 x g for 30s in a microcentrifuge. 
This wash step was repeated using another 500 μl RPE Buffer (Qiagen) but 
samples were spun at 13,000 x g for 2 min. Columns were then transferred to new 
collection tubes and centrifuged at 13,000 x g for 1 min to remove excess wash 
buffer and dry the columns. The columns were then placed into new 1.5ml 
collection tubes and 30 μl dH2O added. Samples were spun in a microcentrifuge at 
13,000 x g for 1 min to elute the RNA. RNA was quantified using a Nanodrop 8000 
spectrophotometer measuring light absorbance at a wavelength of 260 nm.  
 
The integrity of the RNA was also examined on a 2200 TapeStation (Agilent) using 
the RNA ScreenTape System according to manufacturer’s instructions. Briefly, to a 
0.2 ml PCR tube, 5 µl of RNA ScreenTape buffer (Agilent) and 1 µl of RNA or 
ScreenTape Ladder (Agilent) was added. Samples were heated to 72 °C for 3 min 
in a PCR block then immediately cooled on ice for 2 min before being analysed on a 
2200 Tapestation (Agilent) system. An example of a TapeStation profile can be 
found in the Appendix J.  
 
cDNA was synthesised and qRT-RCR was conducted as previously outlined 
(sections 2.7 and 2.8) to confirm levels of ECM1 prior to microarray analysis. 
Microarray analysis was conducted by Tepnel Pharma Services (Hologic). Reverse 
transcription and amplification of total RNA was conducted according to the 
manufacturer’s instructions using the Affymetrix GeneChip® WT PLUS Reagent Kit. 
cDNA was quantified using optical density (Nanodrop), normalised and hybridised 
onto Affymetrix GeneChiP® Human Transcriptome Arrays 2.0 for 16 h at 45 °C. 
Microarrays were washed and stained according to manufacturer’s instructions with 
the Affymetrix GeneChip® Hybridisation, Wash and Stain Kit on the Affymetrix 
Genechip® Fluidics Station 450 and scanned using an Affymetrix Genechip® 7G 
microarray scanner. Quality control was performed on the data using Affymetrix 
Expression Console Software. 
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The Bioconductor Linear Model for Microarray Analysis (LIMMA) package was used 
to determine genes differentially expressed between the ECM1 knockdown and 
control samples. These genes were analysed using MetaCore (Thomson Reuters) 
to determine altered pathways.  
 
2.27 Drug treatments and CellTitre® Blue cell viability assay 
Between 3000 and 7000 cells were plated in 100 µl media in each well of flat 
bottomed 96-well plate (Corning) in order to achieve 80% confluency in the 
untreated control at the end of the 7-day assay. For the LUCC4 cell line, Corning 
Primaria flat bottomed 96-well plates were used. Cells were incubated under 
standard conditions overnight. After 24 h media was aspirated from each well, and 
fresh media containing the appropriate concentration of erlotinib (Cayman 
Chemicals) and/or tivantinib (Selleckchem) was added in 0.1% DMSO. Five 
replicate wells were used for each concentration of drug. Media containing the 
appropriate drug concentration was changed after 72 h. After 110 h total incubation 
time, 20 µl of CellTitre-Blue warmed to 37 °C was added to each well and the plate 
was incubated in a humidified incubator (Sanyo) at 37 °C in 5% CO2 in air for 2 h in 
the absence of light. Fluorescence was measured on a Berthold Mithras LB 940 
Multimode microplate reader with excitation settings at 540 nanometres and 
emission at 590 nanometres. Wells containing media and no cells were used as a 
control to which readings were blanked, and results were normalised to wells 
containing cells treated with 0.1% DMSO but no drug. Dose response equations 
were calculated and curves were generated using GraphPad Prism® in order to 
determine IC50 values. Isobolograms were also generated using GraphPad Prism® 
in order to assess additive effects of combination treatment.  
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Chapter 3  
Identification of a Basal/Squamous subgroup of bladder 
cancer cell lines with high ECM1 and MUC1 expression  
3.1 Introduction 
Muscle-invasive bladder cancer (MIBC) represents 25% of all bladder cancers and 
is a very heterogenous disease. MIBC accounts for the majority of patient deaths 
from bladder cancer and treatment for these patients has changed little over the 
past three decades. The standard of care remains platinum-based chemotherapy 
but response rates are less than 50% and relapse is common. Checkpoint 
immunotherapy was recently approved for second-line therapy in patients whose 
first-line chemotherapy has failed, but the reported overall response rates are 
modest, and robust predictive biomarkers are still currently lacking. 
 
Several studies have assessed MIBC at the molecular level using transcriptome 
profiling of bladder tumours in order to define molecular subtypes that may facilitate 
the stratification of patients into more relevant prognostic and treatment groups, and 
improve treatment options by identifying new approaches to therapy [81]. Six main 
research groups have now described molecular subtypes of MIBC: Baylor [85], UNC 
[74], CIT-Curie [86], MDA [75], Lund [87] and TCGA [32]. A recent study by Kamoun et al. 
(manuscript in press), used a consensus subtyping system to unify the subtypes 
from these published MIBC molecular classification systems into six molecular 
classes of MIBC: Luminal Papillary, Luminal Non-specified, Luminal Unstable, 
Stroma-rich, Basal/Squamous and Neuroendocrine-like (doi: 
http://doi.org/10.1101/488460). The potential clinical utility of such molecular 
subtyping has also been highlighted by a limited number of studies that have 
related molecular stratification to chemotherapy and immunotherapy [75, 76, 79, 148]. 
 
A few studies have also profiled bladder tumour-derived cell line panels [83, 88, 89]. 
These cell line panels represent a valuable resource for use as model systems in 
which to test therapeutic approaches. Molecular profiling of such panels is essential 
in order to ensure that the molecular features of the cell lines are fully characterised 
and that these characteristics faithfully reflect those present in the tumours from 
which they were derived. Prior to the start of this study, our laboratory assembled a 
panel of 45 bladder tumour-derived cell lines and carried out genome-wide gene 
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expression analysis of this panel using GeneChip Human Genome U133 Plus 2.0 
Arrays (Hurst et al., unpublished data). Several of these cell lines have not been 
included in the previous studies that have evaluated the presence of clinically 
relevant subgroups in bladder tumour-derived cell line panels and the data from our 
panel therefore represents a novel resource. Preliminary analysis of this expression 
data using non-negative matrix factorisation (NMF) analysis classified the cell lines 
into 5 molecular subgroups (subgroups 1-5) (Hurst et al., unpublished data).  This 
background data is presented in the current Chapter along with further analysis of 
two genes, extracellular matrix protein 1 (ECM1) and mucin 1 (MUC1), which were 
amongst a subset of genes significantly upregulated in subgroup 2, a potential new 
subset of basal-squamous bladder cancers.  
 
3.2 Results 
3.2.1 Background data - Molecular subgroups of bladder tumour-
derived cell lines  
Data pre-processing and NMF analysis were carried out using web-based modules 
available via GenePattern (Broad Institute) [149]. Normalised probe intensity data 
was pre-processed to remove microarray platform noise and genes that have very 
little variation. The pre-processed dataset consisting of 26,959 probes was used as 
input for the NMF module in order to identify the number of likely clusters in the cell 
line dataset. NMF (Brunet approach) [150] was carried out for k = 2 to k = 7 clusters 
with 20 clusterings per value of k, 2000 NMF iterations per clustering, and the error 
function set to “divergence”. The most appropriate number of clusters (i.e. 
subgroups) was selected as k = 5 based on the maximal value of the cophenetic 
correlation coefficient which was 0.9875 for k = 5 (Figure 3-1).  
 
The alignment of the 5 NMF-assigned cell line subgroups to previously reported 
subtypes of bladder cancer was first of all examined. Marker sets that define the 
MIBC subtypes described by the TCGA [32], LUND group [87], and the UNC group [74] 
were used to construct heatmaps using the cell line expression data (Figure 3-2). 
Mutation status for FGFR3 and TP53 was also available and was overlaid on the 
heatmaps.  
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Figure 3-1: Unsupervised clustering using non-negative matrix factorisation 
(NMF) analysis.  
NMF was performed on genome-wide gene expression microarray data for forty-five bladder 
tumour-derived cell lines. Cophenetic correlation coefficients were calculated for the data in 
a two to seven cluster solution. A recorded consensus matrix from a five-cluster solution of 
the cell line microarray data had the highest cophenetic correlation. Heatmaps for each 
consensus matrix were created. Red indicates agreement of the assigned clustering while 
blue indicates no agreement as samples were never assigned to the same cluster. 
 
Subgroup 3 cell lines have features of luminal bladder tumours expressing high 
levels of markers associated with luminal differentiation (GATA3, FOXA1, PPARG,  
ELF3, KRT20 and uroplakins). Cell lines in this subgroup also have high expression 
of an FGFR3-associated gene expression signature and FGFR3 mutations and 
fusions are more frequent than in any of the other subgroups. The other cell line 
subgroups exhibit features of basal-squamous tumours and have much lower levels 
of expression of the luminal markers that are characteristic of subgroup 3. TP53 
mutations are frequent in these four basal subgroups of cell lines and expression of 
the AXL tyrosine kinase receptor is elevated. Subgroups 2, 4 and 5 express higher 
levels of basal-squamous markers including KRT5, KRT14, KRT6A and KRT6B, 
and the tyrosine kinase receptors EGFR and mesenchymal-epithelial transition 
factor tyrosine kinase receptor (MET). Subgroup 1 cell lines exhibit features 
characteristic of the claudin-low subset of basal tumours described by the UNC 
group [74], expressing low levels of claudins (CLND3, CLND4, CLDN7) and markers 
of epithelial-to-mesenchymal (EMT) transition (high ZEB1, ZEB2, CDH2, SNAI, 
TWIST1, SPARC and VIM and low CDH1 and CDH3).  
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Figure 3-2: Heatmaps showing the level of expression of markers characteristic 
of luminal and basal subtypes of bladder tumours in cell line NMF subgroups. 
In the heatmap, red represents high and green represents low gene expression. The mutation 
status of FGFR3 and TP53 is also shown at the top of the figure, where black represents 
mutant and white represents wildtype.  
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We further examined the differences between each of the subgroups using 
Significant Analysis of Microarrays (SAM) analysis, a supervised approach used to 
identify genes significantly differentially expressed between sets of samples. SAM 
was carried out within a stand-alone version of the Multiple Experiment Viewer 
(MeV) gene expression data analysis toolkit [151]. Data for each of the subgroups 
was compared to that from all other subgroups using SAM as follows: (subgroup 1 
vs subgroups 2, 3, 4 and 5), (subgroup 2 vs subgroups 1, 3, 4 and 5), (subgroup 3 
vs subgroups 1, 2, 4 and 5), (subgroup 4 vs subgroups 1, 2, 3 and 5), (subgroup 5 
vs subgroups 1, 2, 3 and 4). Probes reporting significant differential gene 
expression were identified by setting the fold change to ³2 and the median number 
of false significant genes to zero within the SAM analysis module. Lists of probes 
reporting differential gene expression from each comparison were then used to 
create a Venn diagram (Figure 3-3) and this was used to identify probes unique to 
each comparison. Intensity data for these probes was then extracted and used in 
hierarchical cluster analysis (Figure 3-4). This further analysis indicated that while 
subgroups 1, 3 and 5 bare strong resemblance to subsets of luminal and basal 
bladder tumours previously described by other groups, subgroups 2 and 4 may 
potentially represent novel subgroups of basal tumours. 
 
Subgroup 4 contained 3 cell lines: LUCC7, 94-10 and 97-7. Only two probes 
reported significant differential gene expression in the comparison with all other cell 
lines. One of the probes is unannotated and the other detects keratinocyte 
differentiation associated differentiation protein (KRTDAP), which is upregulated in 
these 3 cell lines relative to all others. As there were only 3 cell lines supporting the 
existence of this basal subset and limited information in the literature regarding the 
role of KRTDAP, this subgroup was not investigated further in the current study.  
 
Subgroup 2 exhibits strong basal-squamous features such as high expression of 
keratins 5 and 6 (Figure 3-2), but also exhibits significant differential upregulation of 
a number of genes. Eighty-seven probes corresponding to 50 genes were uniquely 
upregulated in cell lines from subgroup 2 as compared to all other subgroups 
(Appendix B). A heatmap of the expression of these genes is shown in Figure 3-5. 
One gene that was significantly upregulated in subgroup 2 was ECM1. Previous 
studies have demonstrated that ECM1 expression influences cancer development 
and progression, and it has been associated with poorer overall survival in 
hepatocellular, breast, and gastrointestinal carcinomas [118, 121, 152], however, the role 
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of ECM1 in bladder cancer has not been examined. MUC1 was also uniquely and 
significantly upregulated in subgroup 2. The complex described by Lee et al. was 
proposed to increase Ras/Raf/MEK/ERK signalling thus mediating resistance 
against the HER2 inhibitor trastuzumab [122].  Subtyping studies have shown that 
there are many similarities between molecular subgroups of basal and luminal 
breast cancers and bladder cancers, hence findings of interest in breast cancer are 
worthy of further investigation in bladder cancer. ECM1 and MUC1 were, therefore, 
selected as candidate genes for further investigation in this study.  
 
 
 
 
Figure 3-3: Venn diagram showing the overlap of the number of probes 
reporting differential gene expression in the cell line NMF subgroup 
comparisons.  
Cell line subgroups were compared as indicated in the figure using SAM analysis. Probes 
reporting significant differential gene expression were identified by setting the fold change to 
³2 and the median number of false significant genes to 0 within the SAM analysis module. 
Lists of probes reporting differential gene expression from each comparison were then used 
to create the Venn diagram.   
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Figure 3-4: Hierarchical cluster analysis of gene expression data for probes 
identified by SAM analysis to be differentially expressed in cell line NMF 
subgroups.  
Gene expression data for 1351 probes identified by Venn analysis to be uniquely differentially 
expressed in comparisons of NMF subgroups (Figure 3-3) were used in hierarchical cluster 
analysis. Two-way unsupervised hierarchical cluster analysis was conducted using Euclidean 
distance and average linkage. The features of the main clusters are highlighted on the left-
hand side of the figure. On the heatmap, red represents high and green represents low mRNA 
expression. 
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Figure 3-5: Heatmap of genes significantly upregulated in subgroup 2.  
On the heatmap, red represents high and green represents low mRNA expression 
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3.2.2 qRT-PCR analysis of ECM1 and MUC1 in cell lines 
Microarray data showed elevated mRNA expression of ECM1 and MUC1 in the cell 
lines classified into subgroup 2 (Appendix C). To confirm mRNA expression levels 
across all 45 bladder tumour-derived cell lines qRT-PCR was employed. 
Expression levels of ECM1 were shown to be elevated relative to the NHU-Pool in 
14 cell lines including all six of the cell lines classified into subgroup 2 (LUCC3, 
LUCC4, LUCC5, HT-1376, HT-1197, and 647V) (Figure 3-6). The highest 
expression level of ECM1 in subgroup 2 was seen in LUCC4 which was 
approximately 50x higher than that of the NHU-Pool sample, while 647V had the 
lowest ECM1 expression level which was approximately 0.5x higher compared to 
that of the NHU-Pool sample. MUC1 mRNA levels were elevated in 28 cell lines 
relative to the NHU-Pool sample including five of the six cell lines from subgroup 2, 
the exception being HT-1197 in which expression was reduced relative to the NHU-
Pool sample (0.4x lower) (Figure 3-7). LUCC4 also had the highest expression level 
of MUC1 which was 800x higher than the NHU-Pool sample. A Pearson product-
moment correlation was conducted to test concordance between the microarray 
and qRT-PCR data for MUC1 and ECM1 by measuring the linear correlation 
between the two datasets. qRT-PCR data correlated highly with the microarray 
expression data for both ECM1 (r = 0.934) and MUC1 (r = 0.959). 
 
3.2.3 Western blot analysis of ECM1 and MUC1 in cell lines 
The expression of ECM1 and MUC1 was also examined at the protein level in the 
cell line panel using western blot analysis (Figure 3-8). Of the 14 cell lines that 
showed elevated expression of ECM1 mRNA according to qRT-PCR data, 12 also 
stained positively for ECM1 protein expression on the western blot, including all six 
cell lines of subgroup 2. The most intensive staining for ECM1 was seen in LUCC4, 
LUCC5, HT-1376, HT-1197 and J82. Of the 28 cell lines that had elevated 
expression of MUC1 mRNA according to qRT-PCR, only 7 showed positive staining 
for the protein by western blot analysis (J82, TCC-SUP, 92-1, HT-1376, LUCC4, 
LUCC5, BC-3C). This included 3 of the 6 cell lines of subgroup 2 that had increased 
expression of MUC1 mRNA (HT-1376, LUCC4, LUCC5). Co-expression of both 
proteins was also examined. Five of the seven cell lines that had positive MUC1 
protein expression also had positive ECM1 protein expression (LUCC5, LUCC4, 
HT-1376, TCC-SUP, J82) while of the 21 cell lines that had upregulated MUC1 
mRNA but low protein expression, only LUCC1 had positive protein expression for 
ECM1 and one other (SCaBER) had increased ECM1 mRNA expression. 
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 Figure 3-7: qR
T-PC
R
 analysis of M
U
C
1 in 45 bladder tum
our derived cell lines.  
The relative expression level of M
U
C
1 m
R
N
A w
as determ
ined by qR
T-PC
R
. Expression levels w
ere norm
alised to the control gene SD
H
A and m
easured 
relative to a pooled norm
al urothelial cell sam
ple (N
H
U
-Pool). D
ata is ordered according to m
icroarray results (Appendix C
).
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3.2.4 Immunohistochemical staining analysis of ECM1 and MUC1 
expression 
3.2.4.1 Determination of the optimal antibody dilutions for 
immunohistochemical staining of ECM1 and MUC1  
Optimisation of primary antibody dilutions for immunohistochemical analysis was 
carried out to obtain maximum sensitivity with minimum background staining. 
Sections cut from the FFPE blocks of the primary tumours from which the LUCC4, 
LUCC5 and LUCC6 cell lines were derived were stained with a range of ECM1 or 
MUC1 antibody dilutions (1:100, 1:200 or 1:500). Tumours were selected as 
positive or negative controls based on the mRNA and protein expression levels of 
ECM1 and MUC1 in the corresponding cell lines as determined by microarray, qRT-
PCR, and western blot analysis. The tumour from which LUCC6 was derived was 
used as a negative control and this showed no staining for ECM1 at all antibody 
dilutions, except at the edges of tumour sections (Figure 3-9 A-D). The tumour from 
which LUCC4 was derived was chosen as the positive control and demonstrated 
heterogenous, mainly cytoplasmic staining for ECM1 with some areas staining very 
strongly, and others showing little staining. Some potential membranous staining 
could also be seen (Figure 3-9 E-H). The optimal antibody dilution for ECM1 
immunohistochemistry was determined to be 1:200. The tumour from which LUCC6 
was derived was also used as a negative control for MUC1 staining, and showed no 
positive staining (Figure 3-10 A-D). The tumour from which LUCC5 was derived 
was used as a positive control, and this tumour showed intense mainly cytoplasmic 
staining for MUC1 but there was also some observable membranous and nuclear 
staining. The optimal antibody dilution for MUC1 immunohistochemistry was 
established to be 1:200 (Figure 3-10 E-H).  
 
ECM1 expression was also examined in sections from the FFPE blocks for the 
tumours from which LUCC3 and LUCC5 were derived and the tumours from which 
LUCC4 and LUCC6 were derived were again examined in this mini-panel as 
positive and negative controls, respectively. In the LUCC3 (Figure 3-11 A), LUCC4 
(Figure 3-11 B) and LUCC5 (Figure 3-11 C) tumours staining was again 
heterogenous and largely cytoplasmic. No staining was noted in the LUCC6 tumour 
(Figure 3-11 D).  
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Figure 3-9: Photomicrographs of FFPE bladder tumour sections stained for 
ECM1 by immunohistochemistry.  
FFPE sections of bladder tumours from which the cell lines LUCC6 and LUCC4 were derived 
were stained with an antibody specific to ECM1 using immunohistochemistry with a range of 
antibody dilutions in order to determine the optimal conditions for detection of ECM1 protein 
with minimal background staining. Sections of the LUCC6 tumour sample were used as a 
negative control and were stained at the following antibody dilutions: A) no antibody, B) 1:100, 
C) 1:200, and D) 1:500. Sections of the LUCC4 tumour sample were used as a positive control 
and were stained at the following antibody dilutions: E) no antibody, F) 1:100, G) 1:200, and 
H) 1:500. Images are at a magnification of 400X. Images were also taken at a magnification 
of 40X to assess larger section areas. 
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Figure 3-10: Photomicrographs of FFPE bladder tumour sections stained for 
MUC1 by immunohistochemistry.  
FFPE sections of bladder tumours from which the cell lines LUCC6 and LUCC5 were derived 
were stained with an antibody specific to MUC1 using immunohistochemistry with a range of 
antibody dilutions in order to determine the optimal conditions for detection of MUC1 protein 
with minimal background staining. Sections of the LUCC6 tumour sample were used as a 
negative control and were stained at the following antibody dilutions: A) no antibody, B) 1:100, 
C) 1:200, and D) 1:500. Sections of the LUCC5 tumour sample were used as a positive control 
and were stained at the following antibody dilutions: E) no antibody, F) 1:100, G) 1:200, and 
H) 1:500. Images are at a magnification of 400X. Images were also taken at a magnification 
of 40X to assess larger section areas. 
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Figure 3-11: Photomicrographs of FFPE bladder tumour sections stained for 
ECM1 by immunohistochemistry.  
FFPE sections of bladder tumours from which the cell lines A) LUCC3, B) LUCC4, C) LUCC5 
and D) LUCC6 were derived were stained for ECM1 by immunohistochemistry. Slides were 
stained with an antibody specific to ECM1 at a dilution of 1:200. Images are at a magnification 
of 200X. 
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3.2.4.2 Immunohistochemical staining of ECM1 and MUC1 in fixed 
cell pellets 
In order to investigate how the cellular localisation and staining intensity of ECM1 
and MUC1 in the cell lines used in this study compared to that seen in the original 
tumours, immunohistochemistry was carried out on fixed cell pellets from a small 
panel of cell lines. This was also used as further validation of the ECM1 and MUC1 
antibodies use in immunohistochemistry staining. Cell pellets were chosen based 
on qRT-PCR and western blot analysis to include samples that had high expression 
(LUCC3 and LUCC4), medium expression (LUCC8) and low expression (J’ON and 
KU-19-19) of both proteins (Figure 3-12 and Figure 3-13). TERT NHUC B, a normal 
human urothelial-derived cell line retrovirally transduced to express human 
telomerase reverse transcriptase for immortalisation was also assessed as a 
normal urothelial reference cell line. Protein expression of ECM1 and MUC1 protein 
was not detected in the TERT-B, J’ON and LUCC8 cell lines by 
immunohistochemistry (Figure 3-12 A B D and Figure 3-13 A B D), and MUC1 
expression was not detected in the KU-19-19 cell line (Figure 3-13 C). A small 
degree of positive staining for ECM1 was observed in KU-19-19 (Figure 3-12 C), 
although ECM1 was not detected at the protein level by western blot analysis 
(Figure 3-8) and was down regulated at the mRNA level according to qRT-PCR 
analysis of this cell line (Figure 3-6). LUCC4 exhibited the most intense and uniform 
staining for both ECM1 and MUC1 with around 54% and 95% of cells staining 
positive for each protein respectively (Figure 3-12 F and Figure 3-13 F). LUCC3 
also showed considerable staining for both proteins (Figure 3-12 E and Figure 3-13 
E).  
 
In the LUCC3 and LUCC4 cell lines which exhibited positive staining for ECM1 and 
MUC1, the pattern of staining for both proteins was similar with the most extensive 
staining seen in the cytoplasm, although some potential membranous staining could 
also be seen for ECM1. A small amount of nuclear staining could also be seen for 
MUC1 in the LUCC4 sample (Figure 3-13 F).  
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Figure 3-12: Photomicrographs of FFPE cell pellets stained for ECM1 by 
immunohistochemistry. 
Sections of FFPE bladder tumour-derived cell pellets were stained for ECM1 by 
immunohistochemistry. Slides were stained with an antibody specific for ECM1 at a dilution 
of 1:200. Images show A) TERT NHUC B, B) JO’N, C) KU-19-19, D) LUCC8, E) LUCC3 and 
F) LUCC4 at a magnification of 400X. 
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Figure 3-13: Photomicrographs of FFPE cell pellets stained for MUC1 by 
immunohistochemistry.  
Sections of FFPE bladder tumour-derived cell pellets were stained for MUC1 by 
immunohistochemistry. Slides were stained with an antibody specific for MUC1 at a dilution 
of 1:200. Images show A) TERT NHUC B, B) JO’N, C) KU-19-19, D) LUCC8, E) LUCC3 and 
F) LUCC4 at a magnification of 400X. 
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3.2.5 Immunofluorescence staining of ECM1 and MUC1 
3.2.5.1 Distribution of ECM1 and MUC1 in parental HT-1376  
Immunofluorescence staining was conducted in HT-1376 in order to examine the 
expression and cellular localisation of ECM1 (Figure 3-14 and Figure 3-15) and 
MUC1 (Figure 3-16). Our results showed that ECM1 was mainly expressed in the 
cell cytoplasm where it exhibited a granular staining pattern (Figure 3-15). MUC1 
was also noted to be mainly cytoplasmic, but some cells also demonstrated nuclear 
staining (Figure 3-16). The actin cytoskeleton and nucleus were also stained using 
Phalloidin and DAPI, respectively. This allows the total cell population to be viewed 
and thus the percentage of cells staining positively for ECM1 and MUC1 can be 
assessed. Staining for ECM1 was heterogeneous, with the majority of cells showing 
positive staining but around 10% of cells showing no ECM1 staining. MUC1 staining 
was largely homogeneous with >95% of cells showing positive staining. DAPI 
staining was confined to the nucleus and actin showed mainly cytoplasmic staining 
as expected.  
 
3.2.5.2 Distribution of ECM1 in HT-1376 derived monoclonal cell lines 
In order to determine if the heterogeneous staining for ECM1 seen in HT-1376 was 
the result of a mixed cell population or spaciotemporal regulation of ECM1 
expression, monoclonal cell lines were generated by single cell cloning. ECM1 
expression was examined by immunofluorescence in these lines (Figure 3-17). In 
total 9 individual monoclonal cell lines were established (data not shown). Three 
representative monoclonal cell lines (Clones 1-4) exhibiting different ECM1 staining 
profiles are shown in Figure 3-17. Three monoclonal cell lines including Clone 1 had 
high ECM1 expression with more than 80% of cells staining positively. In three 
monoclonal cell lines, including Clone 2 and Clone 3, approximately 15% of cells 
were positive for ECM1, and in a further three monoclonal cell lines, including Clone 
4, no ECM1 staining was seen.  
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Figure 3-14: Photomicrographs of HT-1376 cells stained for ECM1 by 
immunofluorescence.  
IF staining was carried out for ECM1 in HT-1376 cells cultured on glass cover slips and fixed 
with 4% paraformaldehyde. A) Nuclei were stained with DAPI (emitting at 461 nm – blue 
fluorescence); B) actin was stained with phalloidin (emitting at 568 nm – red fluorescence); 
C) ECM1 antibodies were conjugated with secondary Alexa Flour anti-mouse antibodies 
(Thermo Fisher Scientific) (emitting at 488 nm – green fluorescence); D) composite image. 
Images were taken with an EVOS FL Cell Imaging System (Thermo Fisher Scientific) and 
overlaid using Inkscape picture editing software. The scale bar on the merged image (50 µm) 
is representative of all images.   
 
 
 
 
 
50 µm 
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Figure 3-15: An enlarged photomicrograph of a representative HT-1376 cell 
stained for ECM1 by immunofluorescence.  
IF staining was carried out for ECM1 in HT-1376 cells cultured on glass cover slips and fixed 
with 4% paraformaldehyde. An ECM1 antibody was conjugated with a secondary Alexa Flour 
anti-mouse antibody (Thermo Fisher Scientific) (emitting at 488 nm – green fluorescence). 
Images were taken with an EVOS FL Cell Imaging System (Thermo Fisher Scientific). ECM1 
staining was cytoplasmic and demonstrated a granular appearance.  
  
10µm 
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Figure 3-16: Photomicrographs of HT-1376 cells stained for MUC1 by 
immunofluorescence.  
IF staining was carried out for MUC1 in HT-1376 cells cultured on glass cover slips and fixed 
with 4% paraformaldehyde. A) Nuclei were stained with DAPI (emitting at 461 nm – blue 
fluorescence); B) actin was stained with phalloidin (emitting at 568 nm – red fluorescence); 
C) MUC1 antibodies were conjugated with secondary Alexa Flour anti-mouse antibodies 
(Thermo Fisher Scientific) (emitting at 488 nm – green fluorescence); D) composite image. 
Images were taken with an EVOS FL Cell Imaging System (Thermo Fisher Scientific) and 
overlaid using Inkscape picture editing software. The scale bar on the merged image (50 µm) 
is representative of all images.   
 
 
 
50 µm 
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Figure 3-17: Photomicrographs of HT-1376 monoclonal cell lines stained for 
ECM1 by immunofluorescence.  
IF staining was carried out for ECM1 in single cell clones of the HT-1376 cell line. Cells were 
cultured on glass cover slips and fixed with 4% paraformaldehyde. Nuclei were directly stained 
with DAPI (emitting at 461 nm – blue fluorescence), and ECM1 antibodies which were 
conjugated with secondary Alexa Flour anti-mouse antibodies (emitting at 488 nm – green 
fluorescence). Images were taken with an EVOS FL Cell Imaging System (Thermo Fisher 
Scientific) and overlaid using Inkscape picture editing software. Images show A) the parental 
HT-1376 cell line; B) Clone 1, a high ECM1 expressing clone; C) Clone 2 and D) Clone 3, 
intermediate ECM1 expressing clones; and E) Clone 4 which does not express detectable 
ECM1. 
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3.2.6 Analysis of secreted and glycosylated ECM1  
The granular appearance of ECM1 detected by immunofluorescent staining of 
parental HT-1376 led to the hypothesis that ECM1 was being packaged for 
secretion. In order to address the question of whether ECM1 is secreted by ECM1-
high bladder tumour derived cell lines, conditioned medium was collected from the 
parental HT-1376 cell line and the protein was precipitated out of the medium using 
TCA-precipitation. The protein isolated from the conditioned medium was 
subsequently analysed by western blot analysis and revealed the presence of 
ECM1 (Figure 3-18 A). In order to ensure that the detected ECM1 was not a 
contaminant from detached or non-viable cells in the conditioned medium, samples 
were cleared by centrifugation and passed through a 0.45uM syringe filter prior to 
TCA-precipitation.   
 
A positive control of total protein isolated from the cultured adherent HT-1376 cells 
was also analysed by western blot analysis alongside the protein isolated from the 
conditioned medium (Figure 3-18 A). A comparison of ECM1 detected from the two 
sources revealed that ECM1 isolated from conditioned medium had a higher 
molecular weight than the ECM1 detected in the adherent cell lysate. Previous 
studies have reported that ECM1 N-glycosylation of Asn residues is important for 
the regulation of secretion [153].  It was therefore hypothesised that the higher 
molecular weight ECM1 seen in the secreted fraction may represent a glycosylated 
form of the protein. In order to assess whether this was the case, protein 
precipitated from conditioned medium was subjected to deglycosylation using a 
GlycoprofileTM II Enzymatic In-solution N-Deglycosylation kit. This showed a 
reduction in the size of ECM1 post glycosylation (Figure 3-18 B). 
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Figure 3-18: Western blot analysis of secreted and glycosylated ECM1.  
A) HT-1376 cells were cultured in serum free media for 24 h. Conditioned medium and cell 
lysates were harvested. Conditioned medium and medium naive to cells (no cells) were spun 
at 13,000 rpm for 10 min then passed through a 0.45 µm syringe filter to remove cell debris. 
Protein was precipitated out of the medium using trichloroacetic acid (TCA), quantified and 
resuspended in western blotting loading dye. 20 µl of secreted protein and 30 µg of total 
protein lysate was analysed by western blotting with an antibody specific to ECM1. B) Medium 
was harvested and protein isolated as previously described. A GlycoprofileTM II, Enzymatic In-
solution N-Deglycosylation Kit was used to carry out deglycosylation (DG). 20 µl of DG product 
or 30 µg of total protein lysate was analysed by western blotting with an antibody specific to 
ECM1. n=1. 
 
 
 
3.2.7 Investigation of potential molecular mechanisms associated 
with ECM1 over-expression 
3.2.7.1 DNA copy number analysis of the ECM1 gene region 
In order to assess potential reasons for increased ECM1 expression in the ECM1-
high cell lines of subgroup 2, SNP 6.0 microarray data for all cell lines was 
interrogated for changes in copy number across the region of chromosome 1 
containing the ECM1 gene (1q21.2; hg19 chr1:150,508,011Mb-150,513,789Mb). 
Matched blood or the corresponding Epstein-Barr virus-transformed lymphoblastoid 
(EBV) cell line samples were used as normal reference samples where available. 
Copy number plots for chromosome 1 were viewed using Partek Genomics Suite 
software. All of the cell lines in subgroup 2 except HT-1197 had increased copy 
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number across the region of chromosome 1 encoding ECM1. The corresponding 
normal reference samples for these cell lines (where available) showed no increase 
in this region (data not shown). LUCC5 exhibited high-level amplification of the 
genomic region containing ECM1 (Figure 3-19). Of the remaining thirty-nine cell 
lines that were not part of Subgroup 2, twelve also exhibited increased copy number 
in the ECM1 gene region (data not shown).  
 
 
3.2.7.2 Mutational analysis of the ECM1 gene 
Mutation was also considered as a potential mechanism of ECM1 upregulation. 
COSMIC (Catalogue of Somatic Mutations in Cancer) is an online database 
(http://cancer.sanger.ac.uk/cosmic) that holds information on somatic mutations in 
human cancers assembled from large-scale experiments such as The Cancer 
Genome Atlas (TCGA) and scientific literature. Somatic missense mutations in the 
ECM1 gene were examined in COSMIC. A number of somatic mutations were 
identified that were present in individual samples only and were distributed across 
the whole ECM1 gene. However, two mutations were identified in COSMIC that 
were present in two or more different tumour samples in exons 7 and 10 (hg19 
coordinates: chr1:150483939 G>A, and chr1:150485894 C>T, respectively). A 
further two mutations were identified in two tumour samples in exon 8 that were a 
single base pair apart (hg19 coordinates: chr1:150484937 G>A, and 
chr1:150484939 C>T). PCR and Sanger sequencing were employed to screen the 
6 cell lines from subgroup 2 for mutations in these regions (Figure 3-20). Matched 
normal reference samples were available for three of the cell lines (LUCC3 blood; 
LUCC4 EBV; LUCC5 EBV) and these were also screened to confirm germline or 
somatic status of any variants detected. No mutations were detected in these 
regions, although 2 common single nucleotide polymorphisms (SNPs) were 
identified (rs11801190 and rs13294) (Figure 3-20). LUCC3, LUCC3 blood, HT-1197 
and HT-1376 cell lines were wildtype, LUCC5, and LUCC5 EBV were 
heterozygous, and LUCC4, LUCC4 EBV and 647V were homozygous for the 
rs11801190 SNP. LUCC4 and LUCC4 EBV cell lines were wildtype, 647V, HT-
1197, HT-1376, LUCC5 and LUCC5 EBV were heterozygous, and LUCC3 and 
LUCC3 blood were homozygous for the rs13294 SNP. Where matched normal 
reference samples were available the SNP genotype matched that of the tumour-
derived cell line confirming that the polymorphisms were germline.   
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Figure 3-19: Copy number plots of chromosome 1 for LUCC5 and LUCC5 EBV 
showing amplification of the genomic region containing ECM1.  
Copy number in LUCC5 was determined using SNP 6.0 microarrays and copy number plots 
for chromosome 1 were viewed using Partek Genomics Suite software. A) a reference map 
of chromosome 1 (hg18), B) chromosome 1 copy number plot for LUCC5 showing high level 
DNA amplification at chromosome region 1q21.1 which includes the ECM1 gene, C) 
chromosome 1 copy number plot for LUCC5 EBV showing a normal profile with no 
amplification at 1q21.1, D) magnified view of copy number data for LUCC5 across the region 
containing the ECM1 gene (highlighted by the red box). 
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Figure 3-20: Common SNPs identified in bladder tumour-derived cell lines by 
Sanger sequencing of exons 7 and 8 of the ECM1 gene.   
PCR and Sanger sequencing were employed to screen the 6 cell lines from subgroup 2 for 
mutations in exons 7 and 8 of the ECM1 gene. Two common SNPs were identified: 
rs11801190 (exon 7) and rs13294 (exon 8) in 3 and 6 of the cell lines respectively. Examples 
of cell lines that were wildtype, heterozygous, and homozygous for these SNPs are shown 
above. A) LUCC3 was wildtype, B) LUCC4 homozygous, and C) 647V heterozygous for 
rs11801190. D) LUCC4 was wildtype, E) LUCC3 homozygous, and F) HT-1197 heterozygous 
for rs13294. 
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3.3 Discussion 
Molecular subtyping based on genome-wide information offers the potential to guide 
more refined and personalised treatment approaches and better predict response 
than the traditional MIBC and NMIBC classification of bladder cancer. Moreover, it 
may enable the identification of new targets for treatment. Several subtypes of 
bladder cancer have now been described in primary tumour samples. Cell lines 
derived from primary tumours also represent a potential sample source for 
preliminary identification of subtypes as their molecular features often reflect those 
of the primary tumours from which they were derived. NMF analysis has been 
widely applied for the identification of molecular subtypes [32, 154, 155]. It is useful in a 
biological context as data is modeled on two non-negative matrices producing 
additive data by combining positive vectors. This lack of negative constraints 
supports the physical realities of gene expression, where negative copies of mRNA 
or negative transcription is not possible [156]. Furthermore, NMF compares individual 
pairs of genes thus detecting local behaviour of genes prior to correction for multiple 
comparisons. This allows the detection of sets of genes with correlated expression 
that would remain undetected by global gene behaviour analysis [157]. By using this 
quantitative method of cophenetic coefficient evaluation of subgroups, the analysis 
is not subjective and therefore the subtypes identified through NMF are 
reproducible and robust [150].  Prior to the start of this project, analysis of genome-
wide expression array data from 45 bladder tumour-derived cell lines was analysed 
using NMF analysis and five potential subgroups were identified. 
 
One of the subgroups identified had Basal/Squamous features (subgroup 2) (Hurst 
et al, unpublished data). This subgroup was characterised by 50 genes that were 
significantly upregulated according to significance analysis of microarrays (SAM). 
Within this gene list was extracellular matrix protein 1 (ECM1). ECM1 is of particular 
clinical relevance as increased expression has been associated with increased 
metastatic potential in laryngeal [119] and breast carcinomas [120], reduced overall and 
disease-free survival in patients with hepatocellular carcinoma [118] and poorer 
prognosis in malignant thyroid carcinoma [158]. MUC1 was also highlighted as 
uniquely and significantly upregulated in subgroup 2, and is of particular relevance 
as nearly three quarters of bladder carcinomas demonstrate MUC1 
immunohistochemical staining in the basal and intermediate layers of the urothelium 
[135, 141]. High levels of MUC1 expression is also associated with multifocality [142] and 
higher-grade bladder tumours [143]. Both proteins have also been associated with 
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the formation of a complex in breast cancer cells in which ECM1 interacts with and 
stabilises EGFR, HER3 and MUC1 in the cell membrane of a breast cancer cell 
line. This complex is thought to result in increased EGFR and HER3 signalling 
through Ras/Raf/MEK/ERK, which enables the cells to overcome the inhibitive 
action of trastuzumab a monoclonal antibody used to inhibit the signalling activity of 
HER2 [122]. A number of similarities exist between the basal and luminal subgroups 
of breast cancer and bladder cancer, hence findings of interest in one carcinoma 
are worthy of investigation in the other. ECM1 and MUC1 were, therefore, selected 
as candidate genes for further investigation in this study.  
 
Gene expression profiling using microarrays enables the expression of thousands 
of genes to be interrogated simultaneously, but error due to non-specific binding of 
targets to probes and cross hybridisation of probes to targets may affect the quality 
of gene expression data [159]. As a consequence of this it is good practice to validate 
differentially expressed genes identified by microarray analysis using a second 
independent technique. Here we used qRT-PCR to confirm the expression levels of 
ECM1 and MUC1 in the cell line panel as it represents an inexpensive option with 
high sensitivity and specificity, and rapid generation of results [160]. We found qRT-
PCR and microarray data to be highly correlated, suggesting that the gene 
expression data obtained is representative of the true pattern of expression for 
ECM1 and MUC1. 
 
As mRNA expression does not always relate directly to protein expression, we used 
western blot analysis to establish if ECM1 and MUC1 were also upregulated at the 
protein level. Seventy-five percent of the cell lines that had increased ECM1 mRNA 
also showed positive staining for the protein by western blot analysis, strongly 
implying that translational increases are directly related to increases in the 
transcription of ECM1. Our results suggest that an increase in transcription does not 
always equate to an increase in protein expression for MUC1 as only seven cell 
lines showed positive protein staining for MUC1 despite twenty-eight cell lines 
having upregulated mRNA (25%). Although MUC1 protein expression did not 
correlate absolutely with mRNA expression, an interesting trend was highlighted. 
Six out of the seven cell lines positive for MUC1 protein were also positive for 
ECM1 at the protein and mRNA levels, while only three of the twenty-one cell lines 
that had an increase in MUC1 mRNA but no MUC1 protein expression were 
positive for ECM1. This trend was also reported by Lee et al. [122] and while no 
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biological explanation has been proposed it implies that ECM1 may have post-
translational effects on the expression of MUC1.  
 
In addition to confirming western blot results of protein expression levels, 
immunohistochemistry provides information on the cellular localisation. In order to 
effectively analyse staining patterns antibodies must be validated for use in 
immunohistochemistry. Optimal antibody dilutions must also be established as 
using a concentration that is too high may result in non-specific low-affinity 
interactions generating false positive or high background staining [161] while using 
antibodies at concentration that is too low can result in false negative staining. We 
therefore performed an immunohistochemistry titration experiment for both the 
ECM1 and MUC1 antibodies using sections from tumours selected as positive or 
negative controls based on the mRNA and protein expression levels of the cell lines 
derived from these tumours. The results from this experiment determined the 
optimal antibody dilution to be 1:200 for both the ECM1 and MUC1 antibodies. No 
staining was detected in the negative controls suggesting that false-positivity due to 
non-specific binding of the secondary antibodies used in this study was not 
problematic, and that neither antibodies bind to alternative epitopes when used in 
immunohistochemistry. 
 
Subsequent to antibody validation and dilution factor optimisation, cell pellets were 
also stained using the ECM1 and MUC1 antibodies. In accordance with published 
literature [115, 121, 162] our immunohistochemistry results from both tumour sections 
and cell pellets showed ECM1 staining to be largely cytoplasmic. This may reflect a 
high level of ECM1 synthesis and subsequent packaging of the protein into vesicles 
for secretion. Similar to reports in breast cancer-derived cell lines [122], a small 
amount of membranous staining could also be seen, and this may provide some 
support for the existence of the membrane bound complex involving ECM1 
proposed by Lee et al. [122]. However, ECM1 is also thought to anchor many 
extracellular matrix proteins to keratinocyte membranes in order to maintain the 
skin’s functional integrity [163] hence other membranous interactions may also 
explain the observed staining pattern.  
 
Previous studies have reported MUC1 staining to be membranous [164, 165]. However, 
we observed MUC1 staining to be largely cytoplasmic and where staining for MUC1 
was very intense, as was seen in LUCC4 cell line and the tumour from which 
LUCC5 was derived, the protein was also detected in the nucleus. In bladder 
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cancer, alterations in the cellular localisation of MUC1 have been observed during 
tumour progression [141-143]. In prostate cancer, a more diffused pattern of 
expression throughout the cytoplasm has been noted to be associated with more 
advanced disease [166], and in breast cancer a switch in MUC1 expression from 
membranous to cytoplasmic and nuclear expression is associated with increased 
metastatic potential [167]. Our results have shown MUC1 staining to be cytoplasmic 
and nuclear, and may therefore suggest it is characteristic of more aggressive and 
metastatic bladder tumours, reminiscent of the high-stage, high grade tumours from 
which these cell lines were derived (Appendix A).  
 
Many of the same technical problems that affect immunohistochemistry are also 
encountered when using immunofluorescence, but this technique has the main 
advantage that due to the narrow wavelength ranges of the fluorescent dyes, filters 
that eliminate signals from other wavelengths can be applied to make detection 
highly selective for the specific signal of interest [161]. Furthermore, data generated 
from different wavelengths can be overlaid to assess co-localisation of two proteins 
[161]. Unfortunately, in this study investigation of co-localisation of MUC1 and ECM1 
was not possible as primary antibodies for the two proteins were derived from the 
same species and as a consequence staining with differentially fluorescently 
labelled secondary antibodies could not be used to distinguish between the two. 
Conjugation of primary antibodies to fluorophores that emit light at different wave-
lengths could be an option to overcome this issue in future work. 
 
Despite being unable to assess co-localisation of MUC1 and ECM1, 
immunofluorescent staining in the HT-1376 cell line showed that ECM1 is mainly 
cytoplasmic in localisation, confirming the results seen by immunohistochemistry in 
the LUCC3 and LUCC4 cell lines. This is similar to the pattern of staining for ECM1 
seen by immunofluorescence in laryngeal carcinoma, in which ECM1 was also 
expressed mainly in the cytoplasm [119]. Furthermore, immunofluorescent analysis of 
HT-1376 also revealed that the pattern of cytoplasmic staining was granular in 
nature. Post-translational processing of proteins destined for secretion often occurs 
within the Golgi apparatus where macromolecules are ultimately packaged in 
transport vesicles for secretion and this can result in a granular appearance of the 
cytoplasm when occurring at high levels [168]. The granular appearance of the 
cytoplasm in our bladder-tumour derived cell lines may be indicative of such 
vesicles and imply that ECM1 is being secreted by these cells.  
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ECM1 was originally identified as a secreted protein following TCA protein 
precipitation from the conditioned medium of a murine osteogenic cell line [91] and 
assumptions of similar cellular processing of the human form of ECM1 were made 
due to the highly conserved nature of the murine and human forms of ECM1 [92]. 
Furthermore, in vitro experiments that have demonstrated the ability of human 
ECM1a to interact with extracellular components of the skin such as laminin 332, 
collagen type IV, and fibronectin, suggesting that ECM1 is secreted in order for 
these interactions to occur in vivo [169, 170]. To date there have been no attempts to 
establish if the human form of ECM1 is secreted by bladder tumour cells. In the 
current study, ECM1 could be detected following western blot analysis of the protein 
fraction that was TCA precipitated from conditioned medium of the human bladder 
tumour-derived cell line HT-1376, suggesting human ECM1 is secreted by this cell 
line. 
 
Interestingly, the molecular weight of secreted ECM1 detected in conditioned media 
was larger than ECM1 detected in the cell lysate. Previous work investigating 
Urbacht-Weite disease identified N-glycosylation at asparagine (Asn) residues 
Asn444 and Asn354 encoded on exons 6 and 7 to be important in the regulation of 
the secretion of ECM1 [153].  We therefore hypothesised that the observed difference 
in size noted could be a result of ECM1 glycosylation. This was confirmed by 
enzymatic deglycosylation of ECM1 isolated from conditioned medium which 
resulted in a reduction in the molecular weight of ECM1 as detected by western blot 
analysis. Glycosylation of ECM1 may also explain the granular appearance of 
ECM1 staining seen by immunofluorescence. N-glycosylation occurs when 
preassembled glycans are transferred to Asn residues by glycosidases and 
glycosyltransferases in the endothelial reticulum (ER) and Golgi apparatus, and 
requires the transfer of proteins in membrane bound vesicles between the ER and 
Golgi, and from the Golgi to the membrane for secretion. This can result in a 
granular staining pattern when assessed by immunohistochemistry and 
immunofluorescence [153]. Our observations of granular ECM1 staining may, 
therefore, be indicative of post-translational glycosylation of ECM1 prior to 
secretion.   
 
Immunofluorescent staining of ECM1 in the HT-1376 cell line also revealed that 
roughly 10% of cells were negative for ECM1. Results from immunohistochemical 
staining of ECM1 in FFPE LUCC3 and LUCC4 cell pellets also demonstrated 
heterogenous expression of ECM1 in these cell lines. A number of previous studies 
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have reported ECM1 staining in tumour sections, but there are very few reports of 
immunohistochemistry or immunofluorescent staining of ECM1 in cell pellets. In one 
of the few studies in which such samples have been examined, the hepatocellular 
carcinoma-derived cell line BEL-7407 showed homogenous staining for ECM1 by 
immunohistochemistry [162]. At present the reasons underlying the heterogeneous 
staining we observed in our bladder tumour-derived cell lines is unclear. 
 
In order to investigate the possible cause of heterogeneous ECM1 expression in the 
cell lines, we generated a number of monoclonal cell lines by single cell cloning of 
the HT-1376 parental cell line. These cloned populations were then stained for 
ECM1 by immunofluorescence. It was hypothesised that if the cloned cell lines 
demonstrated homogeneous positive or negative staining for ECM1, this would 
indicate that the heterogeneous staining noted in the parental cell line was due to a 
heterogeneous cell population in the parental line. Conversly, if heterogenous 
expression of ECM1 in the cloned cell lines was observered then this could be 
indicative of regulated expression of ECM1 in response to another spaciotemporal 
factor. Our results showed varied ECM1 expression within the cloned cell lines 
which may suggest spaciotemporal regulation of ECM1 expression. A future study 
analysing cell-cycle-dependent regulation of ECM1 expression, for example by 
synchronising the cell population through inducible knockdown of divers of cell 
progression, or though drug treatments that activate checkpoints or block major 
metabolic pathways may be useful [171].  
 
The expression patterns could also be indicative of diversity in the presumed 
monoclonal populations. The generation of monoclonal cell lines relies on single cell 
plating through limiting dilutions, but due to dividing doublets and intercellular 
interactions achieving single cell suspensions can be difficult and this can result in 
the plating of multiple cells [172]. Furthermore, even with clear documentation of 
single cell origins from light microscopy, variation can arise in a seemingly 
monoclonal population through asymmetric cell division [173]. This in turn can lead to 
differences in gene and protein expression [173, 174]. Our results may imply that the 
single cell clones derived from the HT-1376 parental cell line established were not 
truly monoclonal. In the current study it has not been possible to definitively 
ascertain why ECM1 is differentially expressed in the HT-1376, LUCC3 and LUCC4 
cell line populations, but based on our results the remainder of the study was 
carried out using the parental rather than monoclonal cell lines as the majority of 
cells in the parental lines express high levels of ECM1.  
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As well as investigating expression levels of ECM1, we also aimed to assess 
potential molecular mechanisms associated with increased ECM1 expression in the 
ECM1-high cell lines. Copy number increases or decreases often have functional 
consequences which most commonly result in increased or decreased gene 
expression, respectively [175]. SNP 6.0 microarray data for all cell lines was 
interrogated for changes in copy number across the region of chromosome 1 
containing the ECM1 gene (1q21.2; hg19 coordinates chr1: 150,480,487-
150,486,265). This analysis revealed increased copy number in five of the six 
ECM1-high cell lines (HT-1376, 647V, LUCC3, LUCC4, and LUCC5). Chromosome 
arm 1q commonly exhibits complex genomic rearrangements and amplifications in 
this region are common but heterogenous in bladder tumours, hence, identifying 
candidate genes in regions of amplification is difficult [176]. In a previous study, copy 
number analysis of 261 bladder tumours identified 37 samples with an amplification 
across the 1q21–24 region, and five candidate genes within this region were 
suggested including two that are also encoded on 1q21.2: B-cell lymphoma 9 
(BCL9) - a nuclear component of the Wnt pathway [177], and the myeloid cell 
leukaemia protein 1 gene (MCL1) - a member of the anti-apoptotic B-cell lymphoma 
2 (BCL2) family of genes [176, 178]. ECM1 expression may well be influenced by copy 
number alterations in ECM1-high cell lines, however 1q21.2 is a gene dense region 
and may also contain other oncogenes that may be targets for amplification. 
Moreover, as well as five ECM1-high cell lines, a further seventeen cell lines (JO’N, 
5637, DSH1, LUCC6, LUCC2, 94-10, BFTC905, KU-19-19, CAL29, 97-24, 92-1, 
JMSU-1, 253J, SCaBER, TCC-SUP, LUCC1, and VM-CUB-1) also had increased 
copy number across the same region and of these cell lines, only five had 
upregulated ECM1 at the mRNA level. No definitive conclusion could therefore be 
made regarding copy number increase as the mechanism for increased expression 
of ECM1 in subgroup 2. 
 
Mutation was also considered as a potential mechanism which might lead to 
increased ECM1 expression. Sanger sequencing was employed to screen the 6 cell 
lines from Subgroup 2 for mutations in exons 7, 8 and 10 that were identified by 
interrogation of the COSMIC database. Although mutations were not detected in 
these exons, two common SNPs (rs11801190 and rs13294) were detected. 
rs11801190 was identified in LUCC5 and LUCC5 EBV, LUCC4 and LUCC4 EBV 
and 647V. rs13294 was identified in 647V, HT-1197, HT-1376, LUCC5, and LUCC5 
EBV, LUCC3 and LUCC3 blood. rs11801190 is a SNP in exon 7 of ECM1 that 
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occurs in around 10% of the population, does not result in a change to the amino 
acid sequence and has no apparent clinical significance [179]. The other SNP, 
rs13294, changes the encoded amino acid change (glycine to serine) in the ECM1 
protein sequence however this SNP is not known to have any clinical significance 
and is present in around 30% of the population [179]. As the available normal 
samples exhibited the same SNPs as detected in their respective paired tumour-
derived cell lines, this confirms that the SNPs are germline. Overall the data 
suggests that somatic mutations are not responsible for increased ECM1 
expression, though mutations in other parts of the gene cannot be discounted. 
Recently, our laboratory has exome sequenced all paired cell lines in the ECM1-
high panel. Further insight into the potential contribution of somatic mutation as a 
factor leading to increased expression of ECM1 will become available once this 
data is fully analysed. 
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Chapter 4   
Identification of a subset of primary bladder tumours 
overexpressing ECM1 and phenotypic effects of ECM1 
knockdown. 
4.1 Introduction 
In Chapter 3, ECM1 was shown to be upregulated in a subset of basal-squamous 
bladder tumour-derived cell lines. Cell lines represent an important tool for research 
but resemblance to the original tumours can be lost. An important aim of the project 
was to validate the existence of an ECM1-high subgroup in actual tumour samples. 
Publicly available microarray data generated from primary bladder tumours was 
examined for mRNA expression levels of ECM1. Patient metadata was also 
extracted and examined in order to relate increased expression of ECM1 to overall 
survival. Furthermore, differential gene expression between tumours expressing 
high and low levels of ECM1 was examined and pathway analysis was conducted 
based on these comparisons in order to gain a better insight into the functional role 
of ECM1 in primary bladder tumours. In order to further validate the existence of an 
ECM1-high subgroup in primary bladder tumours, ECM1 expression was assessed 
in four tissue microarrays constructed of over 900 formalin fixed paraffin embedded 
muscle-invasive bladder tumour cores using immunohistochemistry.   
 
In Chapter 3, MUC1 was considered another potentially important candidate gene 
due to its reported association with aggressive, high-grade bladder tumours [180] and 
was confirmed to be upregulated in the cell lines of subgroup 2. MUC1 is also of 
interest as an interaction with ECM1 has been reported in a complex proposed to 
influence resistance to ERBB targeting treatments in breast cancer [122]. Our 
findings in Chapter 3 demonstrated a strong correlation between protein expression 
of MUC1 and ECM1 in the panel of cell lines. In this Chapter we aimed to assess 
the correlation between MUC1 and ECM1 protein expression in primary tumours by 
also assessing MUC1 expression in the tissue microarrays described above. 
 
Previous studies in cell lines derived from normal tissues and other carcinomas 
have reported that ECM1 plays a role in wound healing, angiogenesis and cell 
migration. For example, a cholangiocarcinoma cell line exhibited reduced migration 
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and invasiveness in vitro in response to downregulation of ECM1 [120, 181] and 
downregulation of ECM1 in the breast cancer cell lines Hs578T and MD-AMB-231 
led to a reduction in cell migration and wound healing ability, coupled with impaired 
attachment and invasiveness as determined by cell attachment assay and matrigel 
invasion assay [114]. The phenotypic effects of altering ECM1 in bladder cancer cell 
lines have not previously been described, hence, the expression of ECM1 was 
modulated in a subset of ECM1-high bladder tumour-derived cell lines using shRNA 
lentiviral transduction and the phenotypic impact of ECM1 knockdown was 
examined.  
 
4.2 Results 
4.2.1 Data mining, metadata and pathway analysis of publicly 
available bladder tumour transcriptome data 
R2 provides an interactive interface for the computational language “R” and holds 
publicly available transcriptome data with corresponding patient metadata where 
available (http://r2.amc.nl). Expression array data for 308 fresh-frozen bladder 
tumours of all stages and grades [72], 116 FFPE muscle-invasive bladder tumours 
[75], 142 fresh-frozen muscle-invasive bladder tumours [75], and 412 fresh-frozen 
muscle-invasive bladder tumours [32] was interrogated and visualised in R2. 
Hierarchical clustering based on the mRNA expression levels of ECM1 was used to 
generate dendrograms (Figure 4-1 and Figure 4-2). These dendrograms showed 
that in all datasets, tumours overexpressing ECM1 formed a separate and distinct 
cluster from the low expressing tumours as opposed to a graduation of expression 
from high to low. 
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Subtyping information was available for the Sjödahl and TCGA datasets. We 
examined the subtypes to which the ECM1-high tumours were assigned in the 
original studies (Table 4-1 and Table 4-2). This revealed that the majority of ECM1-
high tumours align with the Basal/Squamous subtypes defined in these studies. 
Analysis of the Sjödahl dataset showed that 9 out of 17 ECM1-high tumours, 9 
werecategorised as SCC-like, a poor prognosis basal group with high expression of 
keratins 4, 6A/B/C, 14, and 16 and EGFR expression. A further 6 ECM1-high 
tumours were classified as “highly-infiltrated”, a subtype which is characterised by a 
high level of immune cell infiltration and the expression of an EMT signature. The 
remaining 2 ECM1-high samples were categorised as genomically unstable, a high-
risk group consisting mainly of muscle-invasive tumours with increased HER2 
expression and TP53 mutations. Of the 26 ECM1-high tumours identified in the 
TCGA dataset, 18 were classified as basal-squamous, a basal group with stem cell 
like features. A further 3 tumours were categorised as neuronal which are 
characterised by a high level of TP53 and RB1 mutations. The remaining 5 ECM1-
high tumours were distributed across the three TCGA luminal subtypes. The TCGA 
dataset also had subtyping information available which categorised selected 
samples into subtypes identified by other research groups. This information was 
available for 16 of the ECM1-high tumours and indicated that the majority of ECM1-
high tumours were categorised into basal subgroups, with relatively few tumours 
assigned to luminal subtypes (Table 4-3).  
 
Patient survival data was available for the TCGA dataset. A Kaplan-Meier plot 
relating ECM1 expression to overall survival was generated (Figure 4-3). Patients 
whose tumours expressed high levels of ECM1 had significantly poorer overall 
survival than patients with tumours expressing low levels of ECM1. Median overall 
survival for patients with ECM1-high tumours was 14.2 months compared to 38.2 
months for patients with ECM1-low tumours (Figure 4-3; Mantel-Cox test, 
p=0.0043). Further analysis of the metadata for the TCGA study revealed a higher 
percentage of patients with ECM1-low tumours remained disease free compared to 
patients with ECM1-high tumours, who demonstrated a higher incidence of 
recurrence and tumour progression to a higher stage after initial resection of the 
tumour (Table 4-4). This is reflective of the poorer overall survival seen in Figure 
4-3. No correlation was noted between ECM1 expression and other metadata such 
as metastasis, age, smoking or previous diagnosis of NMIBC (data not shown).  
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Table 4-1: ECM1-high samples in the Sjodahl dataset and their corresponding 
Lund University subtypes. 
The microarray analysis and visualisation platform R2 was used to generate dendrograms 
based on hierarchical clustering of expression data for all probes that detected ECM1. 
Samples IDs were identified for those samples present in the ECM1-high cluster. Subtyping 
classification data from the Sjödahl study [72] was interrogated and the assigned subtype of 
each ECM1-high sample is displayed in the table. 
 
Sample ID Lund Group Subtype 
GSM814116 genomically unstable (MS2a2) 
GSM814222 genomically unstable (MS2a2) 
GSM814062 highly infiltrated (MS2b1) 
GSM814068 highly infiltrated (MS2b1) 
GSM814146 highly infiltrated (MS2b1) 
GSM814204 highly infiltrated (MS2b1) 
GSM814214 highly infiltrated (MS2b1) 
GSM814238 highly infiltrated (MS2b1) 
GSM814101 SCC-like  (MS2b2.2) 
GSM814126 SCC-like  (MS2b2.2) 
GSM814127 SCC-like  (MS2b2.2) 
GSM814144 SCC-like  (MS2b2.2) 
GSM814173 SCC-like  (MS2b2.2) 
GSM814225 SCC-like  (MS2b2.2) 
GSM814268 SCC-like  (MS2b2.2) 
GSM814344 SCC-like  (MS2b2.2) 
GSM814354 SCC-like  (MS2b2.2) 
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Table 4-2: ECM1-high samples in the TCGA 2017 dataset and their 
corresponding TCGA 2017 subtypes. 
The microarray analysis and visualisation platform R2 was used to generate dendrograms 
based on hierarchical clustering of expression data for all probes that detected ECM1. 
Samples IDs were identified for those samples present in the ECM1-high cluster. Subtyping 
classification data was interrogated from the TCGA study [32] and the assigned subtype of 
each ECM1-high sample is shown in the table. 
 
Sample ID TCGA Subtype 
TCGA-BL-A13I Basal-squamous 
TCGA-BT-A0YX Basal-squamous 
TCGA-CU-A0YN Basal-squamous 
TCGA-DK-AA6R Basal-squamous 
TCGA-E7-A7DV Basal-squamous 
TCGA-FD-A3B4 Basal-squamous 
TCGA-FD-A3N5 Basal-squamous 
TCGA-FD-A3SS Basal-squamous 
TCGA-FD-A5BX Basal-squamous 
TCGA-G2-A2ES Basal-squamous 
TCGA-G2-A3IB Basal-squamous 
TCGA-GU-A764 Basal-squamous 
TCGA-HQ-A5NE Basal-squamous 
TCGA-UY-A8OB Basal-squamous 
TCGA-XF-AAN8 Basal-squamous 
TCGA-ZF-A9RF Basal-squamous 
TCGA-ZF-AA5H Basal-squamous 
TCGA-ZF-AA5N Basal-squamous 
TCGA-BT-A3PH Luminal 
TCGA-K4-A6MB Luminal 
TCGA-DK-A3IQ Luminal-infiltrated 
TCGA-KQ-A41S Luminal-infiltrated 
TCGA-E5-A4TZ Luminal-papillary 
TCGA-FJ-A871 Neuronal 
TCGA-XF-AAMH Neuronal 
TCGA-ZF-AA4R Neuronal 
 Table 4-3: ECM1-high samples in the TCGA 2017 dataset and their corresponding subtypes according to criteria from five previous 
studies.  
The microarray analysis and visualisation platform R2 was used to generate dendrograms based on hierarchical clustering of expression data for all probes 
that detected ECM1. Samples IDs were identified for those samples in the ECM1-high cluster. 16 ECM1-high samples were also assigned to subtypes previously 
described in five other studies [32, 47, 72, 74, 75].
Sample ID 2017 TCGA Subtype 
2014 TCGA 
Subtype UNC Subtype MDA Subtype Lund Subtype 
TCGA.BL.A13I Basal-squamous Cluster-IV Basal Basal Highly infiltrated (MS2b1) 
TCGA.E7.A7DV Basal-squamous Unassigned  Basal Basal Highly infiltrated (MS2b1) 
TCGA.FD.A3SS Basal-squamous Cluster-II Basal Basal Highly infiltrated (MS2a1) 
TCGA.FD.A5BX Basal-squamous Unassigned  Basal TP53-like Highly infiltrated (MS2b1) 
TCGA.CU.A0YN Basal-squamous Cluster-III Basal Basal SCC-like (MS2b2.2) 
TCGA.FD.A3B4 Basal-squamous Unassigned  Basal Basal SCC-like  (MS2b2.2) 
TCGA.FD.A3N5 Basal-squamous Cluster-III Basal Basal SCC-like  (MS2b2.2) 
TCGA.G2.A2ES Basal-squamous Cluster-III Basal Basal SCC-like  (MS2b2.2) 
TCGA.G2.A3IB Basal-squamous Cluster-III Basal Basal SCC-like  (MS2b2.2) 
TCGA.BT.A0YX Basal-squamous Cluster-III Basal Basal Urobasal B (MS2b2.1) 
TCGA.HQ.A5NE Basal-squamous Unassigned  Basal Basal Urobasal B (MS2b2.1) 
TCGA.K4.A6MB Luminal Unassigned  Luminal Luminal Genomically unstable (MS2a1) 
TCGA.BT.A3PH Luminal Cluster-I Luminal Luminal Urobasal A (MS1b) 
TCGA.DK.A3IQ Luminal-infiltrated Unassigned  Basal TP53-like Highly infiltrated (MS2b1) 
TCGA.KQ.A41S Luminal-infiltrated Unassigned  Luminal TP53-like Highly infiltrated (MS2b1) 
TCGA.E5.A4TZ Luminal-papillary Unassigned  Luminal Basal Urobasal B (MS2b2.1) 
10
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In order to investigate the impact of co-expression of ECM1 and MUC1 on patient 
survival a Kaplan-Meier plot was generated for TCGA data comparing tumours 
expressing high levels of ECM1, high levels of MUC1 and high levels of both ECM1 
and MUC1 (Figure 4-4). There was no statistically significant difference between 
survival for patients whose tumours expressed high levels of ECM1 alone 
compared to tumours expressing high levels of both ECM1 and MUC1. For patients 
whose tumours expressed both ECM1 and MUC1 there was a statistically 
significant reduction in overall survival (p= 0.035) compared to patients whose 
tumours expressed MUC1 alone.  
 
To identify other genes of potential interest in ECM1-high tumours, the IDs of the 
fresh-frozen samples that had upregulated ECM1 expression in the Sjödahl and 
Choi datasets were obtained from R2 [75, 182]. LIMMA analysis, conducted using the 
online platform GEO2R, was used to compare ECM1-high and ECM1-low tumours. 
Venn analysis was conducted using Partek Genomics software to identify 
overlapping probes in both datasets (section 2.2). Gene lists were compiled for 
those genes with a fold change greater than 2 or less than -2, and a p value less 
than 0.05 (Appendix E). This analysis identified 307 significantly altered probes. 
After the removal of unannotated probes, and a single representative probe being 
selected per gene, there were found to be 282 significantly altered genes. Eighty of 
these genes were significantly downregulated in the ECM1-high tumours compared 
to the ECM1-low tumours, and 202 genes that were significantly upregulated in the 
ECM1-high tumours compared to the ECM1-low tumours including ECM1. A 
number of extracellular and structural related proteins were also upregulated 
including 9 collagens and 6 keratins. The keratins 6a, 6b, 6c, 14, 16, and 16P2 
which are typically basal [86] were upregulated in the ECM1-high tumours. Other 
upregulated basal markers were PLAU, S100A7, S100A8, and SPRR1B. Four 
luminal markers (TBX3, TOX3, UPK2, and UPK1A) were downregulated in the 
ECM1-high tumours. The EGFR ligand HB-EGF, and the EMT markers vimentin 
(VIM) and snail family transcriptional repressor 2 (SNAI2), were also upregulated in 
the ECM1-high tumours. Pathway analysis was conducted using MetaCore 
(Clarivate Analytics) to gain insight into the features of tumours overexpressing 
ECM1. The top 10 most upregulated and downregulated pathways in tumours 
expressing high levels of ECM1 were identified (Figure 4-5). Upregulated pathways 
were enriched for cell adhesion, TGF-beta signalling and extracellular matrix 
remodelling. Downregulated pathways were mainly related to stem cell 
differentiation and lipid metabolism. 
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Figure 4-3: Kaplan-Meier plot for the TCGA data comparing patient survival 
based on high and low ECM1 expressing tumours.  
The microarray analysis and visualisation platform R2 was used to interrogate expression 
array data from 412 fresh-frozen muscle-invasive bladder tumours (stage T2-T4) generated 
by TCGA [32]. A Kaplan-Meier plot was generated showing overall survival probability of 
patients with tumours expressing high or low levels of ECM1. The Mantel-Cox test was used 
to test whether there was a statistically significant difference in survival between the two 
groups. Patients whose tumours expressed high levels of ECM1 had statistically significant 
reduced overall survival (p = 0.043). 
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Table 4-4: Comparison of metadata from patients with tumours expressing 
high or low levels of ECM1 who remained disease free.  
The microarray analysis and visualisation platform R2 was used to interrogate transcriptome 
data from 412 fresh-frozen muscle-invasive (stage T2-T4) bladder tumours generated by 
TCGA. Metadata was obtained from cBioPortal, the open access database for exploration of 
cancer genomic datasets. A comparison was conducted between patients with tumours that 
expressed high or low levels of ECM1 to determine the percentage of patients remaining 
disease free, and those whose tumours locally recurred or progressed to a higher stage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High (no.) Low (no.) High (%) Low (%) 
Disease Free 5 173 19.2 44.8 
Recurred or Progressed 16 127 61.5 32.9 
No data 5 86 19.23 22.3 
TOTAL 26 386 100 100 
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Figure 4-4: Kaplan-Meier plot comparing overall survival of patients with 
tumours expressing high levels of ECM1, MUC1, or ECM1 and MUC1 (TCGA 
dataset).  
The microarray analysis and visualisation platform R2 was used to interrogate expression 
array data from 412 fresh-frozen muscle-invasive bladder tumours (stage T2-T4) from TCGA 
study [32]. A Kaplan-Meier plot was generated showing overall survival probability of patients 
with tumours expressing high levels of MUC1, ECM1, or both MUC1 and ECM1. The Mantel-
Cox test was used to test whether there was a statistically significant difference in survival 
between the groups. Patients whose tumours expressed both ECM1 and MUC1 had 
statistically significant reduced overall survival compared to patients whose tumours 
expressed MUC1 alone (p = 0.035). Patients whose tumours expressed high levels of ECM1 
also had statistically significant reduced overall survival compared to patients whose tumours 
expressed MUC1 alone (p = 0.003). No statistical significance was seen between the survival 
of patients whose tumours expressed ECM1 or ECM1 and MUC1 (p = 0.809). 
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4.2.2 Immunohistochemistry analysis of ECM1 and MUC1 
expression in a tissue microarray 
Tissue microarrays (TMAs) comprising of 943 MIBC viable cores obtained from a 
collaborator were stained for ECM1 and MUC1 by immunohistochemistry. 108 
cores (11.5%) stained positively for ECM1 of which 32 (3.4%) stained very strongly 
(+++) and 76 (8.1%) stained weakly (+). The remaining 835 (88.5%) were negative 
(-). ECM1 was mainly located in the cytoplasm of the cells, with some staining 
noted on the cell membrane. Nuclear staining was observed rarely. MUC1 staining 
was observed in a greater proportion of cores (n=386; 40.9%) with 111 (11.8%) 
staining moderately (++), and 275 (29.2%) staining weakly (+). The remaining 557 
(59.1%) cores were negative (-). MUC1 staining was mainly located in the 
membrane and cytoplasm. Of the 108 ECM1-positive cores, 101 were also positive 
for MUC1. Staining of ECM1 and MUC1 was seen in similar locations on tumours 
positive for both. Representative examples of the ECM1 and MUC1 staining 
patterns are shown in Figure 4-6. The decode that will provide full metadata, 
including survival data, is awaited.  
 
4.2.3 ECM1 knockdown in ECM1-high bladder tumour-derived 
cell lines 
4.2.3.1 ECM1 isoform expression and selection of shRNAs for 
knockdown  
The human ECM1 gene encodes three main splice variants: ECM1a, ECM1b and 
ECM1c. Reverse transcriptase PCR was performed using primers spanning 
alternatively spliced exons in order to identify the ECM1 isoforms expressed in each 
of the ECM1-high cell lines (Figure 4-7). Four bladder tumour-derived cell lines that 
do not fall into subgroup 2 (LUCC1, 97-7, J82, and VMCUB1) and a pooled sample 
of normal human urothelial cells (NHU-Pool) were also examined in order to 
determine if ECM1 isoform expression differed between the ECM1-high cell lines of 
subgroup 2 and cell lines assigned to the other subgroups (Figure 4-8) (Table 4-5). 
LUCC4 and LUCC5 were the only two cell lines to express all three isoforms of 
ECM1 with no other cell line of subgroup 2 expressing ECM1c. 647V expressed the 
ECM1a and ECM1b isoforms. HT-1376 and HT-1197 may also express ECM1b. 
For HT-1376 a band was seen at 166 bp for primer pair 6 indicative of ECM1b, 
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however a smear was seen below 100 bp for primer pair 4 making conclusive 
assessment of the expression of this isoform difficult. For HT-1197, a clear banding 
pattern indicating ECM1a expression was obtained using primers 1 to 5. Primer pair 
6 failed and smearing below 100 bp for primer pair 4 made assessment of the 
expression of the ECM1b isoform difficult in this cell line. LUCC3 was the only cell 
line of the ECM1-high subgroup that definitively expressed only one isoform, 
ECM1a. J82 was not classified into subgroup 2 according to NMF analysis. 
However this cell line had elevated levels of ECM1 at both the mRNA and protein 
levels and was the only cell line outside of subgroup 2 that expressed isoforms 
other than ECM1a. The NHU-Pool sample also only expressed ECM1a (Table 4-5). 
 
Short hairpin RNAs (shRNAs) delivered using a lentiviral vector system were 
chosen for ECM1 knockdown in four cell lines from subgroup 2 (HT-1376, LUCC4, 
HT-1197 and 647V). Plasmids containing shRNAs targeting the all three main 
splice variants of ECM1 were selected in response to the observed expression 
pattern of the three isoforms in the cell lines.  
 
 
 
Figure 4-7 Primer pairs used to determine ECM1 isoform expression.  
A diagram representing the linearised structures of the ECM1 isoforms a, b, c, illustrating the 
distribution of exons and the 3’ and 5’ untranslated regions (UTRs). The figure also depicts 
primers flanking alternatively spliced exons that were used in PCR analysis to differentiate 
between isoforms based on presence, absence or size of product. The represetntation of the 
ECM1 isoforms has been created from information obtained from the NCBI nucleotide 
database [183]. 
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Figure 4-8: PCR analysis of ECM1 isoform expression in 11 cell lines.  
PCR was used to identify which of the three isoforms of ECM1 (ECM1a, ECM1b and ECM1c) 
each cell line of subgroup 2 was expressing. Isoform expression was also assessed in an 
additional 4 bladder tumour-derived cell lines not classified into subgroup 2 and a pooled 
normal human urothelial sample (NHU-Pool). Water was used in place of cDNA as a negative 
control. Primers flanking alternatively spliced exons were used in order to differentiate 
between isoforms based on presence, absence or size of product. A) Images for each of the 
cell lines from left to right show: Lane 1: 100bp ladder (NEB), Lanes 2-7: PCR products 
generated using primer pairs 1, 2, 3, 4, 5, and 6, respectively, for the determination of ECM1 
isoform expression (Chapter 2), Lane 8: PCR products generated using PICK3A primers as 
a positive control. B) An outline of the expected product sizes for each of the three isoforms. 
Representative of 1 experimental repeat. 
 
 
 
 110 
 
Table 4-5: A summary of ECM1 isoform expression in 11 cell lines.  
PCR was used to identify which of the three isoforms of ECM1 (ECM1a, ECM1b, and ECM1c) 
each cell line of subgroup 2 was expressing. An additional 4 bladder tumour-derived cell lines 
not classified into subgroup 2 and a pooled normal human urothelial sample (NHU-Pool) were 
also analysed. This table summarises which of the isoforms each cell line is expressing. 
Cell Line ECM1a ECM1b ECM1c 
LUCC3 + - - 
LUCC4 + + + 
LUCC5 + + + 
HT-1376 + ? - 
HT-1197 + ? - 
647V + + - 
J82 + + ? 
VM-CUB-1 + - - 
LUCC1 + - - 
97-7 + - - 
NHU-Pool + - - 
 
 
 
 
 
4.2.3.2 Puromycin dose assay.  
shRNA plasmids used for the ECM1 knockdown experiments contain a puromycin 
resistance cassette for the selection of successfully transduced cells. A puromycin 
dose assay was carried out to determine the lowest concentration of puromycin 
needed to efficiently kill untransduced cells. The minimum concentration of 
puromycin that killed all cells after 7 days was used as the selection dose. 647V 
was determined to require the lowest dose of puromycin at 0.3 µg/ml to kill all cells, 
whilst HT-1197 required the highest dose at 2.0 µg/ml (Figure 4-9). The selection 
dose for both HT-1376 and LUCC4 was determined to be 1 µg/ml (Figure 4-9). 
Cells were maintained in half the concentration of selection dose.  
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4.2.3.3 Confirmation of ECM1 knockdown by qRT-RCR and western 
blot analysis 
 
Four cell lines (HT-1376, LUCC4, HT-1197 and 647V) were stably transduced with 
shRNAs targeting ECM1 (KD1 and KD2) or control constructs (scramble and 
non-hairpin shRNAs). To assess the efficiency of knockdown, cDNA was 
generated from total RNA isolated from the transduced cells and real-time 
quantitative PCR (qRT-RCR) analysis conducted (Figure 4-10). For all cell lines 
transduced with KD1 or KD2, ECM1 expression was reduced to a level that was 
at least 80% lower than that seen in the parental cell line. The greatest 
knockdown efficiency (93.2%) was achieved for LUCC4 with KD1. The lowest 
knockdown efficiency was 80.6% for 647V with KD2. All scramble and non-
hairpin (NHP) controls demonstrated levels of ECM1 similar to that of the 
parental cell lines apart from the NHP control for LUCC4 which expressed ECM1 
at a level that was 40% less than that detected in the parental cell line. 
 
Knockdown at the mRNA level does not always correlate with decreased protein 
expression, particularly in the case of stable proteins with long half-lives, and 
previous reports suggest that some genes require >95% knockdown at the mRNA 
level in order to induce changes in protein expression[207]. For this reason, and as 
proteins are widely considered to be the functional effectors of a cell, knockdown 
should also be validated at the protein level by western blot analysis[208]. Protein 
lysates were also harvested from knockdown and control cell lines and ECM1 
protein levels were evaluated by western blot analysis. For HT-1376, LUCC4 and 
HT-1197 ECM1 could no longer be detected at the protein level (Figure 4-11). 
647V ECM1 protein levels also appeared to be reduced in the scramble and NHP 
control cell lines despite these cells exhibiting only a 20-30% reduction in ECM1 at 
the mRNA level as compared to parental cells (Figure 4-11). This may be reflective 
of the much lower ECM1 transcript and protein levels in the 647V parental cell line 
compared to the other ECM1-high cell lines. As protein levels in the 647V parental 
cell line appeared low in western blot analysis, the slight reduction in ECM1 
expression at the mRNA level in the scramble and NHP control of the 647V cell line 
compared to the parental may result in a reduction in protein below detectable 
levels using western blot analysis. 
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Western blot analysis of ECM1 levels was conducted over several subsequent 
passages (Appendix G) and prior to any further experiments to ensure continued 
knockdown of ECM1.  
 
 
4.2.4 Cell-based phenotypic assays on ECM1 knockdown cells 
4.2.4.1 Cell Morphology 
Lentiviral transductions with either the ECM1 knockdown or control shRNAs were 
not associated with any observable differences in the cells’ morphology as 
compared to their corresponding parental cell lines (Figure 4-12). 
 
Figure 4-10: qRT-RCR confirmation of mRNA knockdown of ECM1.  
Two shRNAs targeting ECM1 and two control shRNAs (scramble and non-hairpin control) 
were transduced into A) HT-1376 B) LUCC4 and C) 647V using lentiviral vectors. Only one 
shRNA was successfully transduced into D) HT-1197. Knockdown efficiency was examined 
by qRT-PCR analysis of ECM1. The expression of ECM1 was normalised against that of 
SDHA and relative to each parental cell line. Error bars indicate the range across triplicate 
wells. 
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Figure 4-11: Western blot confirmation of knockdown of ECM1 at the protein 
level.  
Two shRNAs targeting ECM1 and two control shRNAs (scramble control and NHP control) 
were transduced into HT-1376, LUCC4 and 647V using lentiviral vectors. Only one shRNA 
was successfully transduced into HT-1197. Knockdown efficiency was examined by western 
blot analysis using an antibody specific to ECM1. 
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4.2.4.2 Growth curves  
A growth curve for HT-1376 parental, both ECM1 shRNA knockdowns, and both 
controls was conducted (Figure 4-13 A). Five-thousand cells were seeded into 6 
cm2 dishes and cells were counted at 3, 6, 9, 12, 15, 18 and 21 days. One-way 
ANOVA and Tukey’s multiple comparisons tests were applied. No significant 
difference was seen in cell counts between parental cell lines, or the corresponding 
ECM1 knockdown, scramble and NHP controls .  
 
Growth curves for the parental, ECM1 knockdowns and shRNA controls were also 
generated for cell lines LUCC4, HT-1197, and 647V in a similar manner, but cell 
counts were made at a reduced number of time points (1, 7, 14, and 21 days) 
(Figure 4-13 B C D). No significant difference was seen between any of the parental 
cells lines, ECM1 knockdowns or scramble and NHP controls. 
 
Figure 4-13: Growth curves for HT-1376, LUCC4, HT-1197 and 647V parental 
cell lines, ECM1 shRNA knockdowns and shRNA controls.  
Growth curves were generated for A) HT-1376, B) LUCC4, C) HT-1197, and D) 647V 
parental, ECM1 knockdowns (KD1; KD2) and their non-hairpin (NHP) and scramble (Scr) 
control lines. Cell counts were made at 8 time points over 21 days (1, 4, 7, 10, 13, 15, 18, and 
21 days) for HT-1376 and at four time points over 21 days (1, 7, 14 and 21 days) for LUCC4, 
HT-1197, and 647V. Three wells were counted for each time point. One-way ANOVA and 
Tukey’s multiple comparison tests were used and showed that there were no statistically 
significant differences in the growth rates of the parental cell lines, the ECM1 knockdowns, 
scramble controls and NHP controls (P>0.999 in each comparison). Error bars show standard 
error of the mean. Representative of 1 experimental repeat. 
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4.2.4.3 Wound healing assays  
The migration of HT-1376 parental, ECM1 knockdown, and scramble control cells 
was analysed using a wound healing assay (Figure 4-14). The shRNA controls and 
parental cell lines moved into the scratched area and the wound was completely 
closed within 48 h. Knockdown of ECM1 was seen to inhibit wound healing ability 
and movement into the scratched area was much slower for the knockdown cell 
lines with incomplete healing after 48 h. Semi-quantitative analysis was performed 
by measuring wound area using ImageJ software and percentage area closed was 
calculated. Ordinary one-way ANOVA and Tukey’s multiple comparisons revealed a 
significant difference in wound healing after 24 h between KD1 and all control cell 
lines (p < 0.005 in all cases) and between both knockdowns and controls at 48 h (p 
<0.0001 in all cases).  
 
The effect of ECM1 on the migration of LUCC4, HT-1197 and 647V was also 
analysed using wound healing assays. For LUCC4, the scramble control closed the 
scratched area much more rapidly than the ECM1 knockdown (Figure 4-15). Semi-
quantitative analysis was performed by measuring wound area using ImageJ 
software and percentage wound closure calculated. Ordinary one-way ANOVA and 
Tukey’s multiple comparisons revealed a significant difference in wound healing 
between KD1 and the scramble control for the LUCC4 cell lines after 24 h (p= 
0.0079) and 48 h (p <0.0001). For HT-1197 knockdown of ECM1 was seen to 
slightly inhibit wound healing ability and movement into the scratched area was 
fractionally slower for the knockdown cell line compared to the scramble control 
(Figure 4-16). No statistically significant difference was noted between wound 
healing ability of the ECM1 knockdown and scramble control for HT-1197. Both the 
ECM1 knockdown and scramble control for 647V showed rapid closure of the 
scratch area with complete closure of the wound area for both cell lines after 24 h 
(Figure 4-17).  
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Figure 4-14: Wound healing assay carried out using HT-1376 parental, ECM1 
knockdown and control cells.  
The effect of ECM1 knockdown on the wound healing ability of the HT-1376 cell line was 
determined by the use of a wound healing assay. A) Images were captured at 50X 
magnification at 0, 24 and 48 h for the HT-1376 parental cell line, the two ECM1 knockdowns 
(KD1 and KD2) and two shRNA controls (HT-1376 scramble and NHP control). B) Statistical 
analysis of the percentage wound closure after 24 h was conducted using ordinary one-way 
ANOVA and Tukey’s multiple comparisons. This showed KD1 to have a statistically significant 
slower wound healing rate after 24 h than the HT-1376 parental, scramble control, or NHP 
control lines (p = 0.005, 0.008, 0.007, respectively). C) Similar analysis of the percentage 
migration after 48 h showed that both KD1 and KD2 had a statistically significant slower 
wound healing rate than the HT-1376 parental, scramble control or NHP control lines (p < 
0.0001 for all comparisons). Representative of three experimental repeats, each with three 
replicate wounds.  
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Figure 4-15: Wound healing assay carried out using LUCC4 ECM1 KD1 and 
scramble control cells.  
The effect of ECM1 knockdown on the wound healing ability of the LUCC4 cell line was 
determined by the use of a wound healing assay. A) Images were captured at 50X 
magnification at 0, 24 and 48 h for an ECM1 knockdown (KD1) and scramble control line. B) 
Statistical analysis of the percentage wound closure after 24 h was conducted using ordinary 
one-way ANOVA and Tukey’s multiple comparisons. This showed KD1 to have statistically 
significant slower wound healing rate after 24 h than the scramble control line (p = 0.0079). 
C) Similar analysis of the percentage wound closure after 48 h showed the ECM1 KD1 to 
have a statistically significant slower wound healing rate than the scramble control line (p < 
0.0001). Representative of two experimental repeats, each with three replicate wounds. 
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Figure 4-16: Wound healing assay carried out using HT-1197 ECM1 KD1 and 
scramble control cells.  
The effect of ECM1 knockdown on the wound healing ability of the HT-1197 cell line was 
determined by the use of a wound healing assay. A) Images were captured at 50X 
magnification at 0, 24 and 48 h for ECM1 knockdown (KD1) and scramble control lines. B) 
Statistical analysis of the percentage migration after 24 h was conducted using ordinary one-
way ANOVA and Tukey’s multiple comparisons. This showed no significance between the 
wound healing ability of the ECM1 KD and scramble control lines (p = 0.955). C) Similar 
analysis of the percentage wound closure after 48 h was conducted and this showed no 
significant difference in the wound healing ability of the KD1 and the scramble control line (p 
= 0.396). Representative of two experimental repeats, each with three replicate wounds. 
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Figure 4-17: Wound healing assay carried out using 647V ECM1 KD1 and 
scramble control cells.  
The effect of ECM1 knockdown on the wound healing ability of the 647V cell line was 
determined by the use of a wound healing assay. A) Images were captured at 50X 
and 100X magnification at 0 h and 24 h respectively for ECM1 knockdown (KD1) and 
scramble control lines. B) Statistical analysis of percentage migration after 24 h was 
conducted using ordinary one-way ANOVA. This showed no significant difference in the 
wound healing ability of the ECM1 KD and scramble control lines (p > 0.999). Representative 
of two experimental repeats, each with three replicate wounds. 
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In order to assess whether the ECM1-high cells lines were dependent upon ECM1 
expression for the wound healing ability, treatment of the HT-1376 ECM1 KD1 cell 
line with recombinant ECM1 was carried out (Figure 4-18). Wound healing assays 
were conducted using the HT-1376 KD1 cell line in combination with recombinant 
ECM1 at concentrations ranging from 100 ng/ml to 1 µg/ml. As previously observed 
(section 4.2.4.3), KD1 had significantly reduced wound healing ability compared to 
the scramble control at 24 h (p = 0.04) and 48 h (p = 0.0015). A statistically 
significant reduction in wound healing as compared to the scramble control was 
also seen at 24 h for KD1 treated with 200 ng/ml (p = 0.031), 500 ng/ml (p = 0.003) 
and 750 ng/ml (p = 0.021) recombinant ECM1. However no significant difference 
was observed at concentrations of 100 ng/ml (p = 0.069) or 1 µg/ml (p = 0.490). At 
48 h statistically significant reduced wound healing compared to the scramble 
control was noted for KD1 treated with 100 ng/ml (p = 0.0004), 200 ng/ml (p = 
0.0027), 500 ng/ml (p <0.0001) and 750 ng/ml (p < 0.0001). No statistical 
significance was noted between KD1 treated with 1 µg/ml recombinant ECM1 and 
the scramble control (p= 0.276) at 48 h, indicating that treatment with recombinant 
ECM1 at this concentration partially recovers the wound healing ability of the ECM1 
knockdown cells.  
 
4.2.4.4 Transwell Assays 
Further examination of the effect of ECM1 knockdown on migratory ability was 
conducted using transwell assays. No differences in migratory ability of ECM1 
knockdown cells (KD1 and KD2) and the control cell lines (parental, scramble and 
NHP) for HT-1376, HT-1197 or 647V were seen. LUCC4 ECM1 knockdown cell 
lines showed a decrease in migratory capacity of more than 90% as compared to 
the parental cell line and scramble control lines (Figure 4-19). The non-hairpin 
(NHP) control for LUCC4 had a 70% reduction in the number of migrated cells 
compared to the parental and scramble control lines.  
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Figure 4-18: Wound healing assay carried out using HT-1376 scramble control 
and ECM1 knockdown cells treated with recombinant ECM1.  
A wound healing assay was carried out using HT-1376 scramble control and KD1 lines treated 
with a range of recombinant ECM1 concentrations (0, 100, 200, 500, 750 ng/ml, and 1 µg/ml) 
in order to assess the effect of recombinant ECM1 treatment on wound healing ability. A) 
Images were captured at 50X magnification at 0, 24 and 48 h. Three replicate wells were 
treated at each concentration and three images were taken per well for analysis. B) Statistical 
analysis of the percentage migration after 24 h was conducted using ordinary one-way 
ANOVA and Tukey’s multiple comparisons test. This showed KD1 to have a statistically 
significant slower wound healing rate after 24 h than the scramble control, as did KD1 treated 
with 200, 500 and 750 ng/ml recombinant ECM1 (p = 0.04, 0.031, 0.003 and 0.021 
respectively). No statistical significance was noted between KD1 treated with 100 ng/ml or 1 
µg/ml recombinant ECM1 and the scramble control (p =0.069 and 0.490 respectively). C) 
Similar statistical analysis was conducted at 48 h and showed KD1 to have statistically 
significant slower wound healing rate after 48 h than the scramble control, as did KD1 treated 
with 100, 200, 500 and 750 ng/ml recombinant ECM1 (p = 0.0015, 0.0004, 0.0027,  <0.0001 
and <0.0001 respectively). No statistical significance was noted between KD1 treated with 1 
µg/ml recombinant ECM1 and the scramble control (p= 0.276). (Key: * p = 0.05-0.01; ** p = 
0.009-0.001; *** p = 0.0009-0.0001; **** p = <0.0001). Representative of 2 repeats.  
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4.3 Discussion 
The ease of availability and longevity of cell lines makes multiple experiments and 
repeats with the same cell lines possible. However, some resemblance to the 
original tumour can be lost as the conditions under which cells are cultured may not 
truly reflect the original conditions in which the primary tumour developed, for 
example, nutrients are more readily available to cultured cells, there is no immune 
competition and no extracellular matrix components. This can result in different 
characteristics being acquired by cell lines compared to the tumour of origin[75]. In 
order to validate whether the subset of ECM1-high cell lines classified into 
subgroup 2 exhibited characteristics that truly reflected those of primary tumours 
hierarchical clustering based on mRNA expression levels of ECM1 was performed 
using publicly available gene expression data generated from primary bladder 
tumours. We found that ECM1 overexpressing tumours partitioned into distinct 
clusters in four different datasets which suggests a ECM1-high subgroup is also 
present in primary bladder tumours.  
 
Previous studies have shown an association between ECM1 expression and 
decreased survival rates in other carcinomas including laryngeal [119, 184], breast [116] 
and hepatocellular carcinomas [118]. In this study, a Kaplan–Meier plot was using 
transcriptome data obtained from the latest TCGA study [185, 186], revealed that high 
ECM1 expression was significantly associated with reduced overall survival and a 
higher likelihood of progression to a higher stage as compared to tumours 
expressing low levels of ECM1. The association of high ECM1 expression with 
lower survival rates and a higher likelihood of progression may highlight ECM1 as a 
potential prognostic marker in bladder cancer patients. 
 
To gain further insights into the functional role of ECM1 in primary bladder tumours, 
differential pathway analysis was carried out using MetaCore with gene lists 
generated by LIMMA comparisons of ECM1-high and ECM1-low expressing 
bladder tumours in publicly available transcriptome datasets. This determined the 
top 10 most upregulated and downregulated pathways in ECM1-high tumours. An 
interesting feature of the genes identified by LIMMA analysis was the high 
expression of six keratins in the ECM1-high tumours. Keratins are broadly 
categorised into type 1 and type 2 keratins, and form obligate heteropolymers in set 
pairs between these two types [187]. Their normal physiological function is to protect 
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the structural integrity of the epithelium from mechanical and non-mechanical stress 
factors [187], and they are also involved in the regulation of a diverse range of cellular 
functions, including apico-basal polarisation, control of protein translation and 
organisation of the positioning of organelles within the cell [187]. Keratins are also 
used as diagnostic tools and as prognostic markers for a variety of cancer types 
including colorectal, lung and breast cancer, and may play a regulatory role in 
tumorigenesis of cancers of an epithelial origin [187, 188].  
 
Our analysis showed upregulation of each of the three distinct isoforms of keratin 6 
(KRT6a, KRT6b, and KRT6c) [189] and its type two partner keratin 16 (KRT16) were 
upregulated in the ECM1-high tumours. KRT6 and KRT16 are predominantly 
expressed in squamous epithelia [189], and in bladder cancer keratin 6 is highly 
expressed in basal-squamous muscle-invasive tumours, and is associated with 
poor survival outcomes and increased recurrence in patients [190]. In addition to 
keratin 6, 10 markers typical of the basal subtype of bladder cancer were also 
upregulated in the ECM1-high tumours, and four luminal markers were 
downregulated [86]. Furthermore, the majority of ECM1-high tumours fell into basal-
squamous subtypes according to the original studies in which they were classified. 
This suggests that ECM1-high tumours are a Basal/Squamous subgroup. 
 
The EGFR ligand heparin-binding EGF-like growth factor (HB-EGF) was also 
upregulated in the ECM1-high tumours. Increased expression of HB-EGF is seen in 
a number of cancers including ovarian, breast and oesophageal tumours, and is 
associated with tumour progression, cell proliferation and increased metastatic 
potential [191-194]. In bladder cancer, HB-EGF overexpression has been 
demonstrated to enhance tumorigenesis in mice [195], and has been correlated with 
decreased survival rates in patients [196]. It may be proposed that high  expression of 
HB-EGF in the ECM1-high tumours contributes to the decreased survival rates 
noted for these patients.  
 
An association between HB-EGF, and EGFR mediated EMT has been reported as 
increased expression of the mesenchymal marker vimentin (VIM) and decreased 
expression of the epithelial marker e-cadherin was observed at the protein level 
by immunofluorescence staining in stably transduced keratinocytes with 
constitutively expressing HB-EGF [197]. Moreover, in the same model, increased 
expression of EMT markers including SNAI2 and ZEB1 was observed at the 
mRNA level, suggesting that HB-EGF is a mediator of the molecular mechanisms 
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that control EMT and may promote an invasive cell phenotype [197]. In our analysis, 
the EMT markers VIM and SNAI2 were also upregulated in the ECM1-high 
tumours. The transformation of tumour cells from an epithelial to a mesenchymal 
phenotype has long been associated with tumour invasion and metastasis [198], and 
thus our results may suggest that ECM1-high tumours have an increased 
metastatic potential. However, unlike previous findings in breast cancer which 
showed increased likelihood of lymph node metastasis in ECM1 positive tumours 
compared to ECM1 negative tumours [96], our interrogation of the TCGA dataset 
revealed no association between ECM1 expression and metastatic potential in 
MIBC. MIBC has a high risk of metastasis with half of all patients developing 
metastatic disease within 2 years [199]. It is therefore possible that while ECM1-high 
tumours may have a metastatic phenotype, a similar proportion of ECM1-low 
tumours may have similar metastatic potential via ECM1-independent mechanisms.  
 
An interesting feature of the pathway analysis was the upregulation of transforming 
growth factor-beta (TGF-beta) signalling in ECM1-high tumours coupled with a 
downregulation of stem cell differentiation pathways. TGF-beta signalling has 
previously been demonstrated to promote self-renewal of bladder cancer stem cells 
[200], and similarly TGF-beta signalling in glioma cells maintains stemness by 
upregulation of SOX2 [201]. The increase in TGF-beta signalling and downregulation 
of differentiation pathways, may suggest that ECM1-high tumours have a stem cell-
like phenotype. Moreover, initial identification of bladder cancer stem cells 
demonstrated an enrichment of basal-like markers including increased keratin 5 
and decreased keratin 20 [202]. The assignment of ECM1-high tumours to mainly 
Basal/Squamous subtypes high in these markers may further indicate increased 
stemness of these tumours.  
 
To further validate the existence of an ECM1-high subgroup of bladder cancers we 
examined ECM1 and MUC1 protein expression by immunohistochemistry in a set of 
four tissue microarrays (TMAs) consisting of 943 interpretable MIBC specimens. 
TMAs are made up of small cores of FFPE tumour blocks, arranged in a matrix 
embedded in a wax block. These can be sliced and fixed to slides so a large 
number of tumours can be analysed simultaneously thereby saving on time and 
laboratory reagents. Furthermore, the close proximity of multiple tumour cores fixed 
to the same slide reduces the variability of staining between tumours and allows for 
much faster scoring. This makes TMAs a valuable tool for the assessment of 
biomarker expression by immunohistochemistry.  
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Analysis of ECM1 expression in the MIBC TMAs showed mainly cytoplasmic 
staining confirming our observations in Chapter 3 and those of previous studies in 
hepatocellular carcinoma, breast cancer and thyroid carcinoma [96, 115, 118]. Although 
the cellular localisation of ECM1 was similar to reports in hepatocellular and breast 
carcinoma, percentage positivity was much lower. Our findings showed that 11.5% 
of cores stained positively for ECM1 to some extent and with 3.4% staining 
strongly, In contrast, ECM1 positivity has been reported to be 75% in breast cancer 
and 73% in hepatocellular carcinoma [121, 162]. This may reflect the restricted amount 
of tumour tissue available on TMAs, which can pose a problem as heterogeneity 
within tumours may result in false negative staining [203]. Indeed, ECM1 expression 
was seen to be heterogeneous across the tumours from which the LUCC4 and 
LUCC5 cell lines were derived. Often several cores from the same tumour are 
incorporated into the TMA to account for this, and while this is most likely the case 
for our TMAs, the TMA maps are currently unavailable and would need to be 
consulted to confirm this. Nevertheless, the low percentage of positive tumours 
correlates well with the percentage of tumours expressing high levels of ECM1 at 
the transcript level, with around 5% of samples in the TCGA dataset expressing 
high levels of ECM1. The low level of ECM1 staining in the TMAs is therefore likely 
a true reflection of a lower percentage of ECM1 positive bladder tumours compared 
to other carcinomas.  
 
Immunohistochemistry analysis of MUC1 was also conducted on the TMAs, as this 
protein was considered to represent another potentially important candidate that 
was upregulated at the mRNA level in the ECM1-high subgroup of bladder tumour-
derived cell lines. Although ECM1’s role in bladder cancer has not been previously 
investigated, MUC1 is one of the most explored tumour associated antigens in 
urothelial carcinomas [204]. High levels of MUC1 staining in bladder tumours have 
been correlated with increased invasiveness [205]. Previous reports estimate that 
around 60% of bladder tumours across all stages and grades are positive for MUC1 
with significant correlation to higher grade and squamous differentiated tumours [205, 
206]. In the current study a slightly lower percentage of tumours were positive for 
MUC1 (40.9%). This may be affected by the presence of multiple cores from the 
same tumour present on the microarray. This cannot currently be discerned as the 
TMA maps containing information for each core is not available at present. 
 
Previous reports have correlated increased expression of MUC1 in bladder tumours 
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with poor overall survival [137], and our results from mining publicly available data, 
demonstrate that high ECM1 expression in tumours is associated with poorer 
survival in patients. It would be interesting to interrogate survival data for the cohort 
of patients whose tumours were assessed for ECM1 and MUC1 expression on the 
TMA, but this will not be possible until the TMA maps and patient metadata are 
made available. Furthermore, it would be interesting to assess the effects of co-
expression of ECM1 and MUC1 on survival as 101 of the 108 tumours that stained 
positively for ECM1 were also positive for MUC1. While the decode and metadata is 
not available for the TMAs at present, the metadata for the most recent TCGA study 
is publicly available and this was examined. A Kaplan-Meier plot comparing overall 
survival of patients whose tumours expressed high levels of MUC1, high levels of 
ECM1 or ECM1 and MUC1 was generated. Although there was a significant 
decrease in survival of patients expressing both MUC1 and ECM1 compared to 
MUC1 alone, there was no difference in survival between patients expressing 
ECM1 alone and both ECM1 and MUC1. This suggests that ECM1 expression 
could be the major influencing factor associated with reduced survival rates.  
 
Very little is known about the biological mechanisms by which ECM1 acts. 
However, a number of studies have examined the role of ECM1 by modulating 
expression in various carcinoma cell lines [114, 122, 181]. The two most common 
methods used for knockdown studies are small interfering RNA (siRNA), and the 
vector-based approach of short hairpin RNA (shRNA). shRNAs are introduced into 
cells in a plasmid form using bacterial or viral vectors generating a relatively stable 
knockdown of target genes compared to the transient knockdown induced by siRNA 
[207]. For this reason, shRNA knockdown was chosen for the current study. For the 
purpose of this project, a lentiviral-based system was employed as it can also be 
used to infect non-dividing cells [208].  
 
In order to select shRNAs for our knockdown study we conducted PCR analysis of 
ECM1 isoform expression in the ECM1 high cell lines to ensure that the shRNAs 
selected targeted the most relevant isoforms. The human ECM1 gene encodes for 
three main splice variants: ECM1a, ECM1b, and ECM1c. To our knowledge, 
previous investigations into the role of ECM1 in cancer have not specified isoform 
or have focused on the major ECM1a isoform. While all cell lines examined 
expressed the ECM1a isoform, with the exception of LUCC3, the ECM1-high cell 
lines also expressed at least one other isoform. Alternative splicing is a crucial 
mechanism in the regulation of cell differentiation, embryo development, and cell 
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specific functions, while dysregulation of isotype expression is known to be 
important in the pathology of cancer [209]. It is possible that differential ECM1 isoform 
expression in conjunction with increased expression levels play an important role in 
influencing tumour progression. The observed expression of multiple ECM1 
isoforms in the bladder cancer cell lines led to the selection of shRNAs that targeted 
all known isoforms of ECM1 for use in this study. 
 
It has previously been reported that ECM1 siRNA knockdown in the breast cancer 
cell lines Hs578T and MDAMB231 resulted in cytoskeletal rearrangement and 
decreased membrane ruffling [114]. However, similar observations were not made in 
hepatocellular and thyroid carcinomas [115, 162]. In our bladder cancer cell lines, 
ECM1 knockdown did not result in any observable differences in cell morphology.  
 
Treatment with recombinant ECM1 has been reported to promote endothelial cell 
proliferation [122], and in breast cancer-derived cell lines treatment with recombinant 
ECM1 resulted in increased cell proliferation [122]. Furthermore, in cervical cancer 
transfection of HeLa cells with ECM1 resulted in increased cell proliferation [210]. The 
effects of ECM1 expression on cell proliferation are not universal to all carcinomas. 
In thyroid and cholangiocarcinoma cancer cell lines, no changes to cell proliferation 
were observed in response to ECM1 knockdown [115, 181]. Similarly, in the current 
study no differences in cell proliferation were observed in ECM1 knockdown cell 
lines. The lack of an observable impact of ECM1 knockdown on cell proliferation or 
cell morphology could possibly be attributed to the fact that the role of ECM1 in 
bladder cancer cannot be fully elucidated from cell line studies. ECM1 is a secreted 
protein and has been seen to interact with a number of other extracellular 
components [102]. The absence of an extracellular matrix or tumour 
microenvironment under cell culture conditions might mean that the role of ECM1 in 
bladder cancer is not completely reflected in vitro. 
 
We also investigated the impact of ECM1 knockdown on wound healing ability of 
ECM1-high cell lines. In previous studies, silencing of ECM1 using antibody 
treatments or siRNA knockdown has been shown to induce a significant reduction 
in wound healing in breast cancer-derived cell lines [114, 120] and hepatocellular 
carcinoma-derived cell lines [162]. Furthermore, Urbach–Wiethe disease, is 
characterised by disruption to wound healing ability resulting from loss of function 
mutations in ECM1. In the current study we demonstrated that knockdown of ECM1 
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results in reduced wound healing ability, implying that ECM1 plays a regulatory role 
in promoting wound healing in ECM1-high cells. 
 
In order to further confirm the potential role of ECM1 in wound healing, HT-1376 
ECM1 knockdown cells were treated with a range of concentrations of recombinant 
ECM1 and a wound-healing assay was conducted. In cultured healthy endothelial 
cells 20 ng/ml recombinant ECM1 was sufficient to stimulate cell proliferation [93] 
and 200 ng/ml of recombinant human ECM1 induced cell proliferation in breast 
cancer-derived cell lines [122]. Unlike these previous reports, concentrations below 
200 ng/ml had no effect on the wound healing ability of the HT-1376 derived ECM1 
knockdown cells. Furthermore, treatment with concentrations up to 750 ng/ml also 
had no effect on the wound healing ability of this line. There was a slight increase in 
the wound healing ability of cell lines treated with 1 µg/ml recombinant ECM1. It is 
unclear why treatment with recombinant ECM1 at concentrations below 1 µg/ml had 
no effect on the wound healing ability of the HT-1376 knockdown cells, however, 
one possible explanation may relate to isotype. The recombinant ECM1 used was 
the ECM1a isoform according to the protein sequence specified by the 
manufacturer. We have identified that while ECM1a was commonly expressed 
across our panel of cell lines, most ECM1-high cell lines also express at least one 
other isoform. It could therefore be proposed that in this setting it is not ECM1a that 
contributes to the wound healing ability of these cell lines but one of the other 
isoforms, and so treatment with recombinant ECM1a would not have an effect.  
 
The wound healing assay is a relatively cheap and simplistic method for monitoring 
cell migration and requires no specialist equipment [211-213]. However, since images 
are captured at several specific timepoints, wound healing assays can be time 
consuming and variability in initial scratch area means reproducibility is an issue 
[212]. Another method of measuring cell migratory ability is the three-dimensional 
system of transwell assays. Cells are seeded onto a porous insert containing serum 
free media, while media containing serum is placed in the well below. This creates 
a gradient that attracts cells to move through the membrane towards the higher 
concentration of serum and the number of cells that have migrated through the 
membrane can then be stained and counted [213].  
 
Previous reports in breast cancer have demonstrated that cell lines overexpressing 
ECM1 have increased migration ability as determined by a transwell assay [120]. This 
 132 
was echoed in the LUCC4 cell line in which reduced migration by transwell assay 
was observed in the ECM1 knockdown cell line compared to the scramble control 
and parental cell lines. This implies that ECM1 regulates migration ability in this cell 
line. However, HT-1376, HT-1197 and 647V did not exhibit any differences in 
migration ability in relation to the level of ECM1 expression when examined using 
the same assay. A key difficulty with transwell assays is the determination of an 
appropriate endpoint as cells exhibit large variability in response. Alterations to the 
time frame of the transwell assay might have revealed differences in migration for 
knockdown cells derived from the other cell lines, but there was not enough time 
available to repeat the assays. In order to better determine migration over time and 
to obtain kinetic data for the cell lines it is also possible to fluorescently label and 
track cells, however labelling of cells has the potential to alter cell behaviour and 
thus complicates experimental design [212]. This approach is also expensive and 
requires specialist equipment and was beyond the scope of the current project. Our 
current data suggest that there is not a generalisable effect of ECM1 expression on 
migration ability in our panel of ECM1-high cell lines.  
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Chapter 5  
Mediators of ECM1 dependent effects and activation of 
downstream signalling pathways  
5.1 Introduction 
Although the normal physiological function of ECM1 has not been fully elucidated, 
the protein has been linked to angiogenesis [93], [94], cell differentiation (including 
keratinocyte differentiation and endochondral ossification) [95] and cell proliferation 
[96], and it is therefore thought to be important in embryo development and wound 
healing. ECM1 has also been reported to bind to several extracellular matrix 
proteins including collagen type IV, fibronectin, laminin 332, fibulin-1C/1D and 
MMP-9 [90] implicating a role in maintaining the structural integrity of the skin.  
 
In Chapter 4 we showed that patients with ECM1-high tumours have reduced 
overall survival, and that ECM1 plays a role in wound healing in ECM1-high bladder 
tumour derived cell lines in vitro. A role for ECM1 in wound healing has also been 
implicated in other cancers including hepatocellular, breast, and gastrointestinal 
carcinomas [118, 121, 152]. Despite the potential importance of ECM1 in cancer very 
little is understood about the mechanisms and signalling pathways through which 
ECM1 exerts its biological functions. 
 
A potential mechanism by which ECM1 acts could be through the activation of 
EGFR signalling. EGFR has been reported to interact with ECM1 in breast cancer-
derived cell lines, and this was proposed to result in resistance to the ERBB2 
targeting monoclonal antibody trastuzumab through increased Ras/Raf/MEK/ERK 
signalling [122]. In this study we investigated whether a similar physical interaction 
between the two proteins exists in our ECM1-high bladder cancer cell lines using 
co-immunoprecipitation.  We also sought to assess the effects of ECM1 on the 
Ras/Raf/MEK/ERK and PI3K/PTEN/AKT signalling cascades downstream of EGFR 
using the ECM1 knockdown and control cell lines described in Chapter 4 and 
treatment with recombinant ECM1 protein prior to assessment of the 
phosphorylation levels of EGFR and the downstream effector proteins ERK and 
AKT. 
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Molecular subtyping in bladder cancer has led to the identification of tumours 
exhibiting basal features that may be more sensitive to EGFR inhibitors, supporting 
the idea that patient stratification to identify cohorts of patients who are likely to 
respond well prior to treatment can improve success rates [86]. In the complex 
proposed by Lee et al. the interaction of ECM1 and EGFR resulted in resistance to 
ERBB targeting drugs [122], hence, we propose that our ECM-high subgroup 
represents an different subset of basal-like tumours with high EGFR that may not 
respond well to EGFR inhibitiors. In this Chapter we sought to investigate the 
potential impact of ECM1 expression on the response to EGFR inhibition in vitro. 
 
Despite evidence for an interaction between ECM1 and EGFR in breast cancer [122], 
the understanding of ECM1-dependent mediators in carcinogenesis is limited. In 
order to assess a potential role for ECM1 in the activation of EGFR and other 
receptor tyrosine kinases (RTKs), we carried out a screen of the tyrosine 
phosphorylation status of 49 human RTKs using a phospho-RTK array with ECM1 
shRNA knockdown and control cell lines. To relate the findings from the phospho-
RTK array to potential treatment options for patients with ECM1-high bladder 
tumours, we also treated ECM1-high cell lines with agents targeting the RTKs 
identified as being of interest by the phospho-RTK array analysis. 
 
5.2 Results 
5.2.1 Interaction between ECM1 and EGFR 
In order to investigate a potential physical interaction between ECM1 and EGFR co-
immunoprecipitation (co-IP) was conducted using protein lysates from the HT-1376 
and 647V cell lines. Immunoprecipitation using an ECM1 antibody did not show any 
co-immunoprecipitation of EGFR in either cell line as determined by western blot 
analysis (Figure 5-1). Immunoprecipitation with an EGFR antibody and western blot 
analysis using an ECM1 antibody also yielded no evidence of a physical interaction 
(Figure 5-1).  Co-IP was carried out under a range of conditions including omitting 
vortexing and centrifugation steps from the protocol. The protocol was also carried 
out using a buffer containing minimal detergent, but a physical interaction could still 
not be detected between ECM1 and EGFR (data not shown).  
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Unstable and transient interactions can be difficult to detect by co-
immunoprecipitation. Therefore we employed crosslinking prior to 
immunoprecipitation to enable the use of the detergent based RIPA lysis buffer 
without potential disruption to the interaction. Crosslinking was conducted using 
3,3'-Dithiobis(sulfosuccinimidylpropionate) (DTSSP) as it is unable to cross 
membranes, thus reducing the formation of large cross-linked protein complexes 
which may impair formation of specific interactions of interest and create difficulties 
in the detection of co-immunoprecipitated proteins. Moreover, the spacer arm can 
be broken by the beta-mercaptoethanol present in the laemmli buffer used to elute 
proteins from the capture beads [214], so no extra steps are required before 
analysing the samples by western blot. Despite employment of DTSSP, EGFR was 
still not detected in samples immunoprecipitated using an ECM1 antibody (Figure 
5-1).  
 
Successful immunoprecipitation of both EGFR and ECM1 using their respective 
antibodies was confirmed by the positive detection of each protein on western blots 
with and without the use of a crosslinker (Figure 5-2). Neither EGFR or ECM1 were 
detected in the negative control samples that were immunoprecipitated using water 
instead of antibody or an antibody against the viral protein Sv-40 T Ag which does 
not interact with ECM1 or EGFR.  
 
5.2.2 Effects of recombinant ECM1 treatment on EGFR 
phosphorylation and signalling in ECM1 knockdown cells 
5.2.2.1 Time course assay of ECM1 induced EGFR, ERK, and AKT 
phosphorylation 
Although a physical interaction could not be detected between ECM1 and EGFR, 
the potential influence of ECM1 on the activation of EGFR and the downstream 
Ras/Raf/MEK/ERK and PI3K/PTEN/AKT signalling pathways was investigated. The 
levels of phosphorylation of EGFR and the downstream effector proteins ERK and 
AKT were measured using western blot analysis of ECM1 knockdown and scramble 
control cell lines derived from HT-1376 (Figure 5-3), 647V (Figure 5-4), HT-1197 
(Figure 5-5) and LUCC4 (Figure 5-6). ECM1 knockdown cell lines were also treated 
with 1 µg/ml recombinant ECM1 and lysates harvested after 5 min, 10 min, 20 min, 
1 h and 24 h prior to analysis of total EGFR, p-EGFR, total ERK, p-ERK, total AKT, 
and p-AKT by western blot analysis.  
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Figure 5-1: Co-immunoprecipitation of ECM1 and EGFR from HT-1376 and 647V 
cell lysates.  
Total protein lysates harvested from the cell lines A) HT-1376 and B) 647V were used in co-
IP with either anti-ECM1 or anti-EGFR antibodies and IP products were analysed by western 
blotting. Negative controls of water in place of antibody, or an Sv-40 T Ag antibody against a 
protein that does not interact with either ECM1 or EGFR were used. Blots were analysed 
using the ChemiDoc MP system. Representative of multiple experimental repeats. 
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Figure 5-2: Co-immunoprecipitation of ECM1 and EGFR from HT-1376 cell 
lysates following pre-treatment with a crosslinker.  
HT-1376 cells were incubated with the crosslinker DTSSP before lysis. Total protein lysates 
were used in co-IP with either anti-ECM1 or anti-EGFR antibodies and IP products were 
analysed by western blotting. Negative controls of water in place of antibody, or an Sv-40 T 
Ag antibody against a protein that does not interact with either ECM1 or EGFR were used. 
Blots were analysed using the ChemiDoc MP System. Representative of 4 experimental 
repeat. 
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There was slightly less p-EGFR in the untreated ECM1 knockdown compared to the 
scramble control for HT-1376. Treatment of the ECM1 knockdown with recombinant 
ECM1 led to an increase in the level of p-EGFR, with phosphorylation peaking after 
20 min, when a higher level of phosphorylation was seen in comparison to the 
scramble control sample (Figure 5-3). The level of p-ERK in the untreated ECM1 
knockdown was significantly lower than the level seen in the scramble control, with 
p-ERK being undetectable by western blot analysis. Treatment with recombinant 
ECM1 resulted in phosphorylation of ERK to a level comparable to that seen in the 
scramble control within 5 minutes of treatment, and p-ERK remained elevated for 
the full 24 h period (Figure 5-3). The untreated ECM1 knockdown also had a much 
lower level of p-AKT compared to the scramble control. Treatment with recombinant 
ECM1 led to an increase in p-AKT after 5 min to a level that was 40% lower than 
the level seen in the scramble control. The phosphorylation level of AKT decreased 
after 10 min, 20 min and 1 h of treatment to a level more closely resembling that 
seen in the untreated knockdown, and after 24 h the level was comparable to that 
seen in the scramble control after 24 h (Figure 5-3).  
 
Similar results were obtained for 647V. There was 25% less p-EGFR in the 
untreated ECM1 knockdown compared to the scramble control. Treatment with 
recombinant ECM1 resulted in an initial decrease in the level of p-EGFR after 5 
min. The levels of p-EGFR increased after 5 min, and after 20 min the level was 
comparable to that seen in the scramble control (Figure 5-4). The level of ERK 
phosphorylation was similar in the 647V ECM1 knockdown and scramble control 
lines. A 30% increase in p-ERK levels was observed after 5 min of recombinant 
ECM1 treatment after which levels of p-ERK fluctuated but remained elevated in the 
ECM1-treated samples compared to the untreated ECM1 knockdown for 1 h post-
treatment (Figure 5-4). The level of AKT phosphorylation was 60% lower in the 
647V ECM1 knockdown compared to the scramble control. A reduction in p-AKT to 
a level that was half the level in the untreated knockdown line was observed after 5 
min of treatment with recombinant ECM1, and p-AKT remained low for the full 24 h 
treatment period. 
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  Figure 5-4: W
estern blot analysis of total and phosphorylated EG
FR, ER
K
 and A
K
T in 647V.  
Phosphorylation of EG
FR
, ER
K and AKT w
as exam
ined in the 647V-derived scram
ble controls and EC
M
1 knockdow
n (KD
) cells pre- and post-treatm
ent w
ith 
recom
binant EC
M
1. After serum
 starvation for 24 h, EC
M
1 KD
 cells w
ere incubated w
ith 1 µg/m
l recom
binant EC
M
1 at 37 °C
 for 5 m
in, 10 m
in, 20 m
in, 1 h, or 
24 h. Total and phosphorylated levels of EG
FR
, ER
K and AKT w
ere analysed by w
estern blotting. Phosphorylation w
as quantified relative to total expression 
for the protein of interest using Im
age Lab softw
are. W
estern blots are representative of 2 experim
ental repeats, histogram
s represent quantified phosphorylated 
protein expression from
 the presented blot. 
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The level of p-EGFR in HT-1197 was slightly higher in the untreated ECM1 
knockdown cell line compared to the scramble control. A 40% increase in the level 
of p-EGFR was observed after 5 min of treatment with recombinant ECM1. The 
level of p-EGFR then fluctuated across the 24 h period with a 50% decrease in p-
EGFR being detected after 10 min and equivalent level of p-EGFR being detected 
at 1 h as compared to the untreated ECM1 knockdown (Figure 5-5). ERK 
phosphorylation was 60% lower in the untreated ECM1 knockdown compared to 
the control sample for HT-1197. Treatment with recombinant ECM1 did not lead to 
an increase in the phosphorylation of ERK above the level observed in the 
scramble control. AKT phosphorylation was 80% lower in the untreated knockdown 
compared to the scramble control. Treatment with recombinant ECM1 did not lead 
to an increase in the phosphorylation of AKT (Figure 5-5). 
 
The LUCC4 scramble and ECM1 knockdown cell lines had no detectable p-EGFR 
in any of the samples, however, p-ERK was present in all samples (Figure 5-6). p-
ERK levels were slightly lower in the ECM1 knockdown cells than in the scramble 
control cells. Following treatment of the ECM1 knockdown cell line with 
recombinant ECM1, p-ERK levels increased by 20% after 5 min, decreased by 30% 
at 10 and 20 min, and increased again by 70% at 24 h compared to the untreated 
ECM1 knockdown. AKT phosphorylation was also lower in the ECM1 knockdown 
compared to scramble control. Following recombinant ECM1 treatment of the 
ECM1 knockdown cell line, p-AKT levels decreased by 50% after 5 min and 10 min, 
then increased to a level which was 150% higher than the scramble control after 1 h 
and 24 h (Figure 5-6).
  Figure 5-5: W
estern blot analysis of total and phosphorylated EG
FR, ER
K
 and A
K
T in H
T-1197.  
Phosphorylation of EG
FR
, ER
K and AKT w
as exam
ined in the H
T-1197-derived scram
ble controls and EC
M
1 knockdow
n (KD
) cells pre- and post-treatm
ent 
w
ith recom
binant EC
M
1. After serum
 starvation for 24 h, EC
M
1 KD
 cells w
ere incubated w
ith 1 µg/m
l recom
binant EC
M
1 at 37 °C
 for 5 m
in, 10 m
in, 20 m
in, 1 
h, or 24 h. Total and phosphorylated levels of EG
FR
, ER
K and AKT w
ere analysed by w
estern blotting. Phosphorylation w
as quantified relative to total 
expression for the protein of interest using Im
age Lab softw
are. W
estern blots are representative of 1 experim
ental repeat, histogram
s represent quantified 
phosphorylated protein expression from
 the presented blot. 
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5.2.3 Phospho-RTK array analysis  
To identify if there were other receptor tyrosine kinases (RTKs) involved in ECM1 
dependent signalling we employed the use of a phospho-RTK array. The use of this 
array permits assessment of the relative level of tyrosine phosphorylation of 49 
different human RTKs (Figure 5-7 A). Analysis of the phospho-RTK array data 
suggested that ECM1 knockdown leads to a decrease in phosphorylation of EGFR 
(Figure 5-7 B, coordinates B1/B2), and hepatocellular growth factor receptor 
(HGFR), which is also known as MET (Figure 5-7 B, coordinates C3/C4), in the HT-
1376 ECM1 knockdown cell line relative to the scramble control. There was also a 
decrease in phosphorylation of EGFR in HT-1376 knockdown cells treated with 1 
µg/ml recombinant ECM1 relative to the scramble control, however no difference 
was observed between the ECM1 treated and untreated knockdown lines (Figure 
5-7 B and Figure 5-7 C).  
 
As foetal bovine serum used to supplement cell line growth media contains high 
levels of growth factors which may stimulate phosphorylation of receptor tyrosine 
kinases (RTKs), we also assessed the HT-1376 ECM1 knockdown cell line grown 
in the absence of serum for 24 h. A decrease in phosphorylation of both EGFR and 
MET in HT-1376 ECM1 knockdown cells out of serum relative to the scramble 
control was observed. There was a 0.2-fold increase in phosphorylation of EGFR in 
HT-1376 ECM1 knockdown cell line grown out of serum relative to the HT-1376 
ECM1 knockdown cell line grown in serum after an exposure time of 2 min, but no 
difference was noted after a 10 min exposure time (Figure 5-7 B and Figure 5-7 C). 
A 5-fold increase in phosphorylation of MET in HT-1376 knockdown cells out of 
serum relative to the HT-1376 knockdown cell line grown in serum was observed at 
an exposure time of 2 min, and a 3-fold increase after a 10 min exposure time 
(Figure 5-7 B and Figure 5-7 D).  
 
Analysis of two further cell lines, LUCC4 and 647V, also revealed a decrease in 
phosphorylation of EGFR in the ECM1 knockdown cell lines compared to the 
scramble controls (Figure 5-8 B, coordinates B1/B2; and Figure 5-8 C). 
Phosphorylation of MET was also decreased in the LUCC4 ECM1 knockdown cell 
line compared to the scramble control, however, no phosphorylation of MET was 
detected in either the 647V ECM1 knockdown or scramble control lines (Figure 5-8 
B and Figure 5-8 D). In both the LUCC4 ECM1 knockdown and scramble control 
cell lines, phosphorylation of insulin receptor (INS-R) (Figure 5-8B, coordinates 
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B17/B18) and type-1 insulin like growth factor receptor (IGF-IR) (Figure 5-8B, 
coordinates B19/B20) was observed. Phosphorylation was higher for these 
receptors in the LUCC4 ECM1 knockdown cell line compared to the scramble 
control line (Figure 5-8 E and Figure 5-8 F). 
 
5.2.4 Western blot analysis of p-MET levels in ECM1 knockdown 
and scramble control cell lines 
The phosphorylation level of MET in HT-1376, LUCC4, HT-1197 and 647V 
scramble control and ECM1 knockdown cell lines was further assessed using 
western blot analysis (Figure 5-9). In contrast to findings in HT-1376 and LUCC4 by 
phospho-RTK array analysis, these results indicated a slightly higher level of MET 
phosphorylation in the ECM1 knockdown cell lines than in the scramble control cell 
lines for LUCC4, 647V and HT-1197. Western blot analysis showed a lower level of 
MET phosphorylation in the ECM1 knockdown cell line than in the scramble control 
cell lines for HT-1376, confirming the results obtained using the phospho-RTK 
array. We also observed that treatment of the ECM1 knockdown cells with 
recombinant ECM1 resulted in an increase in MET phosphorylation after 5-10 min 
for LUCC4, 647V and HT-1197 but not for HT-1376. For ease of comparison, a 
summary Table of EGFR and MET phosphorylation status according to western blot 
analysis and phospho-RTK array was generated (Table 5-1).  
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Figure 5-7: Analysis of RTK phosphorylation in HT-1376 scramble control, 
ECM1 knockdown (+/- serum), and ECM1 knockdown cells treated with 
recombinant ECM1.  
A) A map outlining coordinates of receptors on the Human Phospho-RTK array (R&D). B) A 
comparative analysis of HT-1376 scramble control and HT-1376 ECM1 knockdown cell  
grown in media supplemented with serum and without serum and treated with 1 µg/ml 
recombinant ECM1 for 5 minutes. Cell lysates were analysed using the phospho-RTK array 
shown in A. Each pair of horizontal spots represents one receptor. Three pairs of spots in the 
top right, top left and bottom left corners are positive p-tyrosine controls. Images were 
captured using a ChemiDoc MP System and Image J software was used to quantify 
phosphorylation at 2 min and 10 min exposure times for C) EGFR and D) MET. 
Representative of 1 experimental repeat. 
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Figure 5-8: Analysis of RTK phosphorylation in LUCC4, 647V and HT-1376 
ECM1 knockdown and scramble control cell lines.  
A) A map outlining coordinates of receptors on the Human Phospho-RTK array (R&D). B) A 
comparative analysis of HT-1376, LUCC4 and 647V ECM1 knockdown and scramble control 
cell lines. Cell lysates were analysed using the phospho-RTK array shown in A. Each pair of 
horizontal spots represents one receptor. Three pairs of spots in the top right, top left and 
bottom left corners are positive p-tyrosine controls. Images were captured using a ChemiDoc 
MP System and Image J software was used to quantify phosphorylation at 2 min and 10 min 
exposure times for C) EGFR, D) MET, E) INS-R and F) IGF-1R. Representative of 1 
experimental repeat. 
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Figure 5-9: Western blot analysis of p-MET levels in ECM1 knockdown cells.  
Phosphorylation of MET was examined in scramble control and ECM1 knockdown cells pre- 
and post-treatment with recombinant ECM1 in A) HT-1376, B) LUCC4, C) HT-1197 and D) 
647V cell lines. After serum starvation for 24 h, ECM1 KD cells were incubated with 1 µg/ml 
recombinant ECM1 at 37 °C for 5 min, 10 min, 20 min, 1 h or 24 h. Total and phosphorylated 
levels of MET were analysed by western blot analysis. Phosphorylation was quantified relative 
to total MET expression for both proteins using Image Lab software. Representative of 1 
experimental repeat. 
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Table 5-1: A summary of the phosphorylation levels of EGFR and MET in ECM1 
knockdown and scramble control cell lines.  
Phosphorylation of EGFR and MET was examined in scramble control and ECM1 knockdown 
(KD) cells for HT-1376, LUCC4, HT-1197, and 647V by western blot analysis and phospho-
RTK array. For western blot analysis, phosphorylation was quantified relative to total 
expression of each protein using Image Lab software. For phospho-RTK array analysis, 
image J software was used to quantify phosphorylation after an exposure time of 2 min. 
Differences in phosphorylation between the scramble control and ECM1 KD cell lines were 
presented relative to the scramble control which was given a unit value of 1. Relative 
phosphorylation is presented as +/- where values of 0 = -, ≤1 = +, >1 to ≤2 = ++, >2 to ≤4 = 
+++, and >4 = ++++. 
 
 
 
 
  
Cell 
Line 
Western Blot Phospho-RTK array 
p-EGFR p-MET p-EGFR p-MET 
Scramble 
Control 
ECM1 
KD 
Scramble 
Control 
ECM1 
KD 
Scramble 
Control 
ECM1 
KD 
Scramble 
Control 
ECM1 
KD 
HT-1376 ++ ++ ++ + ++ + ++ + 
LUCC4 - - ++ ++++ ++ + ++ + 
HT-1197 ++ ++ ++ ++++ N/A N/A N/A N/A 
647V ++ + ++ +++ ++ + - - 
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5.2.5 Microarray analysis of HT-1376 ECM1 knockdown and 
scramble control cell lines 
Microarray analysis using a whole genome transcript array was carried out to 
identify changes in gene expression induced by ECM1 knockdown in the HT-1376 
cell line. Differential gene expression in the HT-1376 ECM knockdown KD1 and 
scramble control cell lines was assessed using LIMMA analysis conducted in R2. A 
list of the differentially expressed genes that exhibited at least a 2-fold difference 
and a p-value less than 0.05 was generated (Appendix J). This analysis identified 
307 significantly altered probes. After the removal of unannotated probes, and a 
single representative probe being selected per gene, 169 genes were found to be 
significantly differentially expressed between the ECM1 knockdown and scramble 
control cell lines. There were a total of 101 genes significantly downregulated in the 
ECM1 knockdown compared to the scramble control, including ECM1. Amongst the 
other significantly downregulated genes in the ECM1 knockdown were 16 genes 
encoding 5S ribosomal RNA (rRNA), 8 keratins (keratins 1, 4, 5, 6A, 6B, 6C, 10 and 
24), the EGFR ligand AREG, and the transcription factor ELF5. Sixty-eight genes 
were significantly upregulated in the ECM1 knockdown compared to the scramble 
control cells. To gain further insights into the consequences of ECM1 knockdown, 
pathway analysis was conducted on the list of significantly differentially expressed 
genes using Metacore. This determined the top ten most highly upregulated and 
downregulated pathways in the ECM1 knockdown compared to the scramble 
control (Figure 5-10). Cell adhesion, keratinocyte differentiation and cytoskeleton 
remodelling were amongst the most highly downregulated pathways. The most 
common features in the top ten upregulated pathways involved developmental 
pathways, in particular pathways mediated by TGF-beta and which involve 
extracellular matrix remodelling. Gene Ontology (GO) localisation analysis was also 
conducted using Metacore (Table 5-2). This examines the most common cellular 
localisations that products of the significantly upregulated and downregulated genes 
are transported to, tethered in, or maintained in some respect. This analysis 
revealed extracellular regions as the main location of interest.  
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 Table 5-2: Top 10 G
ene O
ntology (G
O
) localisations of genes differentially expressed in H
T-1376 EC
M
1 knockdow
n cells com
pared to 
scram
ble control cells. 
M
icroarray analysis w
as conducted on total R
N
A isolated from
 lysates for three sequential passages of H
T-1376 knockdow
n (KD
1) and the scram
ble control cells. 
LIM
M
A analysis w
as conducted to determ
ine genes that w
ere significantly differentially expressed betw
een the EC
M
1 KD
 com
pared to the scram
ble control. Stringency 
settings w
ere applied to include only probes that had a fold change greater than 2 or less than -2, and a LIM
M
A p value less than 0.05. This gene list w
as used to 
conduct G
O
 analysis in M
etacore in order to determ
ine the top 10 m
ost com
m
on cellular localisations of the products of significantly altered genes.  
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D
R
B4, D
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RB1-4, 2B1E, DRB1-10, 2B1D, D
RB1-3, D
RB1-9, 2B1G 
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5.2.6 Drug sensitivity experiments using agents that target 
EGFR and MET 
Differences in the phosphorylation levels of EGFR and MET were detected by 
phospho-RTK array analysis of ECM1 knockdown and scramble control cell lines. 
The pharmacological agents erlotinib and tivantinib (ARQ197) were used to 
determine the sensitivity of ECM1-high cell lines to EGFR and MET inhibition, 
respectively. 
 
5.2.6.1 Erlotinib 
To determine whether an EGFR inhibitor reduces cell viability of ECM1-high cell 
lines, we treated the parental cell lines HT-1376, HT-1197, LUCC4 and 647V with 
the EGFR inhibitor erlotinib (Figure 5-11). Cells were treated with either 0.1% 
DMSO or with erlotinib at a final concentration of 1 nM, 5 nM, 10 nM, 25 nM, 50 nM, 
125 nM, 250 nM, 500 nM or 1 µM over a period of 6 days. For the HT-1376 (Figure 
5-11 A) and 647V (Figure 5-11 D) cell lines a maximal effect of 35-40% growth 
inhibition was achieved at 1 µM. As less than 50% growth inhibition was achieved, 
half the maximal effective concentration (EC50) could not be determined. Half the 
maximal inhibitory concentration (IC50) values for the cell lines 647V and HT-1376 
were 139.0 nM and 252.6 nM, respectively. Compared to the control treatment 
(0.1% DMSO) no dose-dependent changes in cell viability were seen for either HT-
1197 (Figure 5-11 G) or LUCC4 (Figure 5-11 J) which were both highly resistant to 
treatment. Neither EC50 or IC50 could not be calculated using non-linear regression 
analysis due to the limited cell death in these cell lines.  
 
In order to determine if ECM1 influenced resistance against erlotinib, for each of the 
cell lines examined (HT-1376, LUCC4, HT-1197, 647V) an ECM1 knockdown (KD1) 
and scramble control were also treated with either 0.1% DMSO or erlotinib at a final 
concentration of 1 nM, 5 nM, 10 nM, 25 nM, 50 nM, 125 nM, 250 nM, 500 nM, or 1 
µM over a period of 6 days (Figure 5-11). In the HT-1376 cell line a maximal effect 
of 24% growth inhibition for the scramble control (Figure 5-11 B), and 21% for the 
ECM1 knockdown (Figure 5-11 C) was achieved at 1 µM erlotinib. As less than 
50% growth inhibition was achieved for HT-1376, absolute EC50 could not be 
determined. However relative IC50 was calculated as 126.7 nM and 249.3 nM for 
the ECM1 KD and scramble control lines, respectively. For 647V, cell viability was 
reduced to 41% and 47% at 1 µM erlotinib for the scramble control (Figure 5-11 E) 
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and ECM1 knockdown (Figure 5-11 F), respectively. IC50 for the 647V ECM1 
knockdown was determined to be 10.99 µM, and IC50 for the scramble control was 
determined to be 44.32 µM. In the HT-1197 cell line cell viability remained at 100% 
across all treatment concentrations (Figure 5-11 G, H, I). Cell viability in the LUCC4 
ECM1 knockdown and scramble control cell lines remained at between 85-100% 
across all treatment concentrations of erlotinib (Figure 5-11 J, K, L). One-way 
ANOVA was also performed to compare both IC50 and maximal response achieved 
in the parental, scramble control and ECM1 knockdown cell lines. No significant 
difference was noted in IC50 or maximal response in terms of percentage cell 
viability post-treatment for any of the cell lines.   
 
5.2.6.2 Tivantinib 
To explore the effect of the MET inhibitor tivantinib (ARQ197) on the growth of 
ECM1-high bladder tumour-derived cell lines, we treated the parental cell lines HT-
1376, LUCC4, 647V and HT-1197 with either 0.1 % DMSO or tivantinib at a final 
concentration of 10 nM, 100 nM, 500 nM, 1 µM, 2 µM, 4 µM, 6 µM, 8 µM or 10 µM 
over a period of 6 days (Figure 5-12). For the HT-1376 (Figure 5-12 A) and LUCC4 
(Figure 5-12 D) cell lines, complete killing was not achieved. Tivantinib achieved 
maximum effect at 0.1 µM for LUCC4 and 10 µM for HT-1376, representing a 
reduction in cell viability of 50% and 40% respectively. Compared to the control 
treatment of 0.1% DMSO, maximal dose-dependent growth inhibition of 80% was 
achieved at 0.5 µM tivantinib for HT-1197 (Figure 5-12 G). Complete cell death of 
647V cell line was achieved at 1 µM (Figure 5-12 H). As less than 50% growth 
inhibition was achieved in the LUCC4 and HT-1376 cell lines, absolute EC50 could 
not be determined, however IC50 values were calculated to be 0.01 µM for LUCC4, 
2.79 µM for HT-1376, 0.35 µM for 647V and 0.25 µM for HT-1197.  
 
In order to determine if ECM1 influenced resistance of cell lines to the MET 
inhibitor, where less than 80% cell death was noted in the parental cell line (LUCC4 
and HT-1376) an ECM1 knockdown (KD1) and scramble control were also treated 
with tivantinib (Figure 5-12). One-way ANOVA was carried out to compare both IC50 
and maximal response achieved in the parental, scramble control and ECM1 
knockdown for HT-1376 and LUCC4 cell lines treated with tivantinib. For the HT-
1376 scramble control cell lines (Figure 5-12 B) and ECM1 knockdown cell line 
(Figure 5-12 C) treatment with tivantinib resulted in the maximal effect of 50-55% 
reduction in cell viability at concentrations greater than 1 µM, and IC50 was 
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determined to be 0.89 µM and 0.77 µM, respectively. No significant difference was 
observed in IC50 or maximal response for HT-1376 between the ECM1 KD, 
scramble control or parental cell lines. The LUCC4 scramble control (Figure 5-12 E) 
and ECM1 knockdown (Figure 5-12 F) cell lines were also treated with tivantinib. 
Treatment with tivantinib led to a maximal reduction in cell viability of 65% for the 
scramble control and 53% for the ECM1 knockdown, and IC50 was determined to be 
130 nM and 1.21 µM respectively. No significant difference was noted in IC50. 
However, a significant difference was noted for the maximal response to tivantinib, 
with the scramble control demonstrating significantly reduced cell viability compared 
to the parental or ECM1 knockdown cell lines (p = 0.00013). 
 
5.2.6.3 Dual treatment with erlotinib and tivantinib 
Since there are a number of overlapping effector proteins in the MET and EGFR 
pathways, it was proposed that resistance may be due to of crosstalk between the 
two receptors. The effect of simultaneous MET and EGFR dual inhibition in HT-
1376 was examined to identify if dual treatment led to enhanced reduction in cell 
viability compared to individual treatments alone (Figure 5-13). HT-1376 cells were 
treated with either 0.1% DMSO or doses corresponding to 0.1x, 0.125x, 0.25x, 0.5x, 
1x, 2x or 4x the IC50 for each drug. For example, for the HT-1376 parental 0.1x the 
IC50 equates to 25.3 nM erlotinib and 279 nM tivantinib. An isobologram was 
created to determine if dual treatment provides an agonistic or synergistic effect, 
and this suggested dual tivantinib and erlotinib treatment had an additive effect. IC50 
for dual treatment was determined to be 0.01x each drug’s IC50 (2.53 nM erlotinib 
and 27.9 nM tivantinib). The creation of an isobologram requires the calculation of 
each drug’s individual IC50, therefore similar experiments could not be conducted 
for the LUCC4, 647V and HT-1197 cell lines. 
 
Dual tivantinib and erlotinib treatment was also carried out for both the HT-1376 
ECM1 knockdown and scramble control cell lines in order to determine if ECM1 
influenced sensitivity (Figure 5-13). The HT-1376 ECM1 knockdown cell line 
exhibited a maximal reduction in cell viability of 73% and an IC50 of 0.13x each 
drug’s individual IC50 (16.5 nM erlotinib and 116.3 nM tivantinib). For the scramble 
control, a maximal reduction in cell viability of 56% was achieved and the IC50 was 
determined to be 0.21x each drugs IC50 (52.4 nM erlotinib and 160.7 nM tivantinib). 
One-way ANOVA comparing IC50 and maximal response achieved in the parental, 
scramble control and ECM1 knockdown cell lines with dual treatment was 
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conducted and showed no significant differences in terms of percentage cell 
viability post-treatment.  
 
 
 
Figure 5-11: Treatment of HT-1376, LUCC4, HT-1197 and 647V cell lines with 
the EGFR inhibitor erlotinib.  
3000-7000 cells were plated in each well of a 96 well plate in order to achieve 80% confluency 
in the untreated control at the end of the assay for each of the following cell lines: A) HT-1376 
parental, B) HT-1376 scramble control, C) HT-1376 KD, D) LUCC4 parental, E) LUCC4 
scramble control, F) LUCC4 KD, G) HT-1197 parental, H) HT-1197 scramble control, I) HT-
1197 KD, J) 647V parental, K) 647V scramble control and L) 647V KD. Cells were incubated 
with 0.1% DMSO or 1 nM, 5 nM, 10 nM, 25 nM, 50 nM, 125 nM, 250 nM, 500 nM, or 1 µM 
erlotinib for 6 days. Five replicate wells were used for each concentration of drug. Conversion 
of the redox dye resazurin to fluorescent resorufin was measured and was taken as 
proportional to the number of viable cells. Data are displayed as percentage cell viability 
relative to the DMSO control. Representative of 1 experimental repeat. 
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Figure 5-12: Treatment of HT-1376, LUCC4, HT-1197 and 647V cell lines with 
the MET inhibitor tivantinib.  
3000-7000 cells were plated in each well of a 96 well plate in order to achieve 80% confluency 
in the untreated control at the end of the assay for each of the following cell lines: A) HT-1376 
parental, B) HT-1376 scramble control, C) HT-1376 KD, D) LUCC4 parental, E) LUCC4 
scramble control, F) LUCC4 KD, G) HT-1197 parental and H) 647V parental. Cells were 
incubated with 0.1% DMSO or 10 nM, 100 nM, 500 nM, 1 µM, 2 µM, 4 µM, 6 µM, 8 µM or 10 
µM tivantinib for 6 days. Five replicate wells were used for each concentration of drug. 
Conversion of the redox dye resazurin to fluorescent resorufin was measured and was taken 
as proportional to the number of viable cells. Data are displayed as percentage cell viability 
relative to the DMSO control. Representative of 1 experimental repeat. 
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Figure 5-13: Dual treatment of HT-1376 parental, scramble control and ECM1 
KD cell lines with the EGFR inhibitor erlotinib and the MET inhibitor tivantinib.  
3000 cells were plated in each well of a 96 well plate. Cells were incubated with 0.1% DMSO 
or ratios of 0.1x, 0.125x, 0.25x, 0.5x, 1x, 2x or 4x the previously determined IC50 of each 
individual drug for dual treatment over 6 days. Five replicate wells were used for each drug 
concentration. Conversion of the redox dye resazurin to fluorescent resorufin was measured 
and was taken as being proportional to the number of viable cells. Data are displayed as 
percentage cell viability relative to the DMSO control for A) HT-1376 parental, B) HT-1376 
scramble control and C) HT-1376 ECM1 KD cell lines. Isobolograms were created for D) HT-
1376 parental, E) HT-1376 scramble control and F) HT-1376 ECM1 KD cell lines, determining 
the IC50 of dual erlotinib and tivantinib treatment in relation to each drug’s individual action. 
This showed that combination treatment had a synergistic effect as the experimental IC50 falls 
below the additive line. Representative of 1 experimental repeat. 
 159 
5.3 Discussion  
Despite evidence for the involvement of ECM1 in cancer, very little is understood 
about the mechanisms and signalling pathways through which ECM1 mediates its 
effects. It has been suggested that ECM1 may be involved in EGFR signalling, as 
EGFR and ECM1 have been co-immunoprecipitated in breast cancer-derived cell 
lines [122]. This interaction was proposed to increase signalling through the 
Ras/Raf/MEK/ERK pathway, thereby mediating resistance to the ERBB2 targeting 
monoclonal antibody, trastuzumab. 
 
Overexpression of epidermal growth factor receptor (EGFR) has been associated 
with high stage and grade muscle-invasive bladder tumours, poor clinical outcome, 
disease progression and disease recurrence following adjuvant chemotherapy [59, 
215]. Due to its role in MIBC progression and treatment resistance, EGFR represents 
a potential therapeutic target in MIBC. Although several trials have been conducted 
into the use of EGFR inhibitors for the treatment of MIBC, so far these have shown 
limited success. For example, a phase II study with the small molecule inhibitor 
gefitinib showed no improvement in survival or progression when the inhibitor was 
used as a first or second line treatment [216, 217].  
 
Molecular subtyping of MIBC led to the proposal that stratification of patients based 
on the molecular features of the tumours could be beneficial and may increase the 
effectiveness of EGFR inhibitors by enabling pre-selection of patients most likely to 
respond [86]. Rebouissou et al. described an aggressive basal subtype thought to be 
dependent on EGFR for growth that represents around a quarter of all MIBC cases 
[86]. Classification of 22 bladder tumour-derived cell lines using a set of 40 genes 
differentially expressed between basal and non-basal tumours identified eleven of 
the cell lines as basal. Of these 11 cell lines, 9 showed 50% growth inhibition 
following treatment with the EGFR small molecule inhibitor erlotinib at a 
concentration of less than 1 µM. In contrast, only one of the non-basal cell lines 
exhibited sensitivity to the drug [86]. This suggests that the described molecular 
subtypes of MIBC may independently predict response to EGFR inhibitors, and 
highlights the potential for the stratification of MIBC based on molecular subtypes 
as an effective strategy for the allocation of therapeutic options.   
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Although our ECM1-high subtype also exhibits basal-like features for example 
increased of keratins 5 and 6 and EGFR, none of these cell lines were used in the 
study of Rebouissou et al. We proposed that our ECM1-high subgroup may 
represent a subset of basal tumours expressing EGFR that are not sensitive to 
EGFR inhibition as a result of an interaction between ECM1 and EGFR in the 
complex proposed in breast cancer [122]. We investigated the potential for this 
complex to exist in the ECM1-high cell lines using co-immunoprecipitation, but a 
physical interaction between ECM1 and EGFR in our ECM1-high cell lines could 
not be detected.  
 
Although a physical interaction between ECM1 and EGFR not detected we also 
considered the potential for ECM1 to influence EGFR signalling indirectly, for 
example via another mediator. In breast cancer-derived cell lines, recombinant 
ECM1 treatment has been demonstrated to initiate ERK phosphorylation [122], and 
similarly a recent study demonstrated that recombinant ECM1 treatment stimulated 
ERK and AKT phosphorylation in cardiac fibroblast cells grown in culture [218]. We 
examined the effects of ECM1 expression on the phosphorylation of EGFR and two 
effectors of downstream signalling, ERK and AKT. Increased levels of p-EGFR 
were noted in the HT-1376, HT-1197, and 647V cell lines in response to treatment 
with recombinant ECM1. Moreover, ERK phosphorylation was lower in ECM1 
knockdown cell lines compared to the scramble controls for HT-1376 and HT-1197, 
and an increase in the level of ERK phosphorylation was noted for HT-1376, HT-
1197 and 647V in response to recombinant ECM1 treatment. Our results imply that 
ECM1 plays a role in initiating activation of the EGFR pathway, and that ERK is a 
downstream target of EGFR activation. It is interesting that despite changes to ERK 
and AKT signalling, no changes to cell-proliferation were noted in the ECM1 
knockdowns compared to the control cell lines. This suggests the activation of 
another unidentified feedback mechanism by which the ECM1 knockdown cells can 
maintain cell proliferation. 
 
Phosphorylation of EGFR could not be detected in the LUCC4 scramble control cell 
line or ECM1 knockdown (with or without treatment with recombinant ECM1) 
implying that the receptor is not active in these cell lines, and activation is not 
initiated by ECM1. A previous study in breast cancer derived cell lines reported that 
while there was no change in EGFR or ERK phosphorylation in response to 
treatment with recombinant ECM1 alone, treatment with both ECM1 and EGF 
resulted in a significant increase in p-EGFR and p-ERK compared to EGF treatment 
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alone [122]. The HT-1376, HT-1197 and 647V cell lines are grown in media 
supplemented with 10% foetal bovine serum which contains high levels of growth 
factors such as EGF, whereas the LUCC4 cell line is cultured in media 
supplemented with just 1% serum and contains lower levels of growth factors. This 
may explain the absence of EGFR phosphorylation in the LUCC4 cell line, and the 
dual role of ECM1 and EGF in the activation of EGFR in LUCC4 may be an 
interesting line for future investigation.  
 
Despite a lack of EGFR phosphorylation, ERK phosphorylation was observed to be 
slightly reduced in the LUCC4 ECM1 knockdown compared to the scramble control 
cell line, and an increase in the level of p-ERK was seen in response to treatment 
with recombinant ECM1. In this cell line it seems that although the downstream 
Ras/Raf/MEK/ERK pathway is activated by ECM1 it is not initiated through EGFR. 
ERK signalling is initiated by the activation of RAS which can be induced by a 
number of receptor tyrosine kinases such as EGFR, FGFR, and VGFR [219], hence, 
there is the potential that ERK signalling in LUCC4 is initiated through another 
receptor. ERK phosphorylation was lower in the LUCC4 ECM1 knockdown cell lines 
compared to the scramble control suggesting that the Ras/Raf/MEK/ERK pathway 
is a downstream target in all ECM1-high cell lines irrespective of the upstream 
receptor.   
 
A smear instead of one defined band was noted for total AKT in both the ECM1 
knockdown and the scramble controls cell lines for HT-1197, HT-1376 and LUCC4, 
and in the ECM1 knockdown cell line for 647V. Previous studies have 
demonstrated that this may be a consequence of AKT ubiquitination [220-222]. 
Ubiquitination most commonly targets proteins for degradation, however, 
ubiquitination of AKT mediated by K63 has recently been shown to alter cellular 
localisation and increase AKT signalling which in turn can promote cancer 
progression [222]. The smeared appearance of total AKT we noted for the ECM1-
high cell lines may suggest that AKT-ubiquitination is also occuring in our cell lines, 
although the consequences of this ubiquitination are unclear. In the 647V cell line, 
the smearing patter observed for total AKT was accompanied by a reduction in the 
level of p-AKT in the ECM1 knockdowns cells compared to scramble control cells, 
perhaps implying that in this cell line ECM1 reduces ubiquitination of AKT. This in 
turn may result in decreased AKT degradation and increased availability of the 
protein for phosphorylation. A similar trend was not noted in the other cell lines (HT-
1376, HT-1197, and LUCC4) suggesting ubiquitination is independent of ECM1 
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expression status in these cell lines, and it is unclear whether the potential 
ubiquitination we have observed would target AKT for degradation or alter the 
localisation of the protein. Regardless of potential ubiquitination, p-AKT was 
reduced in the untreated ECM1 knockdown samples compared to scramble 
controls for all cell lines, suggesting that like ERK, AKT is a downstream target in 
our ECM1-high cell lines.  
 
Our results suggest that ECM1 influences the Ras/Raf/MEK/ERK and 
PI3K/PTEN/AKT signalling pathways potentially through EGFR activation. 
Activation of other receptor tyrosine kinases may also result in similar downstream 
signalling effects and there is very little information in the literature regarding ECM1 
dependent mediators in carcinogenesis. Phospho-receptor tyrosine kinase 
(Phospho-RTK) array analysis demonstrated reduced levels of p-EGFR in all ECM1 
knockdown cells compared to the scramble control lines providing further evidence 
of a role for ECM1 in EGFR pathway activation.  
 
Phospho-RTK array analysis also identified MET as another potential receptor 
involved in ECM1-mediated signalling. A 10-fold decrease in MET phosphorylation 
was noted in the ECM1 knockdown compared to the scramble control for the HT-
1376 cell line. MET is a transmembrane tyrosine kinase receptor which is activated 
via interaction with its only known endogenous ligand, hepatocyte growth factor 
(HGF). MET initiates signalling through pathways such as Ras/Raf/MEK/ERK and 
PI3K/PTEN/AKT, that promote cell proliferation, migration and regulate apoptosis. 
This receptor plays an important role in embryogenesis and wound-healing [60]. 
These steps are also crucial for the dissemination of tumour cells, and increased 
MET expression and activation has been repeatedly implicated in tumorigenesis, 
progression and metastasis of a number of carcinomas including breast cancer, 
non-small cell lung cancer and hepatocellular carcinoma [223-225]. Increased MET 
signalling in muscle-invasive bladder cancer shows a strong correlation with 
increased metastatic potential and poor outcome [226]. The difference in the level of 
p-MET detected in the HT-1376 ECM1 knockdown and scramble control cells was 
also mirrored in the LUCC4 samples implying that ECM1 influences MET activation. 
MET phosphorylation was not a feature identified by phospho-RTK array analysis of 
647V. This cell line expresses much lower levels of ECM1 at both the mRNA and 
protein levels compared to either LUCC4 or HT-1376 and may respond differently.  
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Results obtained by western blot and phospho-RTK array analysis were not always 
concordant. There are a number of technical differences between the two 
approaches that may have influenced the observed results. One of the most 
notable differences between the techniques is the source of the antibodies used to 
assess tyrosine phosphorylation. Factors such as antibody-antigen affinity and 
cross reactivity can influence detection of a protein and could have contributed to 
the observed differences in the levels of phosphorylation measured [227]. 
Furthermore, differences in the lysis buffers and the phosphatase inhibitors these 
buffers contain could also influence the detected levels of receptor phosphorylation. 
For example, degraded phosphatase inhibitors can result in reduced signal and 
multiple bands on western blots, while transfer and running buffers contaminated 
with sodium azide can inactivate the horseradish peroxidase used in the detection 
step and therefore mask signals which might result in differences being observed 
between the two methods [228, 229].  Regardless of the reason for the discrepancy, it 
is difficult to determine without further analysis which method is a truer 
representation.  
 
Quantification of western blot and phosphoarray results are hard to standardised 
due to a number of differences including image acquisition techniques, analysis 
software and background normalisation methods [230]. These differences become 
accentuated when attempting to quantify phosphorylation status, as differences in 
the affinities of the antibodies used to detect the phosphorylated and total proteins 
by western blotting can lead to ratio calculations being unreliable [231]. It has been 
argued that western blots should not be used in a quantitative respect, but only to 
demonstrate large differences in protein levels that are immediately obvious to the 
naked eye [230].  
 
In the LUCC4 cell line, type 1 insulin-like growth factor receptor (IGF-1R) and 
insulin receptor (INSR) were also highlighted as activated by phospho-RTK array 
analysis. Both receptors are important for the regulation of energy metabolism and 
cell growth [232], and signalling through these receptors has also been reported to be 
widely involved in carcinogenesis and tumour progression [233]. Overexpression of 
INSR is seen in a number of different carcinomas including breast, colon, lung, 
ovary and thyroid, and is reported to provide these cancers with a selective 
advantage over non-malignant tissue as they are more sensitive to the mitogenic 
effects of insulin [234]. IGF-1R is reported to be important in the acquisition of a 
neoplastic phenotype, anchorage independent growth and inhibition of apoptosis 
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[233]. High levels of the IGF-1R ligands IGF-1 and IGF-2, have been reported in 
MIBC and are associated with poorer survival in patients [234]. As higher levels of 
phosphorylation were observed in the LUCC4 ECM1 knockdown cell line compared 
to the scramble control cell line, it may suggest that IGF-1R and INSR activation is 
a feedback mechanism by which LUCC4 ECM1 knockdown cells can maintain cell 
proliferation. As phosphorylation of IGF-1R and INSR was not detected by the 
analysis of HT-1376 and 647V it is unlikely to be a common feature of ECM1 high 
cell lines. Nevertheless, it does highlight that multiple receptors in tumour cells can 
activate pathways that influence factors such as growth, metastasis and drug 
resistance, and could pose difficulties when considering targeted approaches to 
therapy. 
 
In order to investigate the effects of ECM1 knockdown on gene expression, 
microarray analysis was conducted to compare genome-wide expression in the HT-
1376 ECM1 knockdown and scramble control cell lines. A striking feature of this 
analysis was the more than three-fold downregulation of 16 genes encoding 5S 
ribosomal RNA (rRNA) in the ECM1 knockdown compared to the scramble control. 
The ribosome is a complex involved in the synthesis of proteins from mRNA and 5S 
rRNA forms a key structural and functional component of this complex [235, 236]. 
Increased transcription of ribosomal genes is a common feature across many 
human cancers [237]. In a study which examined 721 tumour samples from six 
cancer types (bladder cancer, lung adenocarcinoma, lung squamous cell 
carcinoma, kidney renal clear cell carcinoma, head and neck squamous cell 
carcinoma and stomach adenocarcinoma) a 2 to 10-fold amplification of 5S rDNA 
was detected in almost every cancer genome relative to paired adjacent normal 
tissue [237]. A potential reason for the increase in rRNA is the need for cancer cells 
to increase production of macromolecules such as proteins in order to facilitate cell 
replication [238]. Decreased expression of 5S rRNA in response to ECM1 knockdown 
suggests that ECM1 either directly or indirectly regulates 5S rRNA expression 
which in turn may increase protein synthesis in ECM1-high cells.  
 
The expression of the transcription factor E74-like transcription factor 5 (ELF5) was 
also downregulated in the HT-1376 knockdown cell line compared to the scramble 
control cell line. ELF5 is a member of a large family of transcription factors known 
as the epithelium twenty-six (ETS) family [239]. ELF5 is only expressed in a selected 
set of normal human epithelial tissues, including the salivary glands, skin, breast 
and bladder [240], and plays a regulatory role in cell differentiation of specific cell 
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types, for example, it is upregulated during keratinocyte differentiation in vitro [241]. In 
bladder cancer most evidence indicates that ELF5 plays a tumour suppressor role. 
In a study that compared high and low stage bladder tumours, ELF5 was found to 
be significantly lower in MIBC [239]. Our results appear to contradict this observation 
as knockdown of ECM1 in HT-1376, a cell line derived from a muscle-invasive 
bladder tumour, led to downregulation of ELF5. In breast cancer-derived cell lines 
sustained ELF5 expression leads to a basal-like aggressive subtype, and ELF5 
knockdown results in suppression of a basal pattern of gene expression [242]. 
Moreover, ELF5 expression is significantly higher in basal compared to luminal 
breast cancer subtypes at the mRNA level [242]. Our microarray analysis suggests 
ECM1 may regulate ELF5 expression which in turn could be regulating a more 
basal phenotype. Indeed, a number of genes found to be downregulated in the 
ECM1 knockdown including kallikrein-related peptidases (KLK) 5, 6 and 7, 
keratinocyte differentiation associated protein (KRTDAP), amphiregulin (AREG), 
and five keratins (keratins 1, 10, 4, 5, and 6) have been shown to have higher 
expression at the mRNA level in basal MIBC compared to non-basal MIBC [86]. Joint 
expression of keratin 6 and keratin 5 is also commonly associated with a basal 
subtype of MIBC [74, 190]. As basal markers are downregulated in the HT-1376 ECM1 
knockdown cell line, this implies that ECM1 promotes the expression of genes 
related to a basal phenotype which could potentially be mediated through activation 
of ELF5. 
 
AREG is an EGFR ligand which is expressed at higher levels in basal MIBC and 
was downregulated in the HT-1376 ECM1 knockdown cells. EGFR has multiple 
ligands, and although each ligand binds to EGFR causing dimerization of the 
receptor, it is widely believed that they each have distinct downstream biological 
actions [243-245]. AREG has been reported to influence the EGFR recycling pathway 
[246-248]. Stimulation of the laryngeal carcinoma-derived cell line HEp2 with 
recombinant AREG leads to the ubiquitination and internalisation of EGFR into 
endosomes. However, unlike EGF or TGF-α stimulated degradation, AREG 
stimulated ubiquitination is transient and is quickly lost resulting in EGFR being 
recycled to the cell surface where it can continue to signal [246]. AREG-mediated 
EGFR recycling is thought to lead to a more sustained level of ERK phosphorylation 
as opposed to transient activation [249]. ERK phosphorylation was reduced in the 
HT-1376 ECM1 knockdown cell line according to western blot analysis and a 
decrease in AREG expression was detected in the same cells by microarray 
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analysis. It might be that ECM1-mediated expression of AREG leads to an increase 
in Ras/Raf/MEK/ERK signalling.  
 
Activation of the EGFR pathway by ECM1 was highlighted by phospho-RTK array 
analysis which showed a reduction in the level of p-EGFR in all ECM1 knockdown 
cells compared to the scramble controls. Altered MET phosphorylation was also 
observed in the HT-1376 and LUCC4 ECM1 knockdown cells compared to the 
scramble controls according to phospho-RTK array analysis. Due to the potential 
involvement of ECM1 in the activation of the MET and EGFR pathways we chose to 
assess the response of ECM1 high cell lines to EGFR and MET inhibitors.  
 
There are a wide range of inhibitors that can be used to target EGFR. The two main 
classes of these drugs are monoclonal antibodies such as cetuximab and 
panitumumab, which are currently used in the treatment of advanced metastatic 
colorectal cancer and head and neck cancer [250, 251], and small molecule inhibitors 
such as erlotinib, gefitinib, vandetanib and lapatinib which are currently used to 
treat  pancreatic cancer, NSCLC, advanced medullary thyroid cancer and advanced 
breast cancer [252]. This wide range of accessible inhibitors makes a logical selection 
for use in cell viability assays difficult. Inhibitors may not be selective for EGFR and 
may inhibit other members of the ERBB family due to the closeness in structural 
similarity of the receptors [253], and standardised quantitative descriptions of the 
selectivity of inhibitors is very often inadequate or completely absent [252]. Selective 
entropy, a quantification of the binding distribution of inhibitors in a selectivity panel, 
can be used to overcome this issue. The higher the entropy value, the more 
kinases the drug binds to while low entropy denotes selectivity [252]. The approach of 
selective entropy allows for the assignment of a defined value of a drug’s selectivity 
and can be used to rank inhibitors for use and guide selection.  
 
The small molecule inhibitor erlotinib is highly selective for EGFR. It has one of the 
lowest selective entropy values (0.9) for any EGFR inhibitor [254], and does not 
cross-react with other ERBB receptors. In MIBC, erlotinib has undergone a phase II 
open-label trial in 20 patients with clinical stage T2 disease [255]. Patients in this trial 
were treated with adjuvant erlotinib for four weeks. Upon surgical pathology, 12 
patients were clinically down-staged to T0 or T1, and 15 had organ-confined 
disease suggesting erlotinib may be beneficial prior to surgical resection for MIBC 
[255].  As it may be of clinical benefit to MIBC patients and has high selectivity, 
erlotinib was selected for use in our drug viability assays.  
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The present study found the ECM1-high bladder tumour-derived cell lines to be 
resistant to erlotinib treatment, with LUCC4 and HT-1197 showing complete 
resistance to the drug and only partial growth inhibition being observed for HT-1376 
and 647V. ECM1 has previously been linked to resistance to ERRB targeting drugs 
[122]. In order to investigate the impact of ECM1 expression on resistance to EGFR 
targeting drugs, ECM1 knockdown and scramble control cell lines were treated with 
erlotinib. ECM1 knockdown cell lines showed no difference in cell viability post-
treatment compared to the scramble control cell lines, suggesting that ECM1 
expression alone does not influence resistance to the drug. A previous investigation 
of erlotinib resistance in non-small-cell lung cancer reported a correlation between 
increased expression of EGFR, MET and IGF-1R and erlotinib resistance. It was 
proposed that increased expression of the other two receptors results in sustained 
Ras/Raf/MEK/ERK and PI3K/PTEN/AKT signalling when EGFR is inhibited [256]. As 
the MET and IGF-1R receptors were also highlighted by phospho-RTK array 
analysis, it is possible that the ECM1-high cell lines are not exclusively dependent 
on EGFR signalling and can continue to signal via pathways essential for growth 
and survival despite EGFR inhibition with erlotinib.  
 
MET inhibitors are not yet common place in the clinic, however, there are a number 
of commercially available inhibitors and some are currently undergoing clinical 
trials. The most commonly cited MET inhibitors are SU11274, PHA665752 and 
MGCD265 (glesatinib). There is very little published data on the kinetics of these 
drugs and they are not thought to be highly selective for MET [257]. More recently 
developed inhibitors such as tivantinib (ARQ197) are much more selective. 
Tivantinib is a non-ATP competitive inhibitor which has a high affinity for MET and 
showed no alternative inhibitory effects when tested against a panel of 230 human 
kinases [258]. It was established as safe for human use in a phase 1 open-label trial 
in patients with incurable advanced solid tumours, demonstrating manageable side 
effects such as vomiting and nausea, fatigue and diarrhoea [259]. Tivantinib was 
selected for cell viability assays in the current study due to its relatively high 
specificity and safety as demonstrated in trials.  
 
Tivantinib treatment of ECM1-high cell lines mediated cell growth inhibition to a 
greater extent than erlotinib treatment. Results were comparable to reports of 
tivantinib treatment in myeloma derived cell lines, where complete killing or notable 
levels of cell death (>50%) were achieved with 1 µM tivantinib [260]. In the current 
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study <1µM tivantinib treatment resulted in maximal growth inhibition of 
approximately 50% in HT-1376 and LUCC4, and 80-100% in HT-1197 and 647V. 
Although the action of tivantinib in 647V was promising, MET phosphorylation was 
not detected by phospho-RTK array analysis of this cell line. Total MET was 
detected in 647V by western blot analysis. This implies that phosphorylation of the 
receptor may not be a wholly suitable marker for sensitivity to MET inhibition. 
Indeed, suggestions have been made that tivantinib may not inhibit MET kinase 
activity in the traditional sense but may act to delay activation of MET in the 
dephosphorylated form [261], thus our results may imply that tivantinib is targeting 
dephosphorylated MET in this cell line. Recent reports suggest that tivantinib 
inhibits tubulin synthesis and leading to G2/M phase cell cycle arrest in lung 
carcinoma-derived cell lines [262], and this could pose another mechanism by which 
tivantinib treatment resulted in complete cell death of 647V cell lines.  
 
The impact of ECM1 expression on resistance to tivantinib was also assessed 
through treatment of ECM1 knockdown and scramble control cell lines derived from 
HT-1376 and LUCC4. While HT-1376 ECM1 knockdown and scramble control cell 
lines showed no difference in cell viability post-treatment, a significant difference 
was noted between the maximal response achieved in the LUCC4 ECM1 
knockdown, scramble and parental control, however, it was the scramble control 
that showed the greatest reduction in cell viability in response to treatment, 
suggesting that resistance was not ECM1 mediated. As with erlotinib, these results 
suggest that patients who may benefit from MET inhibition cannot be stratified 
based on the level of ECM1 expression. 
 
Cross-talk between the MET and EGFR pathways may also contribute to a lack of 
sensitivity to erlotinib and tivantinib in the ECM1-high cells. Focal amplification of 
MET in lung cancer has been reported to result in resistance to the EGFR inhibitor 
gefitinib, potentially through MET heterodimerisation with ERBB3 resulting in the 
activation of the PI3K/PTEN/AKT pathway [263]. MET inhibition alone had no effect 
on gefitinib resistant lung cancer cell lines, but these lines were sensitive to 
combination treatment with MET and EGFR inhibitors in vitro [263], suggesting co-
dependence on EGFR and MET signalling. Similarly, in gastric cancer-derived cell 
lines, resistance to MET inhibition correlated with high levels of EGFR activation 
and sustained downstream signalling of the RAS/RAF/MEK/ERK pathway [264, 265]. 
As both resistance to individual treatments targeting EGFR and MET, and high 
levels of ERK phosphorylation were seen in our the ECM1-high cell lines, it was 
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proposed that dual treatment may have greater efficacy. Dual treatment in HT-1376 
resulted in an additive effect of these drugs in combination and may suggest that 
simultaneous inhibition of EGFR and MET could be an effective approach to 
targeted treatment in patients that exhibit resistance to individual EGFR and MET 
treatments. Furthermore, the lower IC50 attained may enable a reduction in the dose 
required for patients and limit side effects. However, as no difference was noted 
between dual inhibition of the HT-1376 ECM1 knockdown compared to the parental 
or scramble control cell lines, ECM1 does not appear to influence the effectiveness 
of dual treatment.  
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Chapter 6  
Final Discussion  
Preliminary work carried out by the Knowles group prior to the start of this study 
identified a subset of bladder-tumour derived cell lines (subgroup 2) that had basal-
squamous features but also exhibited unique and significant upregulation of 50 
genes including ECM1 and MUC1 (Hurst et al. unpublished data). The first aim of 
this project was to confirm the expression levels of ECM1 and MUC1 in the bladder 
tumour-derived cell line panel. qRT-PCR and western blot analysis confirmed high 
levels of ECM1 and MUC1 in subgroup 2 at both the protein and mRNA levels. 
Furthermore, immunohistochemistry analysis confirmed high protein expression in 
formalin-fixed paraffin embedded (FFPE) cell pellets and in the corresponding 
primary tumours for a subset of the cell lines. Conditions under which cells are 
cultured differ from the original conditions in which the primary tumour developed, 
for example, cell lines face no immune competition or contact with extracellular 
matrix components. This may select for differing characteristics in the cell lines 
compared to tumours. However, the results from the immunohistochemistry staining 
suggest that the high ECM1 and MUC1 protein expression detected in the cell lines 
from subgroup 2 is a real feature and truly reflects expression in the original 
tumours.  
 
In both cell lines and tumours, immunohistochemistry analysis revealed that ECM1 
expression was largely cytoplasmic in location, confirming previous observations in 
breast, thyroid and hepatocellular carcinomas [115, 121, 162]. This may suggest an 
interaction between ECM1 and cytoplasmic proteins, or it may reflect a high level of 
protein synthesis and subsequent packaging of the protein into vesicles for 
secretion. Immunofluorescence staining of ECM1 in the HT-1376 cell line revealed 
a granular pattern of cytoplasmic staining which can be indicative of post-
translational processing and packaging into transport vesicles destined for secretion 
by the Golgi apparatus [168]. Secretory vesicles may release proteins directly into the 
extracellular space and whole nanovesicles may also be actively shed by tumour 
cells in the form of exosomes [266]. 
 
Tumour-derived exosomes are small membrane-bound vesicles of around 40–150 
nm in diameter that transport signalling molecules in the form of proteins, mRNAs, 
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miRNAs, and lipids from tumour cells into the microenvironment [267, 268]. These 
vesicles may have a number of pro-carcinogenic signalling functions and have been 
proposed to regulate tumour development and progression, mediate cancer 
immunity and immune invasion, and promote inflammation, angiogenesis and 
metastasis [267, 269-271]. Bladder tumour-derived exosomes have been shown to 
promote the malignant transformation of immortalised non-malignant urothelial cells 
in vitro, and exosomes isolated from the urine of patients with high-grade MIBC, 
induced migration and invasion of a low-grade bladder cancer-derived cell line 
(5637) [267]. Our observation of cytoplasmic vesicles containing ECM1, and the 
detection of ECM1 in conditioned medium, may suggest a role for ECM1 as an 
exosomal protein.  Furthermore, EGFR and MUC1 have previously been detected 
in bladder tumour-derived exosomes [268, 272, 273]. Future work isolating of exosomes 
from ECM1-high bladder tumour-derived cell lines to assess whether ECM1 is 
present within such vesicles, and to and assess if a correlation exists between 
ECM1, EGFR, and MUC1 being present within the same exosomes would be of 
interest.  
 
Previous studies have not yet assessed whether ECM1 is secreted in exosomes, 
however, ECM1 was originally identified as a secreted protein following TCA protein 
precipitation from the conditioned media of a murine osteogenic cell line [91]. 
Furthermore, the human form of ECM1 has been demonstrated to interact with 
extracellular components of the skin such as laminin 332, collagen type IV, and 
fibronectin, suggesting ECM1 is secreted in order for these interactions to occur [169, 
170]. In the current study, ECM1 could be detected following western blot analysis of 
the protein fraction of conditioned media from the human bladder tumour-derived 
cell line HT-1376, suggesting human ECM1 is secreted by this cell line.  
 
Secreted ECM1 may not only influence those cells expressing high levels of the 
protein but also other neighbouring cells and components of the microenvironment. 
Traditionally, cancer has been viewed as a disease of transformed, 
hyperproliferative cells [274, 275]. The influence of the dynamic network of immune 
cells, fibroblasts, vascular tissue, and extracellular matrix that make up the tumour 
microenvironment is increasingly seen as an important influencing factor in tumour 
progression and development [274, 276, 277]. In non-cancer studies, ECM1 has been 
shown to interact with components of the extracellular matrix in the skin [169, 170], and 
has also been noted to modulate immune cell responses. For example, in ECM1 
knockout mice, early mortality within 6 weeks occurs due to high levels of undefined 
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autoinflammatory disease. Furthermore, chimeric mice with ECM1 deficient bone 
marrow also show high inflammatory disease attributed to the lack of migration of T 
helper 2 cells and regulator T cells from the peripheral tissues into areas of 
inflammation [170]. As this study showed that loss of ECM1 led to increased 
autoimmunity, this may suggest that increased expression of ECM1 in tumours 
could be important in tumour cell immune evasion. Therefore, investigating the role 
that ECM1 plays in relation to the tumour microenvironment may warrant further 
investigation, perhaps by assessing potential interactions between ECM1 and 
components of the tumour extracellular matrix, or through comparative assessment 
of immune markers in ECM1-high and ECM1-low tumours.   
 
Immunohistochemistry analysis of primary tumours and cell pellets also showed 
MUC1 staining to be largely cytoplasmic. MUC1 has been reported at the apical 
surface of secretory epithelia [164, 165, 167]. Reports of alterations in the cellular 
localisation of MUC1 are common in malignant disease. In the urothelium MUC1 
expression is normally confined to the apical membranes of superficial umbrella 
cells [136, 137]. However, in three quarters of bladder carcinomas, staining of MUC1 
can be observed and is primarily located in the basal and intermediate layers of the 
urothelium [135, 141]. In prostate cancer a more diffused pattern of expression 
throughout the cytoplasm has been noted to be associated with more advanced 
disease [166], and in breast cancer a switch from membranous MUC1 expression to 
cytoplasmic and nuclear localisation is associated with increased metastatic 
potential [167]. These observations suggest that the cytoplasmic MUC1 staining we 
observed might be associated with more aggressive disease. 
 
The membranous and cytoplasmic staining of MUC1 most likely relates to its roles 
in cell-cell adhesion, lubrication of mucus membranes, and interactions with 
membrane bound and cytoplasmic signalling molecules including EGFR, Wnt–β-
catenin, p53, and NF-κB [180, 278, 279]. The cytoplasmic and extracellular domains of 
MUC1 have also been detected in the nuclei of a number of tumour-derived cell 
lines including human breast epithelial adenocarcinoma, human trophoblast-derived 
choriocarcinoma and pancreatic cancer-derived cell lines [280]. In the current study, 
MUC1 was also detected in the nucleus when staining was very intense as was the 
case in the LUCC4 cell line. Previous studies have suggested that MUC1 can 
translocate to the nucleus following autoproteolysis [281, 282] where it may act as 
transcriptional regulator [278, 280, 283]. In pancreatic ductal adenocarcinoma, MUC1 
has been demonstrated to directly associate with EGFR, leading to the cleavage of 
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the MUC1 cytoplasmic domain and its translocation into the nucleus where it is 
thought to associate with the transcription factor hypoxia-inducible factor-1α (HIF-
1α), which in turn promotes platelet-derived growth factor A (PDGFA) expression 
leading to cell proliferation [284]. The nuclear staining observed in the bladder 
tumour-derived cell lines may, therefore, be suggestive of MUC1 acting as a 
transcriptional co-factor.  
 
Subsets of ECM1-high bladder tumours were also identified by interrogation of 
publicly available transcriptome datasets [32, 72, 75] and by immunohistochemistry 
analysis of ECM1 and MUC1 protein expression in four tissue microarrays (TMAs) 
consisting of 943 muscle-invasive bladder tumour cores. Previous studies have 
shown an association between ECM1 expression and increased metastasis and 
decreased survival rates in laryngeal [119, 184], breast [116], and hepatocellular 
carcinomas [118]. Clinical data is not yet available for the samples on the TMAs used 
in the current study, but patient metadata was available for the publicly available 
microarray data from the latest TCGA study [32]. Survival analysis showed that 
patients with ECM1-high tumours had statistically significant poorer overall survival 
than those with low ECM1 expressing tumours. Furthermore, patients with tumours 
expressing high ECM1 and MUC1 also had statistically significant poorer overall 
survival compared to patients whose tumours expressed high MUC1 alone. There 
was no difference in survival between patients with tumours expressing high ECM1 
alone and those expressing both ECM1 and MUC1, suggesting that ECM1 
expression could be the major influencing factor associated with reduced survival 
rates. Despite a link between high ECM1 expression and increased metastasis in 
other carcinomas, ECM1-high bladder tumours did not exhibit a significant 
difference in metastasis compared to low ECM1 expressing tumours.  
 
We examined somatic mutation and increased DNA copy number as potential 
molecular mechanisms by which ECM1 expression is increased. No somatic 
mutations were detected by PCR and direct sequencing of selected exonic regions 
of the ECM1 gene. Assessment of DNA copy number across the 1q21.2 region 
where the ECM1 gene is located revealed increased copy number in five of the six 
ECM1-high cell lines (HT-1376, 647V, LUCC3, LUCC4 and LUCC5). This may 
explain the increased ECM1 expression noted in these cell lines as copy number 
increases can lead to increased gene expression [175]. However, there are also other 
candidate oncogenes in this region including BCL9, a nuclear component of the 
Wnt pathway, and MCL1, a member of the anti-apoptotic BCL2 family of genes [176-
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178]. ECM1 expression may be influenced by copy number alteration but this highly 
gene dense region may also contain other oncogenes that could be targets for 
activation. 
 
The functional role of ECM1 has been investigated to some extent in other 
carcinomas including breast, thryroid, cholangiocarcinoma and hepatocellular 
carcinomas [114, 115, 120, 181], but its role in bladder cancer had not been examined. 
The current study is the first to investigate the functional role of ECM1 in bladder 
cancer. We examined the phenotypic effects of ECM1 shRNA knockdown on cell 
growth, migration and wound healing capabilities of bladder tumour-derived cells. 
shRNA knockdown of ECM1 in four ECM1-high cell lines did not alter cell growth or 
morphology but reduced wound healing ability was observed. This mirrors previous 
reports in other carcinomas. For example, in multiple breast cancer and 
hepatocellular carcinoma-derived cell lines, silencing of ECM1 using antibody 
treatments or siRNA knockdown induced a significant reduction in wound healing 
ability [114, 120]. Furthermore, a similar effect is seen in the physiological symptoms of 
Urbach–Wiethe disease, in which patients with loss of function mutations to ECM1 
present with disrupted wound healing ability [110].  Wound healing is a process that is 
highjacked during tumour cell migration and metastasis [285], hence, the observed 
effects of ECM1 knockdown on wound healing ability may hint at a role for ECM1 in 
metastasis.  
 
The effect of ECM1 knockdown on the wound healing capability of the HT-1376 
ECM1 knockdown cell line could not be recovered by treatment with recombinant 
ECM1 up to 750 ng/ml. In previous studies concentrations of recombinant ECM1a 
between 20 ng/ml and 200 ng/ml were sufficient to stimulate phenotypic effects, for 
example in cultured healthy endothelial cells 20 ng/ml recombinant ECM1a was 
sufficient to stimulate cell proliferation [93], while 200 ng/ml of recombinant human 
ECM1a also induced cell proliferation in breast cancer-derived cell lines [122]. It is 
unclear why treated with recombinant ECM1 had no effect on the wound healing 
ability of HT-1376 ECM1 knockdown cells at these concentrations, but there are a 
number of possible explanations. In the current study we determined that the ECM1 
high cell lines used in the wound healing assays express ECM1a and at least one 
other isoform. Although the precise role of each isoform has not been fully 
elucidated, there is some suggestion that they have different functions. For 
example, ECM1b expression has previously been reported to be induced in 
differentiated keratinocytes [105], while ECM1a has been associated with 
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angiogenesis and is expressed in the endothelium of developing blood vessels [169]. 
It may be proposed that an isoform other than ECM1a contributes to the wound 
healing ability of our ECM-high bladder tumour-derived cell lines. Assessing the 
effect of conditioned media from the shRNA control or parental cell lines on the 
wound healing ability of ECM1 knockdown cells would have been beneficial in 
identifying if other isoforms secreted by the ECM1-high cell lines alter wound 
healing ability. Previous investigations into the role of ECM1 in cancer have either 
not specified isotype, or focused on the major ECM1a isoform [93, 120, 122]. Alternative 
splicing is a critical mechanism for the regulation of cell specific functions and 
dysregulation of isotype expression is known to be important in the pathology of 
cancer [209]. The expression of different ECM1 isoforms in the ECM1-high cell lines 
may hold information on the role of ECM1 in the pathogenesis of bladder cancer 
and future investigations modulating the expression of specific ECM1 isoforms in 
bladder-tumour derived cell lines may be of interest. 
 
The ineffectiveness of recombinant ECM1 in rescuing the wound healing ability of 
ECM1 knockdown cells may also relate to post-translational modifications of ECM1.  
For example, glycosylation can dramatically change the physical structure and 
integrity of a protein, and this may influence cellular interactions and signaling 
cascades that can have a direct impact on cell growth, survival and metastasis [286]. 
In the current study, the molecular weight of secreted ECM1 detected in the protein 
fraction of conditioned media of HT-1376 was larger than ECM1 detected in the cell 
lysate. N-glycosylation at asparagine residues was reported to be important in the 
regulation of the secretion of ECM1 [153]. Deglycosylation of the secreted ECM1 
isolated from the conditioned media of HT-1376 led to a reduction in molecular 
weight implying that secreted ECM1 is glycosylated. 
 
We also investigated the direct effects of ECM1 knockdown on global gene 
expression by comparing microarray data for the HT-1376 ECM1 knockdown and 
scramble control cell lines. Genes that were downregulated in the ECM1 
knockdown included eight keratins (keratins 1, 4, 5, 6A, 6B, 6C, 10 and 24) and the 
serine proteases known as human kallikrein-related peptidases (KLKs) 5 and 7. 
These genes may be of importance in relation to the reduced wound healing ability 
observed in ECM1 knockdown cell lines, as increased expression of keratins and 
serine proteases are characteristic of hyperproliferative wound healing of epithelial 
tissue [287-289]. The calcium receptor CALB2 and the EGFR ligand AREG were also 
significantly downregulated in the HT-1376 ECM1 knockdown cells compared to the 
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scramble control cells, and both proteins have been associated with wound healing. 
Mesothelial cells cultured from CALB2 knockout mice showed significantly 
decreased wound healing ability compared to CALB2 wildtype cells [290], and a 
previous study has also reported that treatment with recombinant AREG leads to 
increased wound healing ability in bladder tumour-derived cell lines [291]. Our results 
indicate that ECM1 regulates the expression of AREG, CALB2, keratins and 
kallikrein-related peptidases, and this may be suggestive of a role linked to 
increased wound healing in ECM1-high cell lines. 
 
In breast cancer cells ECM1 has been seen to directly interact with EGFR, and this 
in turn stabilises interactions between EGFR and MUC1 as part of a membrane 
embedded protein complex that mediates Ras/RAf/MEK/ERK signalling [122]. Normal 
urothelium express relatively low levels of EGFR [132]. In contrast, approximately half 
of all bladder tumours overexpress EGFR [59], and there is a significant association 
between EGFR expression, tumour grade, invasiveness, and poorer survival for 
patients [55, 133]. Due to the importance of EGFR in bladder cancer and the 
previously discussed similarities that exist between the molecular subtypes of 
bladder and breast cancer, we investigated whether there was a physical 
interaction between the two proteins in our ECM1 high bladder tumour-derived cell 
lines. A physical interaction could not be detected between EGFR and ECM1 by 
coimmunoprecipitation, implying either no interaction or a weak and transient 
physical interaction between the two proteins. However, ECM1 may still influence 
EGFR signalling via an indirect mechanism such as interaction with one of the 
EGFR ligands. ECM1 has previously been reported to interact with EGF-like 
repeats in the vascular regulator perlecan [94]. This motif consists of six cystine 
residues that form three disulphide bonds, and it resembles a key interaction site 
found on the epidermal growth factor [292]. The ability for ECM1 to interact with this 
motif on perlecan suggests it may also be able to interact with ligands of EGFR 
which also harbour this motif such as EGF. In the current study, we evaluated the 
impact of ECM1 on the activation of the EGFR pathway by examining the effects of 
ECM1 knockdown and recombinant ECM1 treatment on the phosphorylation status 
of EGFR and the downstream effector proteins ERK and AKT. Three of the ECM1 
knockdown cell lines treated with recombinant ECM1 exhibited increased 
phosphorylation of EGFR, implying that ECM1 plays a role in initiating activation of 
EGFR. Furthermore, ERK and AKT phosphorylation decreased in response to 
ECM1 shRNA knockdown, while ERK phosphorylation increased in response to 
ECM1 treatment of the ECM1 knockdown cell lines suggesting that both 
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Ras/Raf/MEK/ERK and PI3K/PTEN/AKT are important pathways downstream of 
ECM1. The ability of ECM1 to interact with EGF-like repeats, and the apparent 
ECM1-mediated activation of EGFR signalling warrants further investigation into 
possible interactions between ECM1 and EGFR ligands in the future.   
 
Phospho-RTK array analysis also revealed decreased EGFR phosphorylation in the 
ECM1 knockdown cell lines compared to the scramble controls derived from the cell 
lines HT-1376, LUCC4 and 647V, further suggesting the EGFR pathway is 
activated by ECM1 and may represent a potential target in ECM1 high tumour cells. 
However, treatment of ECM1-high cell lines with the EGFR inhibitor erlotinib 
resulted in a maximal effect on cell viability of only 40%. Furthermore, no significant 
differences in cell viability were observed when ECM1 knockdown and scramble 
control cell lines were treated with erlotinib suggesting that ECM1 does not 
influence resistance to erlotinib. However, a key limitation of this study was that a 
control cell line with known sensitivity to erlotinib was not used. As such, the 
possibility of reduced activity of erlotinib in this batch resulting in lack of sensitivity 
observed cannot be ruled out. It may therefore be important to repeat this analysis 
in the future. 
 
A decrease in MET phosphorylation in HT-1376 and LUCC4 ECM1 knockdown cell 
lines compared to the scramble control cell lines was demonstrated by phospho-
RTK array and western blot analysis, suggesting that ECM1 plays a role in initiating 
activation of MET. We treated the four cell lines of subgroup 2 (HT-1376, HT1197, 
647V and LUCC4) with the MET inhibitor tivantinib and this resulted in varied 
responses to the drug. Complete cell death was achieved for 647V and an 80% 
reduction in cell viability for HT-1197, but a <50% reduction in cell viability was 
noted for HT-1376 and LUCC4. MET inhibition did not result in a significantly 
different reduction in cell viability between the parental, scramble control and ECM1 
knockdown cell lines for HT-1376 or LUCC4 implying ECM1 does not promote 
tivantinib resistance. 
 
Although inhibition of EGFR and MET did not result in complete cell death, both the 
Ras/Raf/MEK/ERK and PI3K/PTEN/AKT pathways were highlighted as activated by 
ECM1 expression, thus downstream inhibition of ERK or AKT may be an attractive 
therapeutic avenue to pursue. Over the past 30 years, ERK has been consistently 
demonstrated to play an important role in cancer but there has been little focus on 
the development of selective ERK inhibitors [293]. This may be beca
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considered the sole downstream target of MEK and thus inhibiting ERK alone was 
not assumed to have any improved benefits over inhibitors targeting upstream 
targets [293, 294]. More recently ERK has been demonstrated to influence other 
pathways that may determine cell fate. For example, ERK was seen to positively 
regulate the expression of the oncogenic factor O-GlcNAc which maintains a 
malignant phenotype in cancer cells [295]. Hence, there may be more benefits to 
therapeutics targeting ERK than previously thought.  Currently only two ERK 
inhibitors are in clinical trials: BVD-523 a competitive ATP kinase inhibitor, and 
GDC0994 a selective inhibitor that prevent phosphorylation of ERK. BVD-523 
demonstrated anti proliferative activity in pancreatic and colorectal cancer-derived 
cell lines with activating BRAF mutations, and is in the recruitment stage of two 
phase I/II clinical trials for solid tumours, melanoma and hematologic malignancies 
[296]. GDC-0994 has demonstrated encouraging activity in RAS-mutated cancer cell 
lines and animal models in combination with the MEK inhibitor cobimetinib, and is 
currently in dose escalation trials in patients with locally advanced or metastatic 
solid tumours [297]. To our knowledge no trials have been conducted in bladder 
cancer patients. 
 
AKT may also represent a potential target for cancer therapy but development of 
AKT inhibitors has proved difficult due to the existence of three isozymes that differ 
in tissue distribution, function and ligand affinity [298]. Very few compounds have 
been included in clinical trials and no AKT inhibitor has been approved for use in 
the clinic [299]. The use of ERK and AKT inhibitors in the treatment of bladder cancer 
is therefore not yet possible, but may be an interesting avenue for future 
investigation if suitable inhibitors were to be developed.  
 
In conclusion our study has described a subgroup of ECM1-high bladder tumour-
derived cell lines with basal-squamous features and high expression of ECM1. We 
have shown that a subset of primary tumours with similar features can be identified 
by analysis of publicly available datasets and immunohistochemical analysis of 
ECM1.  It is unclear whether this subgroup represents a new MIBC subtype in its 
own right, or if it represents a subset of tumours that fit within the current basal-
squamous subtype. High ECM1 expression in this subset of tumours is associated 
with poorer overall survival in patients and highlights ECM1 as a potential 
prognostic marker. Assessment of the phenotypic effects of shRNA knockdown of 
ECM1 in a panel of ECM1-high cell lines enabled us to established that ECM1 
plays a role in promoting wound healing ability. Comparative analysis of microarray 
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data from ECM1 knockdown and scramble control cell lines for one ECM1-high cell 
line (HT-1376) suggested that this could be through ECM1-mediated modulation of 
genes involved in cell migration and wound contraction such as keratins, CALB2, 
and AREG. Confirmation of similar effects in other ECM1-high cell lines is required. 
 
Phospho-array analysis of ECM1 knockdown cell lines treated with recombinant 
ECM1 demonstrated that ECM1 plays a role in the activation of EGFR and MET 
signaling and that ERK and AKT are downstream targets of this. A physical 
interaction between EGFR and ECM1 could not be established, hence, the 
mechanism by which this occurs may differ from that previously described in breast 
cancer cell lines [122]. Despite the apparent ECM1-modulated activation of EGFR 
and MET, inhibitors targeting EGFR and MET showed variable effects in our ECM1-
high cell line panel and resistance to these inhibitors was not ECM1-dependent. 
Further studies assessing the potential efficacy of ERK and AKT inhibitors in ECM1 
high bladder tumour cells is warranted.  
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Appendix A - Cell lines used in the study  
Bladder tumour-derived cell lines used in this study, and their origins, 
stage, grade, and type of tumour from which they were derived.  
A panel of forty-five bladder tumour-derived cell lines was collected for this study. 
Stages and grades of tumours are as described in referenced literature, and is based 
on the tumour-node-metastasis system. ‘NR’ denotes not recorded. 
 
 
Cell 
Line  
Type Grade Stage Origin Reference 
253J  TCC G4 T4  Lymph node 
metastasis, 
retroperitoneal  
[300, 301] 
5637  TCC G2 NR  Bladder, primary  [302] 
639V  TCC G3 "small"  Ureter, primary  [300, 303] 
647V  TCC G2 "malignant" 
"stage B"  
Bladder, primary  [300, 303] 
92-1 TCC G3 T4  Bladder  [304, 305] 
96-1  TCC G2/G3 T3  Bladder, 
recurrence  
[304] [305] 
97-1  TCC G1/G2 T1/T2  Bladder, papillary  [304] [305] 
97-18  TCC G3 T2  Bladder [305] 
97-24  TCC G3  T3  Bladder  [305] 
97-7  TCC G2/G3 T1  Bladder  [305] 
BC3c  TCC G4 "stage C" 
(UICC)  
Bladder, "invasive 
solid TCC"  
[306] 
BFTC905  TCC G3 "stage 
D1"(Jewett)  
Bladder, primary, 
papillary  
[307] 
BFTC909  TCC G3 T4N2M1  Renal pelvis, 
primary  
[307] 
CAL 29  TCC G4 T2  Bladder, primary, 
invasive 
[308] 
DSH1  TCC G2 T1a  Bladder, 
recurrence, 
papillary  
[309] 
HCV-29 TCC NR NR Irradiated cancer-
free bladder from 
patient with 
bladder cancer  
Fogh, 
Unpublished 
HT-1197 TCC G4 "poorly 
differentiated"  
"Invading 
the bladder 
muscularis" 
(T2 at 
least)  
Bladder, 
recurrence  
[310] 
HT-1376  TCC G3 "poorly 
differentiated"  
"Invading 
the bladder 
muscularis" 
(T2 at 
least)  
Bladder, primary  [310] 
J82  TCC G3 "poorly 
differentiated"  
T3  Bladder, primary, 
papillary with solid 
areas 
[311] 
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JMSU-1  TCC G3  T4N2M1  Established from 
malignant ascitic 
fluid of a patient 
with bladder 
cancer  
[312] 
JO'N TCC NR NR Lymph node 
metastasis, 
retroperitoneal  
Unpublished 
KU-19-19  TCC G3   pT3b  Bladder, primary  [313] 
LUCC1 TCC G3  T3bN1 Ureter, primary  Pitt, 
unpublished 
LUCC2  TCC G2  T2  Bladder, primary  Pitt, 
unpublished  
LUCC3  TCC G3  T2 at least  Bladder  Pitt, 
unpublished  
LUCC4  TCC G3  T2 at least  Bladder, 
recurrence  
Pitt, 
unpublished  
 
LUCC5 TCC G3 T2 at least Bladder, primary Pitt, 
unpublished 
LUCC6 TCC G3  Ta Renal pelvis, 
papillary  
Pitt, 
unpublished 
LUCC7 TCC G3  T3 Renal pelvis,  Pitt, 
unpublished  
LUCC8 TCC G2  Ta Bladder, primary Pitt, 
unpublished  
MGH-U3 TCC G1  non-
invasive 
"non- 
Bladder,recurrence 
[314] 
RT112M TCC G2 NR Bladder, primary [315] 
RT4 TCC G1  T2  Bladder, 
recurrence  
 [316] 
SCaBER True 
squamous 
cell 
carcinoma 
NR 
“Moderately 
differentiated” 
T3 Bladder, primary [317] 
SD TCC NR NR Bladder, primary  [318] 
SW-1710 TCC NR NR Bladder, papillary [319] 
SW-780 TCC G1 NR  Bladder, primary  [302, 319] 
T24 TCC G3 NR  Bladder  [320] 
TCCSUP TCC G4  NR confirmed Bladder, 
primary  
[321] 
U-BLC1 TCC G3 T2 least Bladder, 
primary 
[322] 
UM-UC-3 TCC NR  NR Bladder [323] 
VM-CUB-
1 
TCC NR  NR  Bladder, primary  [324] 
VM-CUB-
2 
TCC NR  NR  Lymph node 
metastasis  
 [324] 
VM-CUB-
3 
TCC NR NR Bladder primary  [324] 
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Appendix B - Genes uniquely and significantly upregulated 
in subgroup 2 
Genes uniquely and significantly upregulated in an ECM1-high 
subgroup of bladder cancer derived cell lines.  
Genome-wide microarray-based gene expression profiling was performed on a panel 
of 45 bladder tumour-derived cell lines. NMF analysis of the gene expression data 
defined five subgroups, and SAM analysis was used to identify genes enriched within 
NMF groups. The microarray probe IDs and gene names are shown for the genes 
that were uniquely and significantly upregulated in subgroup 2. 
 
Gene probe IDs Gene symbol Gene name 
225714_s_at; 
230767_at; 235456_at; 
235608_at; 236168_at; 
237732_at; 238727_at; 
240272_at; 241417_at; 
242726_at Unannotated  
226071_at ADAMTSL4 
A disintegrin and metalloproteinase 
with thrombospondin motifs 
ADAMTS-like 4 
204664_at ALPP Alkaline phosphatase, placental 
219714_s_at CACNA2D3 
Calcium channel, voltage-
dependent, alpha 2/delta subunit 3 
206193_s_at CDSN Corneodesmosin 
213385_at CHN2 Chimerin (chimaerin) 2 
232127_at CLCN5 
Chloride channel, voltage-sensitive 
5 
213317_at; 217628_at; 
219866_at CLIC5 Chloride intracellular channel 5 
203104_at CSF1R Colony stimulating factor 1 receptor 
204720_s_at DNAJC6 
Dnaj (Hsp40) homolog, subfamily 
C, member 6 
207324_s_at DSC1 Desmocollin 1 
206642_at DSG1 Desmoglein 1 
209365_s_at ECM1 Extracellular matrix protein 1 
204271_s_at; 
204273_at; 206701_x_at EDNRB Endothelin receptor type B 
209343_at EFHD1 
EF-hand domain family, member 
D1 
1558579_at FLJ37786 Uncharacterized LOC642691 
207112_s_at; 
214987_at; 225998_at; 
226002_at; 229114_at GAB1 
GRB2-associated binding protein 1 
208283_at; 
207086_x_at; 
207739_s_at; 
208155_x_at GAGE1 
G antigen 1 
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206640_x_at GAGE12C  G antigen 12C 
208235_x_at GAGE12F  G antigen 12F 
207663_x_at GAGE3 G antigen 3 
214466_at; 226701_at GJA5 
Gap junction protein, alpha 5, 
40kda 
1560316_s_at; 
225700_at; 225706_at; 
227525_at GLCCI1 
Glucocorticoid induced transcript 1 
209631_s_at; 214586_at GPR37 
G protein-coupled receptor 37 
(endothelin receptor type B-like) 
204515_at HSD3B1 
Hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 
222223_s_at IL1F5  
205403_at; 211372_s_at IL1R2 Interleukin 1 receptor, type II 
229125_at KANK4 
KN motif and ankyrin repeat 
domains 4 
220267_at KRT24 Keratin 24 
232300_at LOC100128309 Uncharacterised LOC100128309  
1560679_at LOC151438 Uncharacterised LOC151438 
226793_at LOC283267 Uncharacterised LOC283267 
207114_at LY6G6C 
Lymphocyte antigen 6 complex, 
locus G6C 
204777_s_at MAL Mal, T-cell differentiation protein 
1554652_s_at MAST4 
Microtubule associated 
serine/threonine kinase family 
member 4 
207847_s_at; 
211695_x_at; 
213693_s_at MUC1 
Mucin 1, cell surface associated 
1569020_at NEDD9 
Neural precursor cell expressed, 
developmentally down-regulated 9 
1553534_at NLRP10 
NLR family, pyrin domain 
containing 10 
1556029_s_at; 
209755_at NMNAT2 
Nicotinamide nucleotide 
adenylyltransferase 2 
204684_at NPTX1 Neuronal pentraxin I 
205259_at NR3C2 
Nuclear receptor subfamily 3, 
group C, member 2 
204802_at; 
204803_s_at; 231100_at RRAD 
Ras-related associated with 
diabetes 
238909_at S100A10 S100 calcium binding protein A10 
219932_at SLC27A6 
Solute carrier family 27 (fatty acid 
transporter), member 6 
216236_s_at; 
222088_s_at SLC2A14  
Solute carrier family 2 (facilitated 
glucose transporter), member 14 
202497_x_at; 
202498_s_at; 
202499_s_at SLC2A3 
Solute carrier family 2 (facilitated 
glucose transporter), member 3 
201534_s_at; 201535_at UBL3 Ubiquitin-like 3 
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Appendix C - Levels of ECM1 and MUC1 in 45 bladder 
tumour-derived cell lines according to microarray 
analysis 
 
The relative expression level of ECM1 and MUC1 was determined at the 
mRNA level in a panel of 45 bladder tumour-derived cell lines by microarray 
analysis using GeneChip Human Genome U133 Plus 2.0 Arrays. Expression 
levels were measured relative to a pooled normal urothelial cell sample (NHU-
Pool). 
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Appendix D - Western blot analysis of beta-actin 
 
 
Western blot analysis of ECM1, MUC1 and beta-actin levels in 6 bladder 
tumour-derived cell lines.  
The expression of ECM1 and MUC1 was examined at the protein level in the cell line 
panel of 45 bladder tumour-derived cell lines using western blot analysis (Figure 3.8). 
For this panel, tubulin-alpha expression was assessed as a loading control, however 
the cell lines DSH1 and RT4 do not express tubulin-alpha. For these cell lines beta-
actin expression was also assessed. The expression of ECM1 and MUC1 was also 
reassessed in parallel for these cell lines, and four ECM1-high cell lines (HT-1376, 
LUCC3, HT-1197, and 647V) were used as positive controls. Total protein lysates 
were harvested for each cell line and 30 µg was analysed by western blot with 
antibodies specific to ECM1, MUC1 and anti-beta actin. Blots were analysed using 
the ChemiDoc MP System and Image Lab software. 
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Appendix E - Data mining and LIMMA analysis of publicly 
available bladder tumour datasets 
 
Genes that were significantly altered in ECM1-high bladder tumours. 
R2 was used to interrogate expression data from the studies of: Sjödhal et al. and 
Choi et al. that used fresh-frozen samples [72, 75]. LIMMA analysis, conducted using 
the online platform GEO2R, was used to compare ECM1-high and ECM1-low 
tumours. Stringency settings were applied to include only probes that had a fold 
change greater than 2 or less than -2 and a p value less than 0.05. Venn analysis 
was conducted on these lists of probes using Partek Genomics software to identify 
overlapping probes in both datasets. Unannotated probes were removed, and a 
single representative probe was selected being selected per gene, generating a list 
of genes significantly upregulated or downregulated in the ECM1-high tumours 
compared to the ECM1-low tumours. 
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Appendix F - ECM1 isoforms, mRNA and amino acid 
sequences 
The human ECM1 gene encodes for four splice variants: ECM1a, ECM1b, 
ECM1c and ECM1d. PCR was performed using primers spanning 
alternatively spliced exons in order to identify which ECM1 isoforms were 
expressed in each of the ECM1-high cell lines, as well as in other bladder 
tumour-derived cell lines that do not fall into this subgroup and normal human 
urothelial cells (NHU-Pool) (section 4.2.3.1). In order to design primers to 
assess which isoforms of ECM1 were expressed intron and exon sequences 
for ECM1a, ECM1b, and ECM1c were obtained from the National Centre for 
Biotechnology Information nucleotide bank [183]. For the ECM1d isoform the 
mRNA sequence was obtained from [106]. The amino acid sequences of each 
isoform were obtained from the NCBI protein bank [325] in order to view 
differences between isoforms in at the protein level.  
 
 
 
Schematic representation of the ECM1 mRNA isoforms.  
A diagram representing the structures of the ECM1 isoforms a, b, c and d, illustrating 
the distribution of exons and the 3’ and 5’ untranslated regions (UTR). The figure has 
been created from information obtained from [183] and [106]. 
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The 5’ -> 3’ mRNA sequence (NM_004425.3) of the ECM1a isoform 
obtained from the NCBI nucleotide database [183]. 
 
 
 
AGAGGAGGAGCAGCTGGGACTGAGTCATGGCAGGAAGCTGAGGAGGGCGGGAGATCA
CACCAGACAATTATAAAAGAAGAGCTGGTCCTGAAGCTCACAACCGTAACAGCCACCAGA
CAAGCTTCAGTGGCCGGCCCTTCACATCCAGACTTGCCTGAGAGGACCCACCTCTGAGTGT
CCAGTGGTCAGTTGCCCCAGGATGGGGACCACAGCCAGAGCAGCCTTGGTCTTGACCTAT
TTGGCTGTTGCTTCTGCTGCCTCTGAGGGAGGCTTCACGGCTACAGGACAGAGGCAGCTG
AGGCCAGAGCACTTTCAAGAAGTTGGCTACGCAGCTCCCCCCTCCCCACCCCTATCCCGAA
GCCTCCCCATGGATCACCCTGACTCCTCTCAGCATGGCCCTCCCTTTGAGGGACAGAGTCA
AGTGCAGCCCCCTCCCTCTCAGGAGGCCACCCCTCTCCAACAGGAAAAGCTGCTACCTGCC
CAACTCCCTGCTGAAAAGGAAGTGGGTCCCCCTCTCCCTCAGGAAGCTGTCCCCCTCCAAA
AAGAGCTGCCCTCTCTCCAGCACCCCAATGAACAGAAGGAAGGAACGCCAGCTCCATTTG
GGGACCAGAGCCATCCAGAACCTGAGTCCTGGAATGCAGCCCAGCACTGCCAACAGGAC
CGGTCCCAAGGGGGCTGGGGCCACCGGCTGGATGGCTTCCCCCCTGGGCGGCCTTCTCCA
GACAATCTGAACCAAATCTGCCTTCCTAACCGTCAGCATGTGGTATATGGTCCCTGGAACC
TACCACAGTCCAGCTACTCCCACCTCACTCGCCAGGGTGAGACCCTCAATTTCCTGGAGAT
TGGATATTCCCGCTGCTGCCACTGCCGCAGCCACACAAACCGCCTAGAGTGTGCCAAACTT
GTGTGGGAGGAAGCAATGAGCCGATTCTGTGAGGCCGAGTTCTCGGTCAAGACCCGACC
CCACTGGTGCTGCACGCGGCAGGGGGAGGCTCGGTTCTCCTGCTTCCAGGAGGAAGCTC
CCCAGCCACACTACCAGCTCCGGGCCTGCCCCAGCCATCAGCCTGATATTTCCTCGGGTCT
TGAGCTGCCTTTCCCTCCTGGGGTGCCCACATTGGACAATATCAAGAACATCTGCCACCTG
AGGCGCTTCCGCTCTGTGCCACGCAACCTGCCAGCTACTGACCCCCTACAAAGGGAGCTG
CTGGCACTGATCCAGCTGGAGAGGGAGTTCCAGCGCTGCTGCCGCCAGGGGAACAATCA
CACCTGTACATGGAAGGCCTGGGAGGATACCCTTGACAAATACTGTGACCGGGAGTATGC
TGTGAAGACCCACCACCACTTGTGTTGCCGCCACCCTCCCAGCCCTACTCGGGATGAGTGC
TTTGCCCGTCGGGCTCCTTACCCCAACTATGACCGGGACATCTTGACCATTGACATCGGTC
GAGTCACCCCCAACCTCATGGGCCACCTCTGTGGAAACCAAAGAGTTCTCACCAAGCATA
AACATATTCCTGGGCTGATCCACAACATGACTGCCCGCTGCTGTGACCTGCCATTTCCAGA
ACAGGCCTGCTGTGCAGAGGAGGAGAAATTAACCTTCATCAATGATCTGTGTGGTCCCCG
ACGTAACATCTGGCGAGACCCTGCCCTCTGCTGTTACCTGAGTCCTGGGGATGAACAGGT
CAACTGCTTCAACATCAATTATCTGAGGAACGTGGCTCTAGTGTCTGGAGACACTGAGAA
CGCCAAGGGCCAGGGGGAGCAGGGCTCAACTGGAGGAACAAATATCAGCTCCACCTCTG
AGCCCAAGGAAGAATGAGTCACCCCAGAGCCCTAGAGGGTCAGATGGGGGGAACCCCAC
CCTGCCCCACCCATCTGAACACTCATTACACTAAACACCTCTTGGATTTGGTGTCCTCATTG
TCTATCTAATGTCTCACCCGCAGTGTTTTAAGTGGATCTTGGTGCCCTGGCCCAGGAGGGC
ACTGGCGTTTTCAGACACACCACAGACAAACACACCCTCCTAAGCCTGCTTGTATTTCCTTC
AGTGCCTGGCCCCTGAGGCCCACGGCCCTGCCCCCTTCACTGAGCAGATGTTCACAGGCT
GTGGGATGCGACCATAACTAAACAGCTTGACGTCAAAAAAAAAAAAAAAAAA 
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The 5’ -> 3’ mRNA sequence (NM_022664.2) of the ECM1b isoform 
obtained from the NCBI nucleotide database [183]. 
 
 
 
 
AGAGGAGGAGCAGCTGGGACTGAGTCATGGCAGGAAGCTGAGGAGGGCGGGAGATCA
CACCAGACAATTATAAAAGAAGAGCTGGTCCTGAAGCTCACAACCGTAACAGCCACCAGA
CAAGCTTCAGTGGCCGGCCCTTCACATCCAGACTTGCCTGAGAGGACCCACCTCTGAGTGT
CCAGTGGTCAGTTGCCCCAGGATGGGGACCACAGCCAGAGCAGCCTTGGTCTTGACCTAT
TTGGCTGTTGCTTCTGCTGCCTCTGAGGGAGGCTTCACGGCTACAGGACAGAGGCAGCTG
AGGCCAGAGCACTTTCAAGAAGTTGGCTACGCAGCTCCCCCCTCCCCACCCCTATCCCGAA
GCCTCCCCATGGATCACCCTGACTCCTCTCAGCATGGCCCTCCCTTTGAGGGACAGAGTCA
AGTGCAGCCCCCTCCCTCTCAGGAGGCCACCCCTCTCCAACAGGAAAAGCTGCTACCTGCC
CAACTCCCTGCTGAAAAGGAAGTGGGTCCCCCTCTCCCTCAGGAAGCTGTCCCCCTCCAAA
AAGAGCTGCCCTCTCTCCAGCACCCCAATGAACAGAAGGAAGGAACGCCAGCTCCATTTG
GGGACCAGAGCCATCCAGAACCTGAGTCCTGGAATGCAGCCCAGCACTGCCAACAGGAC
CGGTCCCAAGGGGGCTGGGGCCACCGGCTGGATGGCTTCCCCCCTGGGCGGCCTTCTCCA
GACAATCTGAACCAAATCTGCCTTCCTAACCGTCAGCATGTGGTATATGGTCCCTGGAACC
TACCACAGTCCAGCTACTCCCACCTCACTCGCCAGGGTGAGACCCTCAATTTCCTGGAGAT
TGGATATTCCCGCTGCTGCCACTGCCGCAGCCACACAAACCGCCTAGAGTGTGCCAAACTT
GTGTGGGAGGATACCCTTGACAAATACTGTGACCGGGAGTATGCTGTGAAGACCCACCAC
CACTTGTGTTGCCGCCACCCTCCCAGCCCTACTCGGGATGAGTGCTTTGCCCGTCGGGCTC
CTTACCCCAACTATGACCGGGACATCTTGACCATTGACATCGGTCGAGTCACCCCCAACCT
CATGGGCCACCTCTGTGGAAACCAAAGAGTTCTCACCAAGCATAAACATATTCCTGGGCT
GATCCACAACATGACTGCCCGCTGCTGTGACCTGCCATTTCCAGAACAGGCCTGCTGTGCA
GAGGAGGAGAAATTAACCTTCATCAATGATCTGTGTGGTCCCCGACGTAACATCTGGCGA
GACCCTGCCCTCTGCTGTTACCTGAGTCCTGGGGATGAACAGGTCAACTGCTTCAACATCA
ATTATCTGAGGAACGTGGCTCTAGTGTCTGGAGACACTGAGAACGCCAAGGGCCAGGGG
GAGCAGGGCTCAACTGGAGGAACAAATATCAGCTCCACCTCTGAGCCCAAGGAAGAATG
AGTCACCCCAGAGCCCTAGAGGGTCAGATGGGGGGAACCCCACCCTGCCCCACCCATCTG
AACACTCATTACACTAAACACCTCTTGGATTTGGTGTCCTCATTGTCTATCTAATGTCTCAC
CCGCAGTGTTTTAAGTGGATCTTGGTGCCCTGGCCCAGGAGGGCACTGGCGTTTTCAGAC
ACACCACAGACAAACACACCCTCCTAAGCCTGCTTGTATTTCCTTCAGTGCCTGGCCCCTGA
GGCCCACGGCCCTGCCCCCTTCACTGAGCAGATGTTCACAGGCTGTGGGATGCGACCATA
ACTAAACAGCTTGACGTCAAAAAAAAAAAAAAAAAA 
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The 5’ -> 3’ mRNA sequence (NM_001202858.1) of the ECM1c isoform 
obtained from the NCBI nucleotide database [183]. 
 
 
AATTATAAAAGAAGAGCTGGTCCTGAAGCTCACAACCGTAACAGCCACCAGACAAGCTTC
AGTGGCCGGCCCTTCACATCCAGACTTGCCTGAGAGGACCCACCTCTGAGTGTCCAGTGG
TCAGTTGCCCCAGGATGGGGACCACAGCCAGAGCAGCCTTGGTCTTGACCTATTTGGCTG
TTGCTTCTGCTGCCTCTGAGGGAGGCTTCACGGCTACAGGACAGAGGCAGCTGAGGCCA
GAGCACTTTCAAGAGGTTGGCTACGCAGCTCCCCCCTCCCCACCCCTATCCCGAAGCCTCC
CCATGGATCACCCTGACTCCTCTCAGCATGGCCCTCCCTTTGAGGGACAGAGTGGAAAGG
AGGGAAGAGGCCCTCGCCCCCACTCCCAGCCCTGGCTAGGAGAAAGGGTGGGCTGCTCA
CACATTCCCCCTTCTATAGTGCAGCCCCCTCCCTCTCAGGAGGCCACCCCTCTCCAACAGGA
AAAGCTGCTACCTGCCCAACTCCCTGCTGAAAAGGAAGTGGGTCCCCCTCTCCCTCAGGAA
GCTGTCCCCCTCCAAAAAGAGCTGCCCTCTCTCCAGCACCCCAATGAACAGAAGGAAGGA
ACGCCAGCTCCATTTGGGGACCAGAGCCATCCAGAACCTGAGTCCTGGAATGCAGCCCAG
CACTGCCAACAGGACCGGTCCCAAGGGGGCTGGGGCCACCGGCTGGATGGCTTCCCCCC
TGGGCGGCCTTCTCCAGACAATCTGAACCAAATCTGCCTTCCTAACCGTCAGCATGTGGTA
TATGGTCCCTGGAACCTACCACAGTCCAGCTACTCCCACCTCACTCGCCAGGGTGAGACCC
TCAATTTCCTGGAGATTGGATATTCCCGCTGCTGCCACTGCCGCAGCCACACAAACCGCCT
AGAGTGTGCCAAACTTGTGTGGGAGGAAGCAATGAGCCGATTCTGTGAGGCCGAGTTCT
CGGTCAAGACCCGACCCCACTGGTGCTGCACGCGGCAGGGGGAGGCTCGGTTCTCCTGCT
TCCAGGAGGAAGCTCCCCAGCCACACTACCAGCTCCGGGCCTGCCCCAGCCATCAGCCTG
ATATTTCCTCGGGTCTTGAGCTGCCTTTCCCTCCTGGGGTGCCCACATTGGACAATATCAA
GAACATCTGCCACCTGAGGCGCTTCCGCTCTGTGCCACGCAACCTGCCAGCTACTGACCCC
CTACAAAGGGAGCTGCTGGCACTGATCCAGCTGGAGAGGGAGTTCCAGCGCTGCTGCCG
CCAGGGGAACAATCACACCTGTACATGGAAGGCCTGGGAGGATACCCTTGACAAATACTG
TGACCGGGAGTATGCTGTGAAGACCCACCACCACTTGTGTTGCCGCCACCCTCCCAGCCCT
ACTCGGGATGAGTGCTTTGCCCGTCGGGCTCCTTACCCCAACTATGACCGGGACATCTTGA
CCATTGACATCGGTCGAGTCACCCCCAACCTCATGGGCCACCTCTGTGGAAACCAAAGAG
TTCTCACCAAGCATAAACATATTCCTGGGCTGATCCACAACATGACTGCCCGCTGCTGTGA
CCTGCCATTTCCAGAACAGGCCTGCTGTGCAGAGGAGGAGAAATTAACCTTCATCAATGA
TCTGTGTGGTCCCCGACGTAACATCTGGCGAGACCCTGCCCTCTGCTGTTACCTGAGTCCT
GGGGATGAACAGGTCAACTGCTTCAACATCAATTATCTGAGGAACGTGGCTCTAGTGTCT
GGAGACACTGAGAACGCCAAGGGCCAGGGGGAGCAGGGCTCAACTGGAGGAACAAATA
TCAGCTCCACCTCTGAGCCCAAGGAAGAATGAGTCACCCCAGAGCCTTAGAGGGTCAGAT
GGGGGGAACCCCACCCTGCCCCACCCATCTGAACACTCATTACACTAAACACCTCTTGG 
 
ACAACCGTAACAGCCACCAGACAAGCTTCAGTGGCCGGCCCTTCACATCCAGACTTGCCTG
AGAGGACCCACCTCTGAGTGTCCAGTGGTCAGTTGCCCCAGGATGGGGACCACAGCCAG
AGCAGCCTTGGTCTTGACCTATTTGGCTGTTGCTTCTGCTGCCTCTGAGGGAGCCTCCCCA
TCCCTTGCTGAAGTCCAGGGAAGGCCCTCCCAGTGGCCCCTGACTTGCCCTTCTTCCCTCC
AGGCTTCACGGCTACAGGACAGAGGCAGCTGAGGCCAGAGCACTTTCAAGAAG 
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The 5’-3’ mRNA sequence of the ECM1d isoform was obtained from 
[106].  
ECM1a 
MGTTARAALVLTYLAVASAASEGGFTATGQRQLRPEHFQEVGYAAPPS
PPLSRSLPMDHPDSSQHGPPFEGQSQVQPPPSQEATPLQQEKLLPAQL
PAEKEVGPPLPQEAVPLQKELPSLQHPNEQKEGTPAPFGDQSHPEPES
WNAAQHCQQDRSQGGWGHRLDGFPPGRPSPDNLNQICLPNRQHVVY
GPWNLPQSSYSHLTRQGETLNFLEIGYSRCCHCRSHTNRLECAKLVWE
EAMSRFCEAEFSVKTRPHWCCTRQGEARFSCFQEEAPQPHYQLRACP
SHQPDISSGLELPFPPGVPTLDNIKNICHLRRFRSVPRNLPATDPLQRELL
ALIQLEREFQRCCRQGNNHTCTWKAWEDTLDKYCDREYAVKTHHHLCC
RHPPSPTRDECFARRAPYPNYDRDILTIDIGRVTPNLMGHLCGNQRVLT
KHKHIPGLIHNMTARCCDLPFPEQACCAEEEKLTFINDLCGPRRNIWRDP
ALCCYLSPGDEQVNCFNINYLRNVALVSGDTENAKGQGEQGSTGGTNIS
STSEPKEE 
ECM1b 
MGTTARAALVLTYLAVASAASEGGFTATGQRQLRPEHFQEVGYAAPPS
PPLSRSLPMDHPDSSQHGPPFEGQSQVQPPPSQEATPLQQEKLLPAQL
PAEKEVGPPLPQEAVPLQKELPSLQHPNEQKEGTPAPFGDQSHPEPES
WNAAQHCQQDRSQGGWGHRLDGFPPGRPSPDNLNQICLPNRQHVVY
GPWNLPQSSYSHLTRQGETLNFLEIGYSRCCHCRSHTNRLECAKLVWE
DTLDKYCDREYAVKTHHHLCCRHPPSPTRDECFARRAPYPNYDRDILTI
DIGRVTPNLMGHLCGNQRVLTKHKHIPGLIHNMTARCCDLPFPEQACCA
EEEKLTFINDLCGPRRNIWRDPALCCYLSPGDEQVNCFNINYLRNVALVS
GDTENAKGQGEQGSTGGTNISSTSEPKEE 
ECM1c 
MGTTARAALVLTYLAVASAASEGGFTATGQRQLRPEHFQEVGYAAPPS
PPLSRSLPMDHPDSSQHGPPFEGQSGKEGRGPRPHSQPWLGERVGC
SHIPPSIVQPPPSQEATPLQQEKLLPAQLPAEKEVGPPLPQEAVPLQKEL
PSLQHPNEQKEGTPAPFGDQSHPEPESWNAAQHCQQDRSQGGWGHR
LDGFPPGRPSPDNLNQICLPNRQHVVYGPWNLPQSSYSHLTRQGETLN
FLEIGYSRCCHCRSHTNRLECAKLVWEEAMSRFCEAEFSVKTRPHWCC
TRQGEARFSCFQEEAPQPHYQLRACPSHQPDISSGLELPFPPGVPTLDN
IKNICHLRRFRSVPRNLPATDPLQRELLALIQLEREFQRCCRQGNNHTCT
WKAWEDTLDKYCDREYAVKTHHHLCCRHPPSPTRDECFARRAPYPNY
DRDILTIDIGRVTPNLMGHLCGNQRVLTKHKHIPGLIHNMTARCCDLPFPE
QACCAEEEKLTFINDLCGPRRNIWRDPALCCYLSPGDEQVNCFNINYLR
NVALVSGDTENAKGQGEQGSTGGTNISSTSEPKEE 
ECM1d 
MGTTARAALVLTYLAVASAASEGASPSLAEVQGRPSQWPLTCPSSLQA
SRLQDRGS 
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The amino acid sequences of all four ECM1 isoforms obtained from 
NCBI protein bank and Horev et al. [106, 325]. 
 
Appendix G - Confirmation of ECM1 knockdown by western 
blot analysis 
Four cell lines (HT-1376, LUCC4, HT-1197 and 647V) were stably 
transfected with shRNAs targeting ECM1 (KD1 and KD2) or scramble and 
non-hairpin (NHP) controls. To assess the efficiency of knockdown protein 
lysates were harvested from knockdown and control cell lines and ECM1 
protein levels were evaluated by western blot analysis (section 4.2.3.3). 
Western blot analysis of ECM1 levels was conducted over several 
subsequent passages and prior to any further experiments to ensure 
continued knockdown of ECM1. For HT-1376, HT-1197, and LUCC4 ECM1 
could no longer be detected at the protein level between 1 and 10 passages. 
For 647V also demonstrated reduced levels of ECM1 in knockdown 
compared to parental cells for all 10 passages, however reduced ECM1 was 
also seen in the control samples. 
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Western blot confirmation of knockdown of ECM1 at the protein level in 
HT-1376 over 10 passages.  
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Western blot confirmation of knockdown of ECM1 at the protein level in 
LUCC4 over 10 passages.   
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Western blot confirmation of knockdown of ECM1 at the protein level in 
HT-1197 over 10 passages.  
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Western blot confirmation of knockdown of ECM1 at the protein level in 
647V over 10 passages.  
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Appendix H  - Wound healing assay with recombinant ECM1 
In Chapter 4, wound healing assays were conducted using the HT-1376 KD1 
cell line in combination with treatment with recombinant ECM1 at 
concentrations ranging from 100 ng/ml to 1 µg/ml. No statistical significance 
was observed between knockdown cells treated at any concentrations of 
recombinant ECM1, and the untreated knockdown at 24 h or 48 h. However, 
at the highest concentration of recombinant ECM1 treatment (1 µg/ml) 
resulted in a slight increase in wound healing although this was not statistically 
significantly different as compared to the scramble control. Treatment with a 
higher concentration (2 µg/ml) of recombinant ECM1 was also assessed in 
wound healing assays. A) Images were captured at 50x magnification at 0, 24 
and 48 h for the HT-1376 scramble control cell line and ECM1 knockdown cell 
lines treated with two different concentrations of recombinant ECM1 (1 µg/ml 
and 2 µg/ml). Three replicate wells were treated at each concentration, and 
three images were taken per well for analysis. B) Statistical analysis of the 
percentage migration after 24 h was conducted using ordinary one-way 
ANOVA and Tukey’s multiple comparisons test. This showed the knockdown 
cells to have a statistically significant slower wound healing rate after 24 h 
than the scramble control cells, as did the knockdown cells treated with 1 
µg/ml and 2 µg/ml recombinant ECM1 (p = 0.035, 0.034, and 0.022 
respectively). C) Knockdown cells also had a statistically significant slower 
wound healing rate than the scramble control after 48 h, as did the same cells 
treated with 1 µg/ml and 2 µg/ml recombinant ECM1 (p <0.0001, <0.0001, = 
0.0004 respectively). (Key: * p = 0.05-0.01; ** p = 0.009-0.001; *** p = 0.0009-
0.0001; **** p = <0.0001). 
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Appendix I - Co-immunoprecipitation of ECM1 and EGFR full 
blots 
 
 
Full western blot images showing results from the co-
immunoprecipitation of ECM1 and EGFR in HT-1376 and 647V cell 
lysates.  
Total protein lysates harvested from the cell lines A) HT-1376 and B) 647V cell lines 
were used in co-immunoprecipitation with either anti-ECM1 or anti-EGFR antibodies 
and immunoprecipitation products were analysed by western blotting. Negative 
controls of water in place of antibody, or an Sv-40 T Ag antibody against a protein 
that does not interact with either ECM1 or EGFR were used. Blots were analysed 
using the ChemiDoc MP stystem. 
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Full western blot images showing results from the co-
immunoprecipitation of ECM1 and EGFR in HT-1376 cell lysates 
following pre-treatment with a crosslinker.  
HT-1376 cells were incubated with the crosslinker DTSSP before lysis. Total protein 
lysates were used in co-immunoprecipitation with either anti-ECM1 or anti-EGFR 
antibodies and immunoprecipitation products were analysed by western blotting. 
Negative controls of water in place of antibody, or an Sv-40 T Ag antibody against a 
protein that does not interact with either ECM1 or EGFR were used. Blots were 
analysed using the ChemiDoc MP system. 
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Appendix J - Microarray analysis of HT1376 knockdown and 
scramble control lines 
J.1 Analysis of RNA concentration and quality  
The RNA ScreenTape System (Agilent) uses electrophoresis to separate 
RNA samples on microfabricated chips. Laser induced florescent detection 
is then used to detect separated RNA samples, and Bioanalyzer software 
(Agilent) is used to display details such as concentration in a sample 
information table.  The software also generates an electropherogram for the 
visual assessment of the quality of the RNA sample. Using an algorithm 
developed from the assessment of over 1300 human, mouse, and rat RNA 
samples, the software also determines an RNA integrity number (RIN) to 
each sample which is a quantitative measurement of the quality of the RNA 
samples. This is based on a numbering system from 1- 10 with 10 being the 
most intact, and 1 being a highly degraded sample. 
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Well RINe 28S/18S 
(Height) 
28S/18S 
(Area) 
Conc. 
[ng/µl] Sample Description Alert Observations 
Total 
RNA 
Area 
rRNA 
Area 
A1 - - - 216 Ladder  Ladder - - 
B1 9.1 2.1 2.8 213 HT1376 scramble 
1   8.60 3.08 
C1 9.5 2.0 3.1 124 HT1376 scramble 
2   4.99 1.63 
D1 9.5 2.0 2.8 201 HT1376 scramble 
3   8.10 2.85 
E1 9.8 1.9 3.0 189 HT1376 KD 1   7.65 2.79 
F1 9.7 2.0 3.0 265 HT1376 KD 2   10.69 3.90 
G1 10.0 2.0 3.1 183 HT1376 KD 3   7.39 2.73 
H1 9.9 2.1 3.0 287 HT-1376 parental 
1   11.60 4.34 
A2 9.9 1.9 3.1 182 HT-1376 parental 
2   7.33 2.72 
B2 9.6 2.2 3.3 338 HT-1376 parental 
3   13.66 5.09 
 
A representative 2200 TapeStation (Agilent) sample information table.  
The integrity of RNA lysates from HT-1376 scramble control, ECM1 KD, and parental 
cell lines was assessed and a sample information table was generated with the 
Agilent 2200 TapeStation system.  
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A representative 2200 TapeStation (Agilent) electropherogram.  
The integrity of RNA lysates from HT-1376 scramble control, ECM1 KD, and parental 
cell lines was assessed and an electropherogram was generated with the Agilent 
2200 TapeStation system. The automatically determined RIN values are also shown 
for each sample. Sample order is as indicated in the sample information Table 
(section J.1). 
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J.1.1 Quality control and normalisation of microarray 
transcriptome expression data 
The following figures show the quality control data for the assessment of the 
raw data (CEL files) obtained from Affymetrix GeneChip HTA 2.0 
transcriptome analysis of the HT-1376 ECM1 knockdown (KD) and scramble 
control cell lines. CEL files were imported into Affymetrix Expression 
Console™ version 1.4 in order to assess the quality of the RNA microarray 
data. Data was then normalised to enable comparison of gene expression 
across the samples. Three biological replicates were assessed for the 
knockdown and the control cell lines.  
 
The area under the receiver operator curve was greater than or equal to 0.98 
for all microarray samples, indicating a low false positive rate and high true 
positive rate for the microarray positive and negative controls. 
 
 
 
The area under the receiver operator curve.  
The receiver operator curve plots the true positive rate against the false positive rate. 
Analysis of the area under the curve (AUC) was conducted in Affymetrix Expression 
Console™. The AUC gives an indication of how successfully the positive and 
negative microarray controls were identified, the closer the AUC is to 1, the more 
accurate the identification of the controls. For our samples the AUC was greater than 
or equal to 0.98 indicating a low false positive rate and high true positive rate.  
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The Eukaryotic hybridisation controls (spike controls) were detected with 
signal values from lowest to highest: bioB, bioC, bioD and cre. This matches 
the concentrations at which these controls were spiked into the hybridisation 
cocktail. Affymetrix state that bioC, bioD and cre should be present in every 
array sample and bioB should be present in a minimum of 70% of array 
samples. As the eukaryotic hybridisation controls are present in all our 
samples, this indicates successful hybridisation.  
 
 
 
 
 
Eukaryotic hybridisation controls (spike controls). 
Analysis of the spike controls was conducted in Affymetrix Expression Console™. 
The transcripts ‘bioB’, ‘bioC’ and ‘bioD’ take their sequence from genes of the E.coli 
biotin synthesis pathway, and the probe ‘cre’ takes its sequence form the 
bacteriophage P1 recombinase gene. As these are all non-eukaryotic genes, they 
are not expressed in human cells. These controls are spiked into the hybridisation 
control at different, known concentrations to enable signal alignment during image 
analysis.  
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Array labelling controls.  
Analysis of the labelling controls was conducted in Affymetrix Expression Console™. 
The transcripts ‘lys’, ‘phe’, ‘thr’ and ‘dap’ take their sequence from D. Subtilis genes. 
As these are all non-eukaryotic genes, they are not expressed in human cells. 
Different known concentrations of these transcripts were amplified and labelled with 
the assay samples to examine the labelling process.  
 
 
 
Normalisation of the microarray data was conducted in the Affymetrix 
Expression Console™ version 1.4. As probe cell intensities are prior to 
normalisation, experimental variation such as that occurring during the 
fluorescent labelling of cDNA and hybridisation of cDNA to the microarray, 
means some differences in distributions may be expected. However, there 
was no significant variability between the probe cell intensity data of our 
microarray samples measured from CEL files prior to normalisation.  
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Log probe cell intensity.  
The log probe cell intensity box plot was generated in Affymetrix Expression 
Console™ and shows the intensity of the signal from each array. No significant 
variations in median signal intensity were observed. 
 
 
 
Signal Space Transformation-Robust Multichip Average (SST-RMA) 
normalisation was conducted using the raw data from the CEL files in order to 
adjust for the variability in probe cell intensity between microarray samples. 
This generated CHP files. SST removes significant fold-change compression 
and RMA minimises probe variance [326]. After normalisation, CHP file 
summarised probe set signal values have no variability compared to the probe 
cell intensity values of microarray samples measured from CEL files. This 
indicates that the data normalisation was successful and array samples can 
now be compared.  
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Log expression signal of CHP files generated from the CEL files through 
SST-RMA normalisation.  
The box plot shows the signal intensity of each array following the SST-RMA 
normalisation conducted in Affymetrix Expression Console™. There are no 
differences in signal intensities between arrays indicating successful normalisation. 
 
 
 
J.1.2 LIMMA analysis to detect differentially expressed 
genes  
Microarray analysis using a whole genome transcript array was carried out 
to identify changes in gene expression induced by ECM1 knockdown in the 
HT-1376 cell line. Differential gene expression in HT-1376 ECM knockdown 
and scramble control cell lines was assessed using LIMMA analysis. Lists of 
the differentially expressed genes that were significantly upregulated and 
significantly downregulated. 
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Appendix K - List of suppliers 
Agilent Technilogies LDA UK Limited, Life Sciences & Chemical Analysis 
Group, Lakeside, Cheadle Royal Business Park, Stockport, Cheshire SK8 
3GR https://www.agilent.com/cs/agilent/en/contact-us/united-kingdom 
 
Beckman Coulter, Oakley Court Kingsmead Business Park, Londn Road, 
High Wycombe, HP11 1JU 
https://www.beckmancoulter.com/en/support/contact-us 
 
Bethyl Laboratories, P.O. Box 850, Montgomery, Texas, USA, 77356 
https://www.bethyl.com/Form/Contact  
 
Bio-Rad Laboratories Ltd., The Junction, Station Road, Watford, 
Hertfordshire, WD17 1ET http://www.bio-rad.com/en-uk/contact-us  
 
Cell Signalling Technology, Hamilton House, Mabledon Place, Lonson, 
WC1H 9BB https://www.cellsignal.co.uk/   
 
Leica Biosystems, Larch House, Woodlands Business Park, Breckland, 
Linford Wood, Milton Keynes, MK14 
6FG https://www.leicabiosystems.com/contact-us 
 
New England Biolabs (NEB), 75/77 Knowl Piece, Wilbury Way, Hitchin, 
Hertfordshire, SG4 0TY https://www.neb.uk.com/support/customer-services  
 
Promega, Delta House, Southampton Science Park, Southampton, SO16 
7NS https://www.promega.co.uk/support/contact-promega  
 
Qiagen, Skelton House, Lloyd St N, Manchester M15 6SH 
https://www.qiagen.com/gb/about-us-old/contact  
 
R&D Systems, 19 Barton Lane, Abingdon Science Park, Abingdon, OX14 
3NB 
https://www.rndsystems.com/support/contact-us  
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Santa Cruz Biotechnology, Bergheimer Strasse, 89-2, 69115, Heidelberg, 
Germany 
https://www.scbt.com/scbt/customer-care/contact-us  
 
Sigma-Aldrich, The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT 
https://www.sigmaaldrich.com/united-kingdom/customer-service.html  
 
Thermo Fisher Scientific, Fisher Science UK Ltd, Bishop Meadow Road, 
Loughborough, LE11 5RG https://www.fishersci.co.uk/gb/en/contact-us.html  
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